Drug-induced life-threatening arrhythmias and sudden cardiac death: A clinical perspective of long QT, short QT and Brugada syndromes | Revista Portuguesa de Cardiologia (English edition)

array:25 ["pii" => "S2174204918301685" "issn" => "21742049" "doi" => "10.1016/j.repce.2017.07.010" "estado" => "S300" "fechaPublicacion" => "2018-05-01" "aid" => "1184" "copyright" => "Sociedade Portuguesa de Cardiologia" "copyrightAnyo" => "2018" "documento" => "article" "crossmark" => 1 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "rev" "cita" => "Rev Port Cardiol. 2018;37:435-46" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 1985 "formatos" => array:3 [ "EPUB" => 101 "HTML" => 1573 "PDF" => 311 ] ] "Traduccion" => array:1 [ "en" => array:20 [ "pii" => "S0870255117300586" "issn" => "08702551" "doi" => "10.1016/j.repc.2017.07.010" "estado" => "S300" "fechaPublicacion" => "2018-05-01" "aid" => "1184" "copyright" => "Sociedade Portuguesa de Cardiologia" "documento" => "article" "crossmark" => 1 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "rev" "cita" => "Rev Port Cardiol. 2018;37:435-46" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 3507 "formatos" => array:3 [ "EPUB" => 145 "HTML" => 2821 "PDF" => 541 ] ] "en" => array:12 [ "idiomaDefecto" => true "cabecera" => "Review Article" "titulo" => "Drug-induced life-threatening arrhythmias and sudden cardiac death: A clinical perspective of long QT, short QT and Brugada syndromes" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "pt" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "435" "paginaFinal" => "446" ] ] "titulosAlternativos" => array:1 [ "pt" => array:1 [ "titulo" => "Arritmias potencialmente fatais e morte súbita cardíaca induzidas por fármacos: uma perspetiva clínica das síndromes do QT longo, QT curto e Brugada" ] ] "contieneResumen" => array:2 [ "en" => true "pt" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Diogo Ramalho, João Freitas" "autores" => array:2 [ 0 => array:2 [ "nombre" => "Diogo" "apellidos" => "Ramalho" ] 1 => array:2 [ "nombre" => "João" "apellidos" => "Freitas" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S2174204918301685" "doi" => "10.1016/j.repce.2017.07.010" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2174204918301685?idApp=UINPBA00004E" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0870255117300586?idApp=UINPBA00004E" "url" => "/08702551/0000003700000005/v1_201805250945/S0870255117300586/v1_201805250945/en/main.assets" ] ] "itemSiguiente" => array:20 [ "pii" => "S2174204918301697" "issn" => "21742049" "doi" => "10.1016/j.repce.2017.02.019" "estado" => "S300" "fechaPublicacion" => "2018-05-01" "aid" => "1185" "copyright" => "Sociedade Portuguesa de Cardiologia" "documento" => "simple-article" "crossmark" => 1 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "crp" "cita" => "Rev Port Cardiol. 2018;37:447.e1-6" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 1515 "formatos" => array:3 [ "EPUB" => 120 "HTML" => 1170 "PDF" => 225 ] ] "en" => array:13 [ "idiomaDefecto" => true "cabecera" => "Case report" "titulo" => "Massive organ embolization from primary aortic thrombosis" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "pt" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "447.e1" "paginaFinal" => "447.e6" ] ] "titulosAlternativos" => array:1 [ "pt" => array:1 [ "titulo" => "Embolização orgânica maciça de trombose primária da aorta" ] ] "contieneResumen" => array:2 [ "en" => true "pt" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0010" "etiqueta" => "Figure 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr2.jpeg" "Alto" => 1773 "Ancho" => 2501 "Tamanyo" => 477028 ] ] "descripcion" => array:1 [ "en" => "CT scan of the abdomen/pelvis showing total hypodensity of the spleen representing a complete infarct, without contrast enhancement except for a fine capsule. Splenic artery occlusion. Hypodense ill-defined lesion in the pancreas tail, measuring 55×38 mm with adjacent fat densification, but without contrast enhancement leading to a differential diagnosis between ischemic infarct and malignant neoplasm. Heterogeneous contrast enhancement of both kidneys, with triangular parenchymal areas of lower attenuation, suggestive of ischemic renal foci. Heterogeneous hepatomegaly with areas of non-contrast enhancement, the biggest one in segments VII and VIII; similar area on the liver border and smaller hypodense areas that, in this context, can represent occlusive arterial conditions. Small parietal thrombus (9mm) in the left lateral aortic wall, in the axial plane of the celiac trunk, with no evident atheromatous lesions." ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Catarina Patrício, Mariana Marques Silva, Pedro Eduardo Silva, João Oliveira, Luís Bagulho" "autores" => array:5 [ 0 => array:2 [ "nombre" => "Catarina" "apellidos" => "Patrício" ] 1 => array:2 [ "nombre" => "Mariana Marques" "apellidos" => "Silva" ] 2 => array:2 [ "nombre" => "Pedro Eduardo" "apellidos" => "Silva" ] 3 => array:2 [ "nombre" => "João" "apellidos" => "Oliveira" ] 4 => array:2 [ "nombre" => "Luís" "apellidos" => "Bagulho" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S0870255116302888" "doi" => "10.1016/j.repc.2017.02.020" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0870255116302888?idApp=UINPBA00004E" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2174204918301697?idApp=UINPBA00004E" "url" => "/21742049/0000003700000005/v1_201806100418/S2174204918301697/v1_201806100418/en/main.assets" ] "itemAnterior" => array:20 [ "pii" => "S2174204918301673" "issn" => "21742049" "doi" => "10.1016/j.repce.2018.05.007" "estado" => "S300" "fechaPublicacion" => "2018-05-01" "aid" => "1208" "copyright" => "Sociedade Portuguesa de Cardiologia" "documento" => "simple-article" "crossmark" => 1 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "dis" "cita" => "Rev Port Cardiol. 2018;37:433-4" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 1035 "formatos" => array:3 [ "EPUB" => 105 "HTML" => 684 "PDF" => 246 ] ] "en" => array:10 [ "idiomaDefecto" => true "cabecera" => "Editorial comment" "titulo" => "Obesity and hypertension in children: A worldwide problem" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "433" "paginaFinal" => "434" ] ] "titulosAlternativos" => array:1 [ "pt" => array:1 [ "titulo" => "Obesidade e hipertensão arterial nas crianças: um problema à escala mundial" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Sofia Ferreira" "autores" => array:1 [ 0 => array:2 [ "nombre" => "Sofia" "apellidos" => "Ferreira" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S0870255118302841" "doi" => "10.1016/j.repc.2018.04.006" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0870255118302841?idApp=UINPBA00004E" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2174204918301673?idApp=UINPBA00004E" "url" => "/21742049/0000003700000005/v1_201806100418/S2174204918301673/v1_201806100418/en/main.assets" ] "en" => array:16 [ "idiomaDefecto" => true "cabecera" => "Review Article" "titulo" => "Drug-induced life-threatening arrhythmias and sudden cardiac death: A clinical perspective of long QT, short QT and Brugada syndromes" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "435" "paginaFinal" => "446" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "Diogo Ramalho, João Freitas" "autores" => array:2 [ 0 => array:4 [ "nombre" => "Diogo" "apellidos" => "Ramalho" "email" => array:1 [ 0 => "silva.josediogo@gmail.com" ] "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "*" "identificador" => "cor0005" ] ] ] 1 => array:3 [ "nombre" => "João" "apellidos" => "Freitas" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "b" "identificador" => "aff0010" ] ] ] ] "afiliaciones" => array:2 [ 0 => array:3 [ "entidad" => "Departamento de Medicina, Faculdade de Medicina, Universidade do Porto, Porto, Portugal" "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:3 [ "entidad" => "Serviço de Cardiologia, Centro Hospitalar de São João EPE, Porto, Portugal" "etiqueta" => "b" "identificador" => "aff0010" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "titulosAlternativos" => array:1 [ "pt" => array:1 [ "titulo" => "Arritmias potencialmente fatais e morte súbita cardíaca induzidas por fármacos: uma perspetiva clínica das síndromes do QT longo, QT curto e Brugada" ] ] "textoCompleto" => "IntroductionSudden cardiac deathRemarkably, sudden cardiac death (SCD) accounts for about a quarter of the 17 million deaths attributable to cardiovascular diseases every year worldwide.<a class="elsevierStyleCrossRef" href="#bib0465">1</a>Coronary artery disease (CAD) is still the leading cause of these deaths, particularly in the elderly. However, primary cardiac arrhythmias and cardiomyopathies are the most common causes of SCD in young people.<a class="elsevierStyleCrossRefs" href="#bib0470">2,3</a> Ventricular fibrillation (VF) is the most common arrhythmia in SCD.<a class="elsevierStyleCrossRef" href="#bib0480">4</a> In fact, around 50% of SCD cases are due to VF and/or ventricular tachycardia (VT).<a class="elsevierStyleCrossRef" href="#bib0475">3</a> They predominantly occur out-of-hospital, explaining the low survival rates (i.e., <10%) of patients with VF.<a class="elsevierStyleCrossRef" href="#bib0485">5</a> Conversely, asystole and pulseless electrical activity (PEA) have been emerging in SCD for indefinite reasons.<a class="elsevierStyleCrossRef" href="#bib0475">3</a> Interestingly, in patients with reported out-of-hospital sudden cardiac arrest (SCA), antipsychotic drugs have shown to be significant predictors of PEA versus VF/VT.<a class="elsevierStyleCrossRef" href="#bib0490">6</a>SCD can be caused by an acquired and/or a genetic background of susceptibility, arising from either electrophysiological (e.g., inherited channelopathies) or structural cardiac abnormalities (e.g., CAD).<a class="elsevierStyleCrossRef" href="#bib0465">1</a>Inherited channelopathiesLong QT syndrome (LQTS), Brugada syndrome (BrS) and short QT syndrome (SQTS) are rare inherited arrhythmia disorders arising from ion channel abnormalities, which in turn are termed channelopathies. These syndromes are highly concerning, particularly in young people, due to their high propensity to suffer severe ventricular arrhythmias and sudden cardiac death.<a class="elsevierStyleCrossRef" href="#bib0495">7</a>Since the overwhelming majority of patients with inherited channelopathies have no structural heart diseases, an electrocardiogram (ECG) is a valuable tool both in detecting features of these syndromes and in early SCD risk stratification.<a class="elsevierStyleCrossRefs" href="#bib0465">1,7</a>QT prolongation, torsades de pointes and congenital long QT syndromeThe QT interval represents the electrocardiographic index of ventricular repolarization and depolarization.<a class="elsevierStyleCrossRef" href="#bib0500">8</a> Because the QT interval varies inversely with heart rate, several correction formulas (e.g., Bazett, Fridericia) allow us to determine a heart rate-corrected QT (QTc) interval. Fridericia's formula provides a more accurate assessment at extremes of heart rate than Bazett's formula and, therefore, it is preferred in such cases.<a class="elsevierStyleCrossRefs" href="#bib0505">9,10</a>The expert group from the American College of Cardiology Foundation and the American Heart Association (ACCF/AHA) gives an upper limit of normal (i.e., estimated 99th percentile) for abnormally prolonged QTc intervals of 470 ms and 480 ms in otherwise healthy post-pubertal males and females, respectively.<a class="elsevierStyleCrossRef" href="#bib0515">11</a> Patients with an absolute QTc interval of >500 ms are considered to be at risk for developing torsades de Pointes (TdP), a polymorphic ventricular tachycardia that may shift into VF and lead to SCD.<a class="elsevierStyleCrossRefs" href="#bib0515">11,12</a>Congenital QT prolongation is due to various genetically based LQTSs. Thirteen congenital types of LQTS have been reported thus far. The KCNQ1 (LQTS 1), KCNH2 (LQTS 2) and SCN5A (LQTS 3) genes encompass approximately 90% of all genotype-positive cases.<a class="elsevierStyleCrossRefs" href="#bib0465">1,3</a> LQTS types 1 and 2 are caused by the loss-of-function mutations of the KCNQ1 and KCNH2 genes encoding the α-subunit of slow (IKs) and rapid (IKr) components of the delayed rectifier potassium currents, respectively.<a class="elsevierStyleCrossRefs" href="#bib0495">7,13,14</a> Gain-of-function mutations of the SCN5A gene encoding the α-subunit of the cardiac voltage-gated sodium channels are responsible for LQTS type 3.<a class="elsevierStyleCrossRef" href="#bib0535">15</a> Genetic testing identifies a disease-causing mutation in about 75% of clinically definite LQTS, which proves its diagnostic significance.<a class="elsevierStyleCrossRef" href="#bib0540">16</a>TdP may clinically present as syncope, SCA or SD,<a class="elsevierStyleCrossRefs" href="#bib0475">3,13</a> beginning on average at the age of 12.<a class="elsevierStyleCrossRef" href="#bib0495">7</a>The Schwartz risk score is still a widely used diagnostic tool, and is based on clinical presentation, family history and ECG characteristics. The authors currently consider a cut-off value of ≥3.5 to be highly accurate in showing a high probability of having LQTS.<a class="elsevierStyleCrossRef" href="#bib0545">17</a> Additionally, the panel of experts for the latest guidelines from the European Society of Cardiology proposed a QTc ≥480 ms in repeated 12-lead ECG as diagnostic criteria, or detection of at least one unequivocally gene culprit mutation, regardless of QT interval duration. A QTc ≥460 ms can also be diagnostic in a scenario of unexplained syncope. In all the above-mentioned criteria, other causes for QT prolongation should previously be ruled out.<a class="elsevierStyleCrossRef" href="#bib0465">1</a>Short QT syndromeA rare inheritable channelopathy, called Short QT Syndrome (SQTS), was first clinically described in 2000, in three members of one family who presented with abnormally short QT intervals and tall peaked T-waves in the precordial ECG leads.<a class="elsevierStyleCrossRef" href="#bib0550">18</a>Gain-of-function mutations in genes encoding cardiac repolarizing K+ channels (i.e., KCNH2, KCNQ1 and KCNJ2) and loss-of-function mutations of calcium channel CACNA1C, CACNB2 and CACNA2D1 genes have been associated with SQTS.<a class="elsevierStyleCrossRefs" href="#bib0465">1,7,10</a> However, the diagnostic yield of genetic testing remains low (i.e., about 20%).<a class="elsevierStyleCrossRef" href="#bib0540">16</a>SQTS is diagnosed when QTc interval is ≤340 ms or, alternatively, should be considered if QTc interval is ≤360 ms along with one or more of the following: (1) survival from a VT/VF episode, in the absence of cardiac disease; (2) a confirmed pathogenic mutation; (3) a family history of SQTS, or (4) a family history of sudden death at the age of <40 years.<a class="elsevierStyleCrossRef" href="#bib0465">1</a>Apart from congenital SQTS, other clinical scenarios, such as electrolyte disturbances (e.g., hypercalcemia, hyperkalemia), acidosis, increased heart rate and increased levels of acetylcholine or catecholamine can shorten QT interval.QT shortening can degenerate into paroxysmal atrial fibrillation (AF) and/or VT and potentially lead to SCD.<a class="elsevierStyleCrossRefs" href="#bib0550">18,19</a>Brugada syndromeBrugada syndrome (BrS) is a relatively recent clinical entity, first described in 1992 by a set of distinctive ECG features, especially right bundle branch block and ST-segment elevation in right precordial leads (i.e., V1 to V3), in the absence of other concurrent factors (e.g., ischemia, structural heart disease or electrolyte imbalance).<a class="elsevierStyleCrossRef" href="#bib0560">20</a>BrS is inherited through an autosomal dominant mode of transmission. Approximately 20 culprit genes have been reported thus far.<a class="elsevierStyleCrossRef" href="#bib0565">21</a> The pathogenesis of congenital BrS is more commonly due to loss-of-function mutations in the SCN5A gene. Currently, over 300 SCN5A gene mutations have been described, accounting for the vast majority (i.e., approximately 75%) of genotype-positive cases.<a class="elsevierStyleCrossRef" href="#bib0570">22</a> Nevertheless, genetic testing identifies such mutations in only about 20-25% of BrS patients.<a class="elsevierStyleCrossRef" href="#bib0540">16</a> The increase in the transient outward potassium current (Ito) and the decrease in the L-type Ca2+ current (ICa,L) have also been postulated to contribute to the pathogenesis of BrS.<a class="elsevierStyleCrossRefs" href="#bib0535">15,21</a>Patients with a BrS ECG pattern are often clinically concealed at the time of diagnosis, which in turn is often incidental.<a class="elsevierStyleCrossRef" href="#bib0565">21</a> In fact, patients may persist asymptomatically for life, but a subgroup of BrS patients can experience syncope, nocturnal agonal respiration and palpitations associated with high risk of fatal arrhythmias (e.g., VT/VF) and SCD, which generally occur in the third or fourth decades of life, mainly at rest or during sleep.<a class="elsevierStyleCrossRefs" href="#bib0525">13,15,21</a> Although BrS affects both males and women, the condition appears to be 8 to 10 times more common in males.<a class="elsevierStyleCrossRef" href="#bib0510">10</a>BrS ECG patterns have been categorized as type 1, 2 or 3 according to detailed characteristics of surface ECGs. A coved ST-segment elevation ≥2 mm followed by a negative T wave is representative of a type 1 ECG pattern. Type 2 comprises a saddleback ST-segment elevation of ≥0.5 mm (i.e., usually ≥2 mm in V2) in at least 1 right precordial lead (i.e., V1-V3), followed by a convex shape. T-wave morphology differs in V1 and it is characteristically positive in V2. Type 3 pattern is characterized by either a coved or a saddleback appearance with an ST-segment elevation <1 mm.<a class="elsevierStyleCrossRef" href="#bib0575">23</a> Nonetheless, only type 1 is recognized as diagnostic. Type 2 and type 3 are not specific to BrS and, therefore, it is currently uncertain whether or not they should be considered BrS patterns. However, physicians should be aware and recognize these patterns as they can be an electrocardiographical presentation of some genuine BrS patients.<a class="elsevierStyleCrossRef" href="#bib0565">21</a>The diagnostic criteria of BrS were recently updated in the 2016 expert consensus conference on J-wave syndromes,<a class="elsevierStyleCrossRef" href="#bib0575">23</a> since the criteria proposed in the 2015 guidelines<a class="elsevierStyleCrossRef" href="#bib0465">1</a> and in the previous 2013 consensus statement<a class="elsevierStyleCrossRef" href="#bib0580">24</a> tend to overdiagnose cases of the type 1 ECG pattern. Overdiagnosis is unmasked after intravenous sodium-channel blocker challenge with ajmaline, flecainide, pilsicainide or procainamide. In such patients, BrS diagnosis should require that the patient also present with at least 1 of the following: (1) nocturnal agonal respiration, (2) syncope of probable arrhythmic cause, (3) family history of SCD at less than 45 years old with negative autopsy, (4) documented polymorphic VT or VF, or (5) coved-type ECGs in family members. A spontaneous type 1 ECG pattern in at least 1 right precordial lead (i.e., V1, V2 and V3, placed in the 2nd, 3rd and 4th intercostal spaces, respectively) is an independent BrS diagnostic criterion.<a class="elsevierStyleCrossRef" href="#bib0575">23</a>Since other acute (e.g., coronary events, metabolic disorders, electrolyte disturbances) and chronic (e.g., ventricular hypertrophy, autonomic nervous system disorders) conditions can bring about ST-segment elevation patterns, diagnosis of BrS is feasible only after these scenarios are ruled out.<a class="elsevierStyleCrossRefs" href="#bib0565">21,23</a>AimThe aim of this article is to comprehensively and critically review the recently published evidence with regard to drug-induced life-threatening arrhythmias and sudden cardiac death. It will take into account the provision of data to physicians that are useful in the identification of the culprit drugs, and thus, contribute to the prompt recognition and management of these serious clinical conditions.MethodsA comprehensive search was carried out through PubMed to identify human-based studies published in English and/or Portuguese, between January 1, 2011 and January 12, 2017. The following keywords were used in combination, both as Medical Subject Headings (MeSH) terms and text words: “sudden cardiac death”, “cardiac arrhythmias”, “long QT syndrome”, “torsades de pointes”, “Brugada syndrome”, “drug-related side effects and adverse reactions” and “pharmaceutical preparations”. Additionally, the text words “arrhythmias”, “proarrhythmia”, “torsade de pointes”, “short QT syndrome”, “adverse effects”, “drugs” and “drug-induced” were combined with the abovementioned search terms. The literature search encompassed relevant studies regarding drug-induced proarrhythmia and SCD, especially those which aimed to address the so-called congenital and acquired arrhythmia syndromes LQTS, SQTS or BrS. A clinical perspective was chosen due to the wide range of data within this field. Case reports were excluded, unless they displayed original evidence or were the only source of a causal relationship. Papers that only aimed to address detailed therapeutic strategies were not considered.A total of 496 studies were identified. Titles and abstracts were initially screened, and full-text articles were retrieved. The reference list of the identified articles was checked for potentially relevant papers. Two reviewers (i.e., first and last author) independently analyzed each study to minimize bias.The final review ended up comprising a total of 90 articles. Two additional websites (i.e., <a id="intr0025" class="elsevierStyleInterRef" href="http://www.crediblemeds.org/">www.crediblemeds.org</a><a class="elsevierStyleCrossRef" href="#bib0585">25</a>; <a id="intr0030" class="elsevierStyleInterRef" href="http://www.brugadadrugs.org/">www.brugadadrugs.org</a><a class="elsevierStyleCrossRef" href="#bib0590">26</a>) were included as they provide useful information regarding the aim of this review.Drug-induced proarrhythmia and SCDDrug-induced proarrhythmia is the outcome of prior or concomitant use of any drug with life-threatening proarrhythmic effects and SCD risk.<a class="elsevierStyleCrossRefs" href="#bib0510">10,27</a> Growing evidence suggests the implication of an increasing number of drugs in acquired forms of long QT (<a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>), short QT to a lesser extent (<a class="elsevierStyleCrossRef" href="#tbl0010">Table 2</a>) and Brugada syndrome (<a class="elsevierStyleCrossRef" href="#tbl0015">Table 3</a>).<a class="elsevierStyleCrossRef" href="#bib0510">10</a><elsevierMultimedia ident="tbl0005"></elsevierMultimedia><elsevierMultimedia ident="tbl0010"></elsevierMultimedia><elsevierMultimedia ident="tbl0015"></elsevierMultimedia>Drug-induced LQTSAcquired LQTS is undoubtedly more common than inherited LQTS.<a class="elsevierStyleCrossRef" href="#bib0505">9</a> Drugs are undeniably the leading cause of acquired LQTS.<a class="elsevierStyleCrossRef" href="#bib0600">28</a> Notably, in the last decade, drug-induced TdP was the single most common cause of the withdrawal or restriction of the use of drugs that have already been marketed.<a class="elsevierStyleCrossRef" href="#bib0520">12</a>The ACCF/AHA scientific statement recognized a QTc interval of >500 ms, or an increase after drug administration of QTc >60 ms from the pre-drug baseline, as alarming signals that should warrant prompt management and correction.<a class="elsevierStyleCrossRef" href="#bib0515">11</a> In fact, the majority of drug-induced TdP cases has been reported with QTc intervals of >500 ms.<a class="elsevierStyleCrossRef" href="#bib0510">10</a>However, data suggests that the magnitude of QTc prolongation does not directly correlate with the risk of developing TdP. Amiodarone and ranolazine are two paradigmatic cases, which undoubtedly cause QT prolongation, but with few reported cases of TdP. Apparently, these agents attenuate the dispersion of ventricular repolarization, which balance out with the QT prolongation effect.<a class="elsevierStyleCrossRef" href="#bib0510">10</a> Although not yet proven in congenital forms of LQTS, indirect assessment of transmural dispersion of ventricular repolarization using Tpeak-end interval and the Tpeak-Tend/QT ratio (e.g., significantly increased in cigarette smokers) has been demonstrated to properly predict the risk of potentially life-threatening arrhythmias in drug-induced LQTS.<a class="elsevierStyleCrossRefs" href="#bib0505">9,10,29,30</a> QT dispersion (i.e., difference between the longest and shortest QT interval in the 12 ECG leads), is another potential surrogate marker for ventricular repolarization heterogeneity, which was shown to increase with the use of psychotropic drugs.<a class="elsevierStyleCrossRef" href="#bib0615">31</a>Nevertheless, the QT interval is still widely used in clinical practice to assess the risk of TdP and SCD, notwithstanding its poor predictive value.<a class="elsevierStyleCrossRefs" href="#bib0505">9,32</a>Drug interactions with cardiac ion channels are the main mechanisms involved in potentially life-threatening arrhythmias.<a class="elsevierStyleCrossRef" href="#bib0595">27</a> Theoretically, almost all drugs associated with QT prolongation and TdP block the rapid delayed rectifier potassium current, IKr, but not all IKr inhibitors prolong the QT interval and cause TdP.<a class="elsevierStyleCrossRefs" href="#bib0520">12,14</a> However, the use of these channel blockers in the general population has been associated with high risk of SCD.<a class="elsevierStyleCrossRef" href="#bib0625">33</a>Various drugs are metabolized by intestinal or hepatic cytochrome P450 (CYP450) enzymes.<a class="elsevierStyleCrossRefs" href="#bib0530">14,27</a> Methadone (i.e., CYP2C19, notably, the *2 variant that is associated with QTc prolongation,<a class="elsevierStyleCrossRef" href="#bib0630">34</a> CYP3A4 and to a lesser extent the CYP2D6, CYP2B6 and CYP1A2 enzymes<a class="elsevierStyleCrossRef" href="#bib0635">35</a>), clarithromycin and erythromycin (CYP3A enzymes),<a class="elsevierStyleCrossRef" href="#bib0640">36</a> domperidone (CYP3A4)<a class="elsevierStyleCrossRef" href="#bib0645">37</a> and clozapine (CYP2D6)<a class="elsevierStyleCrossRef" href="#bib0650">38</a> are examples of such drugs. If those pathways are more prone to be inhibited by the concurrent use of other drugs or their activity is impaired by certain gene polymorphisms, extremely elevated drug serum levels and fatal outcomes are expected to occur.<a class="elsevierStyleCrossRef" href="#bib0595">27</a>Recently, the nitric oxide synthase 1 adaptor protein (NOS1AP) genetic variation has been identified as a new genetic marker in modulating QT prolongation and SCD, both in congenital and drug-induced LQTS.<a class="elsevierStyleCrossRefs" href="#bib0600">28,39</a> In fact, along with P-glycoprotein, a transmembrane efflux pump (i.e., domperidone is one of its substrates<a class="elsevierStyleCrossRef" href="#bib0645">37</a>), the NOS1AP gene appears to be implicated in the bioavailability of various QT-prolonging drugs, especially calcium channel inhibitors (e.g., verapamil and diltiazem), since it is involved in the inhibition of L-type Ca2+ channels.<a class="elsevierStyleCrossRef" href="#bib0530">14</a>Apart from subclinical congenital LQTS, drug-induced TdP depends on a multitude of risk factors, which comprise female gender, advanced age and common clinical conditions, such as bradycardia, hypertension, structural heart diseases (e.g., congestive heart failure, hypertrophic cardiomyopathy) and electrolyte imbalances (e.g., hypokalemia, hypomagnesemia, hypocalcemia).<a class="elsevierStyleCrossRefs" href="#bib0515">11,12,38,40,41</a>An up-to-date list of cardiovascular and non-cardiovascular drugs (i.e., mainly psychotropics and antimicrobials<a class="elsevierStyleCrossRef" href="#bib0510">10</a>) implicated in QT prolongation and/or TdP is currently available at <a id="intr0035" class="elsevierStyleInterRef" href="http://www.crediblemeds.org/">www.crediblemeds.org</a>.<a class="elsevierStyleCrossRef" href="#bib0585">25</a>Antiarrhythmic drugsAntiarrhythmic drugs are among the most harmful regarding their high risk of life-threatening arrhythmias. Vaughan Williams class III drugs (e.g., sotalol, dofetilide, ibutilide) lead to the greatest concern for TdP within antiarrhythmics.<a class="elsevierStyleCrossRef" href="#bib0595">27</a> Apart from the well-known QTc prolongation effect, amiodarone exhibits a low risk of TdP, when used alone.<a class="elsevierStyleCrossRefs" href="#bib0505">9,10,42</a> Nevertheless, TdP has already been reported with concomitant use (e.g., erythromycin and haloperidol).<a class="elsevierStyleCrossRef" href="#bib0660">40</a> Therefore, ECG monitoring is required in all intensive care unit (ICU) patients receiving amiodarone, since this subset of patients has a high incidence of concomitant use of other QT-prolonging drugs.<a class="elsevierStyleCrossRef" href="#bib0670">42</a>Notably, pilsicainide, a class Ic antiarrhythmic drug, triggered TdP in an elderly patient who ended up dying suddenly, two days after receiving it to convert his paroxysmal AF to sinus rhythm.<a class="elsevierStyleCrossRef" href="#bib0675">43</a>Antianginal drugsIn spite of its known QT-prolonging effect, low risk of TdP and SCD have been reported with ranolazine,<a class="elsevierStyleCrossRefs" href="#bib0510">10,27</a> including when it is used to treat non-ST elevation acute coronary syndrome in patients with prolonged baseline QTc intervals.<a class="elsevierStyleCrossRef" href="#bib0680">44</a>Antidepressant and antipsychotic drugsTricyclic antidepressants are well-known risk factors for QT prolongation and TdP, especially in overdose cases.<a class="elsevierStyleCrossRefs" href="#bib0595">27,45</a>Overall, selective serotonin-reuptake inhibitors (SSRIs) increase the QTc interval, but citalopram and escitalopram seem to incite a more pronounced QTc prolongation in a dose-dependent fashion.<a class="elsevierStyleCrossRefs" href="#bib0690">46–48</a> Nevertheless, the role of citalopram as a trigger of TdP and SCD remains controversial, as there are no concomitant risk factors for QT prolongation and TdP.<a class="elsevierStyleCrossRef" href="#bib0705">49</a>Although bupropion and venlafaxine prolong the QTc interval almost exclusively in overdose scenarios, generally, newer non-SSRIs pose a low risk of such effect at therapeutic doses. Their shorter market life may explain the limited data.<a class="elsevierStyleCrossRef" href="#bib0710">50</a>In a cohort study, no considerable differences regarding sudden death and ventricular arrhythmia (SD/VA) risks were detected among 11 antidepressants and paroxetine. High risk of SD/VA was only reported with mirtazapine, but the authors reminded us that such outcome was biased by confounding factors. Therefore, cardiac safety was considered similar among antidepressants.<a class="elsevierStyleCrossRef" href="#bib0715">51</a>Given the numerous adverse effects of antipsychotics, drug-induced LQTS is truly one of the most dangerous.<a class="elsevierStyleCrossRef" href="#bib0595">27</a> Overall, first-generation antipsychotics are considered to be more likely to prolong QT interval and have higher risks of ventricular arrhythmias (VAs) and SCD than second-generation antipsychotics.<a class="elsevierStyleCrossRefs" href="#bib0500">8,52</a>The Food and Drug Administration Adverse Event Reporting System (FAERS) database has been systematically analyzed to detect signals of torsadogenicity.<a class="elsevierStyleCrossRefs" href="#bib0725">53,54</a> In this regard, detecting new potential signals of torsadogenicity (e.g., with amisulpride, cyamemazine and olanzapine) provided new insights for pharmacovigilance in antipsychotics. This is because it allowed updating the Arizona Center for Education and Research on Therapeutics (AZCERT<a class="elsevierStyleCrossRef" href="#bib0585">25</a>) drug list.<a class="elsevierStyleCrossRef" href="#bib0730">54</a> One year later, Fanoe et al. combined pharmacovigilance data from various international databases. Only haloperidol, pimozide, sertindole and ziprasidone were considered to be class B* drugs (i.e., “a drug with pronounced QT prolongation, documented cases of TdP, or other serious arrhythmias”).<a class="elsevierStyleCrossRef" href="#bib0735">55</a> Alternatively, the data analysis of three national spontaneous reporting systems (i.e., France, Germany and Italy) demonstrated that in all of the national databases studied, TdP events were reported only with amisulpride, aripiprazole, haloperidol, olanzapine and risperidone.<a class="elsevierStyleCrossRef" href="#bib0740">56</a>Therefore, available data on haloperidol have consistently favored its marked QT prolongation effect and high risk for TdP and SCD,<a class="elsevierStyleCrossRefs" href="#bib0725">53–57</a> but such outcomes have been disparate for clozapine (low risk of QTc prolongation<a class="elsevierStyleCrossRef" href="#bib0750">58</a>; “very strong signals of torsadogenicity”<a class="elsevierStyleCrossRefs" href="#bib0725">53,54</a>) and olanzapine (“a drug considered to be without any risk of QT prolongation or TdP”<a class="elsevierStyleCrossRef" href="#bib0735">55</a>; “potential signal of torsadogenicity”<a class="elsevierStyleCrossRef" href="#bib0730">54</a>; “very strong signal of torsadogenicity”<a class="elsevierStyleCrossRef" href="#bib0725">53</a>). Despite ziprasidone having QT-prolonging and torsadogenic effects,<a class="elsevierStyleCrossRefs" href="#bib0725">53–55</a> studies have failed to prove an increased risk of SD, SCD or nonsuicide mortality.<a class="elsevierStyleCrossRefs" href="#bib0755">59–61</a> Aripiprazole has a low risk of TdP and SCD, at least in otherwise healthy patients. However, in patients at risk for TdP, it may represent a safety concern, since few studies have been carried in these vulnerable subsets.<a class="elsevierStyleCrossRefs" href="#bib0770">62,63</a> Cases of QTc prolongation, TdP and SCD have been reported with quetiapine, but only with concomitant risk factors for QT prolongation or TdP.<a class="elsevierStyleCrossRef" href="#bib0780">64</a> Increased QTc prolongation and higher risk of SCD have been documented with risperidone during nighttime, when compared to olanzapine users.<a class="elsevierStyleCrossRef" href="#bib0785">65</a> These perilous effects are likely due to the increased serum levels of risperidone's active metabolite paliperidone in a dose-dependent manner and not to risperidone alone.<a class="elsevierStyleCrossRef" href="#bib0790">66</a> Two retrospective cohort studies also made a comparison with olanzapine, but both risperidone and quetiapine were not implicated in higher risk of SD or VAs. According to the authors, olanzapine was chosen as the referent, since it is not linked to substantive QT prolongation.<a class="elsevierStyleCrossRef" href="#bib0745">57</a>Exposure to phenothiazine antipsychotics also carries a risk of QTc prolongation and TdP both in therapeutic and overdose settings, particularly with levomepromazine, chlorpromazine and promethazine.<a class="elsevierStyleCrossRef" href="#bib0685">45</a>Despite increasing safety concerns, widespread use of antipsychotics with torsadogenic potential has been reported in some European countries in recent years, mostly with haloperidol and thioridazine.<a class="elsevierStyleCrossRef" href="#bib0795">67</a>ECG monitoring is strongly recommended at hospital admission in patients with acute psychosis (i.e., recently treated with antipsychotics), due to the increased risk of QTc prolongation.<a class="elsevierStyleCrossRef" href="#bib0800">68</a> Conversely, Correll et al. affirmed that, unless other comorbidities are present (e.g., cardiac diseases, obesity, hypokalemia), ECG monitoring could potentially be restricted in young people treated with antipsychotics, as significantly prolonged QTc interval was not demonstrated in this subset of patients. Nevertheless, the authors reinforced the idea that larger studies are required in this regard.<a class="elsevierStyleCrossRef" href="#bib0805">69</a>Antimicrobial drugsMacrolide antibiotics are one of the most prescribed non-cardiovascular QT-prolonging agents, and exhibit increased risk of fatal ventricular arrhythmias or SCD.<a class="elsevierStyleCrossRefs" href="#bib0595">27,36</a> Azithromycin was once considered to be relatively free of adverse cardiac effects. However, new data has been emerging regarding its cardiac safety.<a class="elsevierStyleCrossRefs" href="#bib0810">70,71</a>Quinolones are broad-spectrum antimicrobials with known risk of QT prolongation.<a class="elsevierStyleCrossRefs" href="#bib0595">27,42</a> It is noteworthy that in a United States veterans study,<a class="elsevierStyleCrossRef" href="#bib0815">71</a> levofloxacin was significantly associated with serious arrhythmias and death, throughout the 10-day course of therapy.QT prolongation and TdP have also been reported with antifungal agents, mainly fluconazole.<a class="elsevierStyleCrossRef" href="#bib0595">27</a>Anesthetic drugsOverall, inhaled anesthetics can prolong the QTc interval or increase dispersion of ventricular repolarization to variable degrees. However, only sevoflurane has been associated with TdP risk, though most likely with concomitant risk factors.<a class="elsevierStyleCrossRef" href="#bib0555">19</a>An ICU population-based study revealed that a flurane agent had been administered during anesthesia in the overwhelming majority of postoperative patients with QT interval prolongation. Therefore, the authors emphasized the need for QTc interval monitoring in all postoperative ICU patients.<a class="elsevierStyleCrossRef" href="#bib0670">42</a>A case of SCA following documented QTc interval prolongation (i.e., 580-600 ms) was reported in a 30-month-old boy during anesthesia induction with sevoflurane and nitric oxide before undergoing plastic surgery for bilateral cutaneous syndactyly. Timothy Syndrome, LQTS type 8 with typical features, including syndactyly, was established by detecting the p.Gly406Arg mutation in the CACNA1C gene encoding Cav1.2 L-type calcium channel.<a class="elsevierStyleCrossRef" href="#bib0820">72</a>Anticholinergic drugs (e.g., atropine, glycopyrronium bromide) can prolong the QT interval when simultaneously used with anticholinesterases in healthy patients, but TdP may occur when used alone in LQTS patients.<a class="elsevierStyleCrossRef" href="#bib0555">19</a>Antiemetic drugsDomperidone can prolong the QTc interval and increase the risk of serious VAs and SCD.<a class="elsevierStyleCrossRefs" href="#bib0645">37,73</a> SCD risk seems to be higher in the first two weeks of treatment, in patients older than 60 years and those with doses over 30 mg/day.<a class="elsevierStyleCrossRef" href="#bib0830">74</a>Serotonin-receptor antagonists (e.g., dolasetron, granisetron and ondansetron) are also known QT-prolonging drugs, but their clinical significance remains unclear, due to few reported cases of fatal cardiac arrhythmias and SCD.<a class="elsevierStyleCrossRefs" href="#bib0555">19,75</a>Antihistaminic drugsApart from not appearing at the forefront of the most common events, adverse cardiac effects are one of the most serious events for patients using first- or second-generation antihistamines.<a class="elsevierStyleCrossRef" href="#bib0840">76</a>The low number of antihistamines on the AZCERT drugs list<a class="elsevierStyleCrossRef" href="#bib0585">25</a> demonstrates the scarcity of pharmacovigilance data reporting TdP events. An analysis of safety reports from the FAERS database revealed new evidence on torsadogenic activity for loratadine, desloratadine, cetirizine and fexofenadine, in addition to diphenhydramine,<a class="elsevierStyleCrossRef" href="#bib0840">76</a> which was already on the AZCERT list.<a class="elsevierStyleCrossRef" href="#bib0585">25</a>Antineoplastic drugsHigh TdP event rates are almost exclusively reported with arsenic trioxide. However, BRAF inhibitor vemurafenib, histone deacetylase inhibitors (e.g., depsipeptide and vorinostat) and tyrosine kinase inhibitors (e.g., dasatinib, nilotinib, lapatinib, sunitinib, vandetinib) are also commonly linked to QTc prolongation to varying degrees.<a class="elsevierStyleCrossRefs" href="#bib0845">77,78</a>Opioid replacement drug therapyAlthough more commonly reported at high doses (>200 mg/day), QT prolongation, TdP and SD can occur even at lower doses of methadone (<100 mg/day). This is predominantly in early periods of treatment and/or during concomitant use of either QT-prolonging agents or those which impair methadone metabolism.<a class="elsevierStyleCrossRef" href="#bib0635">35</a>Attention deficit hyperactivity disorder drug therapyQT prolongation is associated with atomoxetine use in overdose.<a class="elsevierStyleCrossRef" href="#bib0855">79</a> Nevertheless, there is scarce evidence regarding the involvement of stimulants in fatal arrhythmias and SCD.<a class="elsevierStyleCrossRefs" href="#bib0855">79,80</a>In a non-randomized cohort study conducted in adults, the risk of VA or SD was significantly associated with methylphenidate use. However, the authors argued that the lack of a dose-response effect did not suggest a causal relationship.<a class="elsevierStyleCrossRef" href="#bib0865">81</a>Non-therapeutic drugsData collected from a large sample representative of the general US population revealed that binge drinkers displayed substantially prolonged QT intervals, compared to non-binge drinkers or non-drinkers.<a class="elsevierStyleCrossRef" href="#bib0870">82</a>TdP was reported in a previously healthy 43-year-old woman who presented with syncope after excessive intake of ginseng for 6 months.<a class="elsevierStyleCrossRef" href="#bib0875">83</a>Ozturk S et al. described the case of a 59-year-old woman who developed TdP after two days of drinking 5-6 glasses of licorice root tea for constipation. The authors hypothesized that glycyrrhizin was the culprit compound due to its known effects on both cardiac depolarization and repolarization.<a class="elsevierStyleCrossRef" href="#bib0880">84</a>Drug-induced SQTSDrug-induced SQTS is still a rarely reported condition.<a class="elsevierStyleCrossRef" href="#bib0885">85</a> Therefore, its clinical significance is still unclear, since few fatal arrhythmias and SCD cases have been described thus far.<a class="elsevierStyleCrossRef" href="#bib0890">86</a>Antiepileptic drugsRufinamide has been reported as a QT shortening agent. In patients receiving rufinamide, the concomitant use of lamotrigine and valproic acid has been associated with a significant decrease in the QT interval.<a class="elsevierStyleCrossRef" href="#bib0890">86</a>Drug-induced BrSEvidence suggests that a rising number of drugs universally used in daily clinical practice can reveal the typical ECG pattern of BrS and, thus, potentially lead to fatal arrhythmias.<a class="elsevierStyleCrossRef" href="#bib0895">87</a>Aside from drugs, other clinical scenarios, including febrile state (e.g., hyperthermia, hypothermia) and electrolyte disturbances (e.g., hyperkalemia, hypokalemia, hypercalcemia, hyponatremia), can trigger a type 1 pattern and modulate the occurrence of potentially life-threatening arrhythmias. Some refer to these modifying factors as “phenocopies”. However, at least for now, it is not proper to do so, due to the lack of data regarding genetic predisposition.<a class="elsevierStyleCrossRefs" href="#bib0565">21,23</a> These conditions are actually more suitably designated as acquired forms of Brugada ECG pattern or BrS.<a class="elsevierStyleCrossRef" href="#bib0575">23</a>Psychotropic and anesthetic drugs are the most common non-cardiovascular agents involved in BrS ECG phenotype.<a class="elsevierStyleCrossRef" href="#bib0895">87</a> Postema et al. founded the website <a id="intr0040" class="elsevierStyleInterRef" href="http://www.brugadadrugs.org/">www.brugadadrugs.org</a> to guarantee the worldwide availability of cardiac safety information regarding drug prescription in BrS patients.<a class="elsevierStyleCrossRef" href="#bib0590">26</a>Antiarrhythmic drugsType 1 BrS ECG pattern is aggravated by drugs that block the cardiac Na+ channel. Corroborating this finding, some of them (i.e., ajmaline, flecainide, pilsicainide and procainamide) are currently used for diagnostic purposes to unmask such a typical pattern in concealed BrS patients.<a class="elsevierStyleCrossRef" href="#bib0535">15</a> Nevertheless, it is noteworthy that flecainide has demonstrated an increased risk of SCD when administered to treat AF.<a class="elsevierStyleCrossRef" href="#bib0900">88</a>BrS ECG type 1 and type 3 patterns were reported while amiodarone was prophylactically used for AF, following coronary artery bypass grafting.<a class="elsevierStyleCrossRef" href="#bib0905">89</a>Antidepressants and antipsychotic drugsSome tricyclic and SSRI antidepressants and antipsychotics (e.g., lithium) can induce a BrS ECG phenotype by blocking INa currents.<a class="elsevierStyleCrossRefs" href="#bib0650">38,87</a>In a population-based study, nortriptyline, an example of such a drug, was associated with a significant 4.5-fold increase in the risk for SCA.<a class="elsevierStyleCrossRef" href="#bib0485">5</a>Although fluvoxamine and paroxetine at therapeutic doses and fluoxetine in overdose can trigger a BrS ECG pattern, no severe VAs have been reported thus far. Similarly, phenothiazine antipsychotics (including cyamemazine, perphenazine and thioridazine) are well-known culprit agents in drug-induced BrS, but without causing fatal VAs.<a class="elsevierStyleCrossRef" href="#bib0895">87</a>Epilepsy and antiepileptic drug therapyEpilepsy is considered to be an independent risk factor for life-threatening arrhythmias and SCD. In fact, epilepsy has been associated with a two- to three-fold higher risk for SCD than in the general population and with a six-fold higher risk in poorly controlled patients.<a class="elsevierStyleCrossRef" href="#bib0910">90</a>Recently, Ishizue et al. concluded that the concomitant use of sodium channel-blocking antiepileptic drugs, including carbamazepine, phenytoin and lamotrigine, significantly caused a BrS type 1 pattern. Conversely, the authors admitted the inability to assess the 12-lead ECGs of a large proportion of epilepsy patients, before and after antiepileptic therapy. As a result, epilepsy as a confounding factor cannot be ruled out.<a class="elsevierStyleCrossRef" href="#bib0915">91</a>Bardai et al. revealed the increased risk of SCD with the use of sodium channel-blocking antiepileptics in epilepsy patients (i.e., carbamazepine and gabapentin) that was independent from the underlying epileptic condition. In addition, off-label drug use in non-epileptic patients has also been correlated with increased risk for SCD, similarly to epilepsy per se. If we transfer these conclusions to clinical practice, measures involving seizure control with antiepileptic drugs are required, but the risk of SCD must always be taken into account.<a class="elsevierStyleCrossRef" href="#bib0910">90</a>Anesthetic drugsDespite having one of the safest profiles within modern anesthetics, high doses of propofol can lead to SCD, a condition termed “propofol infusion syndrome”. A Brugada ECG pattern is commonly seen before “propofol infusion syndrome” occurs. Thus BrS is, until proven otherwise, an underlying mechanism for potentially life-threatening arrhythmias and SCD.<a class="elsevierStyleCrossRefs" href="#bib0510">10,87</a>Antiemetic drugsMetoclopramide has been reported to trigger typical BrS ECG features at therapeutic doses, without being involved in serious arrhythmias.<a class="elsevierStyleCrossRef" href="#bib0895">87</a>In a population-based nested case-control study, oral exposure to metoclopramide demonstrated higher risk for developing SCD than oral exposure to domperidone. However, the authors alleged that this was an unexpected outcome and thus recommended further research in this regard.<a class="elsevierStyleCrossRef" href="#bib0830">74</a>Antihistaminic drugsBoth first- and second-generation antihistamines (e.g., diphenhydramine almost exclusively in overdose and terfenadine) have been involved in drug-induced BrS.<a class="elsevierStyleCrossRef" href="#bib0895">87</a>Non-therapeutic drugsType 1 Brugada ECG pattern was documented in a woman with a family history of SCD, who used topical nicotine patches for smoking cessation at high doses.<a class="elsevierStyleCrossRef" href="#bib0920">92</a>Cocaine and alcohol are two well-known triggers of BrS-like ECG pattern and VF, both alone or with cocaethylene, the ensuing metabolite of their combined use.<a class="elsevierStyleCrossRefs" href="#bib0535">15,87</a>Discussion and conclusionsAn increasing number of cardiovascular and non-cardiovascular drugs have been broadly associated with proarrhythmia and SCD. In fact, drug-induced proarrhythmia should always be viewed as a prelude to SCD.<a class="elsevierStyleCrossRef" href="#bib0510">10</a> Hence, it has been a growing challenge for physicians, the regulatory agencies responsible for assessing drug safety and the pharmaceutical industry due to the pressure to create newer and safer agents.<a class="elsevierStyleCrossRef" href="#bib0895">87</a>Physicians should weigh the risks of potentially fatal outcomes against therapeutic benefits when making decisions about drug prescriptions. In the event of a suspicious drug-induced proarrhythmia, withdrawal of the offending drugs is recommended, but only after ruling out other concomitant risk factors.<a class="elsevierStyleCrossRef" href="#bib0520">12</a>Physicians who are aware of inherited arrhythmia syndrome should provide a letter or a similar useful tool to their patients and family members.<a class="elsevierStyleCrossRef" href="#bib0535">15</a> Postema et al. provide an example of such a letter, available in various languages on their website, which contains drugs that should be avoided or contraindicated in BrS patients.<a class="elsevierStyleCrossRef" href="#bib0590">26</a>The uncertainty regarding the correlation between the magnitude of QT interval prolongation and the risk of TdP events should lead to a search for more knowledge on risk stratification of drug-induced TdP, given the possible devastating consequences.Post-approval safety studies provide reliable data for physicians about drug safety. Given the tremendous significance in clinical practice, this review highlights the need for synergy among physicians, regulatory agencies and drug manufacturers, and the need for routine spontaneous reporting and drug utilization analyses.Future studies to obtain further knowledge and a better understanding of genetic variants related to pharmacokinetics and pharmacodynamics are crucial to more accurately predict drug-induced fatal outcomes for at-risk patients and to clarify which drugs can be administrated more safely. This may avoid the inappropriate withdrawal of certain drugs from the market. Undoubtedly, the field of genetics is growing faster than expected, and it will surely play a key role in this major health concern." "textoCompletoSecciones" => array:1 [ "secciones" => array:10 [ 0 => array:3 [ "identificador" => "xres1041011" "titulo" => "Abstract" "secciones" => array:1 [ 0 => array:1 [ "identificador" => "abst0005" ] ] ] 1 => array:2 [ "identificador" => "xpalclavsec994073" "titulo" => "Keywords" ] 2 => array:3 [ "identificador" => "xres1041012" "titulo" => "Resumo" "secciones" => array:1 [ 0 => array:1 [ "identificador" => "abst0010" ] ] ] 3 => array:2 [ "identificador" => "xpalclavsec994072" "titulo" => "Palavras-chave" ] 4 => array:3 [ "identificador" => "sec0005" "titulo" => "Introduction" "secciones" => array:5 [ 0 => array:2 [ "identificador" => "sec0010" "titulo" => "Sudden cardiac death" ] 1 => array:2 [ "identificador" => "sec0015" "titulo" => "Inherited channelopathies" ] 2 => array:2 [ "identificador" => "sec0020" "titulo" => "QT prolongation, torsades de pointes and congenital long QT syndrome" ] 3 => array:2 [ "identificador" => "sec0025" "titulo" => "Short QT syndrome" ] 4 => array:2 [ "identificador" => "sec0030" "titulo" => "Brugada syndrome" ] ] ] 5 => array:2 [ "identificador" => "sec0035" "titulo" => "Aim" ] 6 => array:2 [ "identificador" => "sec0040" "titulo" => "Methods" ] 7 => array:3 [ "identificador" => "sec0045" "titulo" => "Drug-induced proarrhythmia and SCD" "secciones" => array:22 [ 0 => array:2 [ "identificador" => "sec0050" "titulo" => "Drug-induced LQTS" ] 1 => array:2 [ "identificador" => "sec0055" "titulo" => "Antiarrhythmic drugs" ] 2 => array:2 [ "identificador" => "sec0060" "titulo" => "Antianginal drugs" ] 3 => array:2 [ "identificador" => "sec0065" "titulo" => "Antidepressant and antipsychotic drugs" ] 4 => array:2 [ "identificador" => "sec0070" "titulo" => "Antimicrobial drugs" ] 5 => array:2 [ "identificador" => "sec0075" "titulo" => "Anesthetic drugs" ] 6 => array:2 [ "identificador" => "sec0080" "titulo" => "Antiemetic drugs" ] 7 => array:2 [ "identificador" => "sec0085" "titulo" => "Antihistaminic drugs" ] 8 => array:2 [ "identificador" => "sec0090" "titulo" => "Antineoplastic drugs" ] 9 => array:2 [ "identificador" => "sec0095" "titulo" => "Opioid replacement drug therapy" ] 10 => array:2 [ "identificador" => "sec0100" "titulo" => "Attention deficit hyperactivity disorder drug therapy" ] 11 => array:2 [ "identificador" => "sec0105" "titulo" => "Non-therapeutic drugs" ] 12 => array:2 [ "identificador" => "sec0110" "titulo" => "Drug-induced SQTS" ] 13 => array:2 [ "identificador" => "sec0115" "titulo" => "Antiepileptic drugs" ] 14 => array:2 [ "identificador" => "sec0120" "titulo" => "Drug-induced BrS" ] 15 => array:2 [ "identificador" => "sec0125" "titulo" => "Antiarrhythmic drugs" ] 16 => array:2 [ "identificador" => "sec0130" "titulo" => "Antidepressants and antipsychotic drugs" ] 17 => array:2 [ "identificador" => "sec0135" "titulo" => "Epilepsy and antiepileptic drug therapy" ] 18 => array:2 [ "identificador" => "sec0140" "titulo" => "Anesthetic drugs" ] 19 => array:2 [ "identificador" => "sec0145" "titulo" => "Antiemetic drugs" ] 20 => array:2 [ "identificador" => "sec0150" "titulo" => "Antihistaminic drugs" ] 21 => array:2 [ "identificador" => "sec0155" "titulo" => "Non-therapeutic drugs" ] ] ] 8 => array:2 [ "identificador" => "sec0160" "titulo" => "Discussion and conclusions" ] 9 => array:1 [ "titulo" => "References" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "PalabrasClave" => array:2 [ "en" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec994073" "palabras" => array:6 [ 0 => "Sudden cardiac death" 1 => "Long QT syndrome" 2 => "Torsades de pointes" 3 => "Short QT syndrome" 4 => "Brugada syndrome" 5 => "Pharmaceutical preparations" ] ] ] "pt" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Palavras-chave" "identificador" => "xpalclavsec994072" "palabras" => array:6 [ 0 => "Morte súbita cardíaca" 1 => "Síndrome do QT longo" 2 => "Torsades de pointes" 3 => "Síndrome do QT curto" 4 => "Síndrome de Brugada" 5 => "Preparações farmacêuticas" ] ] ] ] "tieneResumen" => true "resumen" => array:2 [ "en" => array:2 [ "titulo" => "Abstract" "resumen" => "Sudden cardiac death is a major public health challenge, which can be caused by genetic or acquired structural or electrophysiological abnormalities. These abnormalities include hereditary channelopathies: long QT, short QT and Brugada syndromes. These syndromes are a notable concern, particularly in young people, due to their high propensity for severe ventricular arrhythmias and sudden cardiac death.Current evidence suggests the involvement of an increasing number of drugs in acquired forms of long QT and Brugada syndromes. However, drug-induced short QT syndrome is still a rarely reported condition. Therefore, there has been speculation on its clinical significance, since few fatal arrhythmias and sudden cardiac death cases have been described so far.Drug-induced proarrhythmia is a growing challenge for physicians, regulatory agencies and the pharmaceutical industry. Physicians should weigh the risks of potentially fatal outcomes against the therapeutic benefits, when making decisions about drug prescriptions. Growing concerns about its safety and the need for more accurate predictive models for drug-induced fatal outcomes justify further research in these fields.The aim of this article is to comprehensively and critically review the recently published evidence with regard to drug-induced life-threatening arrhythmias and sudden cardiac death. This article will take into account the provision of data to physicians that are useful in the identification of the culprit drugs, and thus, contribute to the prompt recognition and management of these serious clinical conditions." ] "pt" => array:2 [ "titulo" => "Resumo" "resumen" => "A morte súbita cardíaca é um desafio significativo para a saúde pública, pode desencadear-se de anormalidades estruturais ou eletrofisiológicas, tanto genéticas como adquiridas, e abranger as assim chamadas canalopatias hereditárias: síndromes do QT longo, QT curto e Brugada. Essas síndromes são um problema considerável, particularmente para os jovens, pela sua elevada propensão para arritmias ventriculares graves e morte súbita cardíaca.A evidência atual sugere o envolvimento de um número crescente de fármacos nas formas adquiridas das síndromes do QT longo e Brugada. No entanto, a síndrome do QT curto induzida por fármacos é ainda uma condição raramente reportada. Consequentemente, especulação tem surgido sobre o seu significado clínico, uma vez que poucos casos de arritmias fatais e de morte súbita cardíaca foram descritos até ao momento.A pró-arritmia induzida por fármacos é um desafio crescente tanto para médicos como para entidades reguladoras e indústria farmacêutica. Os médicos devem pesar o risco de desfechos potencialmente fatais com os benefícios terapêuticos, aquando da tomada de decisões na prescrição de fármacos. As preocupações crescentes sobre a sua segurança e a necessidade de modelos preditivos mais precisos para desfechos fatais induzidos por fármacos justificam pesquisas adicionais nesses domínios.O objetivo deste artigo foi rever, de forma abrangente e crítica, a evidência publicada recentemente, no que diz respeito às arritmias potencialmente fatais e morte súbita cardíaca induzidas por fármacos, tendo em consideração o fornecimento de dados úteis para médicos na identificação dos fármacos responsáveis e, assim, contribuir para o pronto reconhecimento e gestão desses quadros clínicos graves." ] ] "multimedia" => array:3 [ 0 => array:8 [ "identificador" => "tbl0005" "etiqueta" => "Table 1" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at1" "detalle" => "Table " "rol" => "short" ] ] "tabla" => array:3 [ "leyenda" => "Adapted from the website <a class="elsevierStyleInterRef" target="_blank" id="intr0005" href="http://www.crediblemeds.org/">www.crediblemeds.org</a><a class="elsevierStyleCrossRef" href="#bib0585">25</a> (accessed January 12, 2017). For an extensive and systematically updated list of all available evidence about the offending drugs and corresponding TdP risk categories, please visit <a class="elsevierStyleInterRef" target="_blank" id="intr0010" href="http://www.crediblemeds.org/">www.crediblemeds.org</a>.Abbreviations: GI: gastrointestinal; SNRI: serotonin and norepinephrine reuptake inhibitors; SSRI: selective serotonin reuptake inhibitors; TdP: torsades de pointes." "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Drug Class \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Risk category<a class="elsevierStyleCrossRef" href="#tblfn0030">***</a> \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Generic name \t\t\t\t\t\t\n \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="table-entry " rowspan="2" align="left" valign="top">Antianginals</td><td class="td" title="table-entry " align="left" valign="top">Known \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Bepridil<a class="elsevierStyleCrossRef" href="#tblfn0020">§</a><a class="elsevierStyleCrossRefs" href="#bib0510">10,38</a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Conditional \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Ranolazine<a class="elsevierStyleCrossRef" href="#bib0510">10</a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Antiarrhythmics, class Ia \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Known \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Disopyramide,<a class="elsevierStyleCrossRefs" href="#bib0555">19,38</a> Procainamide,<a class="elsevierStyleCrossRef" href="#bib0555">19</a> Quinidine<a class="elsevierStyleCrossRefs" href="#bib0525">13,14,19,27</a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Antiarrhythmics, class III \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Known \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Amiodarone,<a class="elsevierStyleCrossRefs" href="#bib0465">1,10,14,19,27,38,40,42</a><a class="elsevierStyleCrossRef" href="#tblfn0015">‡</a> Dofetilide,<a class="elsevierStyleCrossRefs" href="#bib0530">14,19,27</a> Ibutilide<a class="elsevierStyleCrossRefs" href="#bib0555">19,27,38</a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Antiarrhythmics/Beta blockers \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Known \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Sotalol<a class="elsevierStyleCrossRefs" href="#bib0465">1,10,13,14,19,27,38</a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Antibiotics, macrolides \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Known \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Azithromycin,<a class="elsevierStyleCrossRefs" href="#bib0640">36,42,71</a> Clarithromycin,<a class="elsevierStyleCrossRefs" href="#bib0465">1,27,36</a> Erythromycin<a class="elsevierStyleCrossRefs" href="#bib0465">1,27,36,38,40</a><a class="elsevierStyleCrossRef" href="#tblfn0015">‡</a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Antibiotics, quinolones \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Known \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Ciprofloxacin,<a class="elsevierStyleCrossRef" href="#bib0670">42</a> Grepafloxacin,<a class="elsevierStyleCrossRef" href="#tblfn0020">§</a><a class="elsevierStyleCrossRef" href="#bib0595">27</a> Levofloxacin,<a class="elsevierStyleCrossRefs" href="#bib0670">42,71</a> Moxifloxacin,<a class="elsevierStyleCrossRef" href="#bib0530">14</a> Sparfloxacin<a class="elsevierStyleCrossRef" href="#tblfn0020">§</a><a class="elsevierStyleCrossRef" href="#bib0595">27</a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " rowspan="2" align="left" valign="top">Antiemetics</td><td class="td" title="table-entry " align="left" valign="top">Known \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Domperidone,<a class="elsevierStyleCrossRefs" href="#bib0645">37,73</a> Ondansetron<a class="elsevierStyleCrossRefs" href="#bib0555">19,42,75</a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Possible \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Dolasetron,<a class="elsevierStyleCrossRef" href="#bib0555">19</a> Granisetron<a class="elsevierStyleCrossRef" href="#bib0555">19</a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " rowspan="2" align="left" valign="top">Antifungals</td><td class="td" title="table-entry " align="left" valign="top">Known \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Fluconazole,<a class="elsevierStyleCrossRef" href="#bib0595">27</a> Pentamidine<a class="elsevierStyleCrossRef" href="#bib0650">38</a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Conditional \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Voriconazole<a class="elsevierStyleCrossRef" href="#bib0595">27</a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Antihistamines \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Conditional \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Diphenhydramine<a class="elsevierStyleCrossRef" href="#bib0840">76</a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Antimania \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Possible \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Lithium<a class="elsevierStyleCrossRefs" href="#bib0505">9,38,55,87</a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " rowspan="2" align="left" valign="top">Antimalarials</td><td class="td" title="table-entry " align="left" valign="top">Known \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Halofantrine<a class="elsevierStyleCrossRef" href="#bib0650">38</a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Conditional \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Quinine sulfate<a class="elsevierStyleCrossRef" href="#bib0650">38</a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " rowspan="2" align="left" valign="top">Antineoplastics</td><td class="td" title="table-entry " align="left" valign="top">Known \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Arsenic trioxide,<a class="elsevierStyleCrossRef" href="#bib0845">77</a> Vandetanib<a class="elsevierStyleCrossRef" href="#bib0845">77</a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Possible \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Dasatinib,<a class="elsevierStyleCrossRef" href="#bib0845">77</a> Lapatinib,<a class="elsevierStyleCrossRef" href="#bib0845">77</a> Nilotinib,<a class="elsevierStyleCrossRef" href="#bib0845">77</a> Sunitinib,<a class="elsevierStyleCrossRef" href="#bib0845">77</a> Vemurafenib,<a class="elsevierStyleCrossRefs" href="#bib0845">77,78</a> Vorinostat<a class="elsevierStyleCrossRef" href="#bib0845">77</a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " rowspan="2" align="left" valign="top">Antipsychotics</td><td class="td" title="table-entry " align="left" valign="top">Known \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Haloperidol,<a class="elsevierStyleCrossRefs" href="#bib0500">8,9,14,27,38,40,41,48,53–56,63,67</a> Levomepromazine,<a class="elsevierStyleCrossRefs" href="#bib0500">8,45,48,53,55,63</a> Mesoridazine,<a class="elsevierStyleCrossRef" href="#tblfn0020">§</a><a class="elsevierStyleCrossRef" href="#bib0650">38</a> Pimozide,<a class="elsevierStyleCrossRef" href="#bib0735">55</a> Thioridazine<a class="elsevierStyleCrossRefs" href="#bib0500">8,9,14,38,41,67</a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Possible \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Cyamemazine (cyamepromazine),<a class="elsevierStyleCrossRefs" href="#bib0725">53,54,63</a> Flupentixol,<a class="elsevierStyleCrossRefs" href="#bib0735">55,56</a> Perphenazine<a class="elsevierStyleCrossRef" href="#bib0685">45</a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " rowspan="3" align="left" valign="top">Antipsychotics, atypical</td><td class="td" title="table-entry " align="left" valign="top">Known \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Sulpiride<a class="elsevierStyleCrossRef" href="#bib0735">55</a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Possible \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Aripiprazole,<a class="elsevierStyleCrossRef" href="#bib0740">56</a> Clozapine,<a class="elsevierStyleCrossRefs" href="#bib0650">38,41,53–55,63</a> Iloperidone,<a class="elsevierStyleCrossRef" href="#bib0530">14</a> Paliperidone,<a class="elsevierStyleCrossRefs" href="#bib0650">38,55,66</a> Risperidone,<a class="elsevierStyleCrossRefs" href="#bib0530">14,38,41,53–56,63,65</a> Sertindole,<a class="elsevierStyleCrossRefs" href="#bib0505">9,38,63</a> Tiapride<a class="elsevierStyleCrossRef" href="#bib0740">56</a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Conditional \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Amisulpride,<a class="elsevierStyleCrossRefs" href="#bib0725">53–56,63</a> Olanzapine,<a class="elsevierStyleCrossRefs" href="#bib0530">14,41,53,54,56,63</a> Quetiapine,<a class="elsevierStyleCrossRefs" href="#bib0530">14,27,38,39,41,53–55,63,64</a> Ziprasidone<a class="elsevierStyleCrossRefs" href="#bib0500">8,9,14,38,41,53–55,63</a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " rowspan="2" align="left" valign="top">Antipsychotics/antiemetics</td><td class="td" title="table-entry " align="left" valign="top">Known \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Chlorpromazine,<a class="elsevierStyleCrossRefs" href="#bib0500">8,38,45,53,54,63</a> Droperidol<a class="elsevierStyleCrossRefs" href="#bib0555">19,53,54</a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Possible \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Promethazine<a class="elsevierStyleCrossRef" href="#bib0685">45</a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">GI stimulants \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Known \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Cisapride,<a class="elsevierStyleCrossRef" href="#tblfn0020">§</a><a class="elsevierStyleCrossRef" href="#bib0510">10</a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">General anesthetics \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Known \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Sevoflurane<a class="elsevierStyleCrossRefs" href="#bib0555">19,72</a><a class="elsevierStyleCrossRef" href="#tblfn0015">‡</a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Opioid agonists \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Known \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Levomethadyl acetate,<a class="elsevierStyleCrossRef" href="#tblfn0020">§</a><a class="elsevierStyleCrossRef" href="#bib0555">19</a> Methadone<a class="elsevierStyleCrossRefs" href="#bib0505">9,14,19,34,35,55</a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Opioid receptor modulator \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Possible \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Buprenorphine<a class="elsevierStyleCrossRef" href="#bib0555">19</a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Psychostimulants \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Possible \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Atomoxetine<a class="elsevierStyleCrossRef" href="#bib0855">79</a><a class="elsevierStyleCrossRef" href="#tblfn0010">†</a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">SNRI antidepressants \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Possible \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Venlafaxine<a class="elsevierStyleCrossRefs" href="#bib0650">38,41,50,55</a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " rowspan="2" align="left" valign="top">SSRI antidepressants</td><td class="td" title="table-entry " align="left" valign="top">Known \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Citalopram,<a class="elsevierStyleCrossRefs" href="#bib0500">8,27,41,46–48,55</a> Escitalopram<a class="elsevierStyleCrossRefs" href="#bib0500">8,27,38,41,46,48,55</a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Conditional \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Fluoxetine,<a class="elsevierStyleCrossRef" href="#bib0665">41</a> Sertraline<a class="elsevierStyleCrossRef" href="#bib0665">41</a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " rowspan="2" align="left" valign="top">Tricyclic antidepressants</td><td class="td" title="table-entry " align="left" valign="top">Possible \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Clomipramine,<a class="elsevierStyleCrossRefs" href="#bib0685">45,55</a> Desipramine,<a class="elsevierStyleCrossRef" href="#bib0685">45</a> Imipramine (melipramine),<a class="elsevierStyleCrossRefs" href="#bib0665">41,45,55</a> Nortriptyline<a class="elsevierStyleCrossRefs" href="#bib0665">41,45,55</a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Conditional \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Amitriptyline,<a class="elsevierStyleCrossRefs" href="#bib0685">45,55</a> Doxepin<a class="elsevierStyleCrossRef" href="#bib0735">55</a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Other therapeutic drugs \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Not applicable<a class="elsevierStyleCrossRef" href="#tblfn0005">*</a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Amoxapine,<a class="elsevierStyleCrossRef" href="#bib0685">45</a> Atropine,<a class="elsevierStyleCrossRef" href="#bib0555">19</a> Bromperidol,<a class="elsevierStyleCrossRef" href="#bib0725">53</a> Bupropion,<a class="elsevierStyleCrossRef" href="#bib0710">50</a><a class="elsevierStyleCrossRef" href="#tblfn0010">†</a> Cetirizine,<a class="elsevierStyleCrossRef" href="#bib0840">76</a> Chlorprothixene,<a class="elsevierStyleCrossRefs" href="#bib0725">53,55,63</a> Clotiapine,<a class="elsevierStyleCrossRef" href="#bib0700">48</a> Depsipeptide,<a class="elsevierStyleCrossRef" href="#bib0845">77</a> Desflurane,<a class="elsevierStyleCrossRef" href="#bib0555">19</a> Desloratadine,<a class="elsevierStyleCrossRef" href="#bib0840">76</a> Enflurane,<a class="elsevierStyleCrossRef" href="#bib0555">19</a> Fexofenadine,<a class="elsevierStyleCrossRef" href="#bib0840">76</a> Fluphenazine,<a class="elsevierStyleCrossRefs" href="#bib0725">53,63</a> Ganciclovir,<a class="elsevierStyleCrossRef" href="#bib0740">56</a> Glycopyrrolate,<a class="elsevierStyleCrossRef" href="#bib0555">19</a> Halothane,<a class="elsevierStyleCrossRef" href="#bib0555">19</a> Hydroquinidine,<a class="elsevierStyleCrossRef" href="#bib0650">38</a> Isoflurane,<a class="elsevierStyleCrossRef" href="#bib0555">19</a> Levocetirizine,<a class="elsevierStyleCrossRef" href="#bib0740">56</a> Loratadine,<a class="elsevierStyleCrossRef" href="#bib0840">76</a> Mizolastine,<a class="elsevierStyleCrossRef" href="#bib0650">38</a> Moclobemide,<a class="elsevierStyleCrossRef" href="#bib0735">55</a> Nitric oxide,<a class="elsevierStyleCrossRef" href="#bib0820">72</a><a class="elsevierStyleCrossRef" href="#tblfn0015">‡</a> Oxatomide,<a class="elsevierStyleCrossRef" href="#bib0740">56</a> Oxycodone,<a class="elsevierStyleCrossRef" href="#bib0555">19</a> Pentobarbital,<a class="elsevierStyleCrossRef" href="#bib0510">10</a> Pilsicainide,<a class="elsevierStyleCrossRef" href="#bib0675">43</a> Promazine,<a class="elsevierStyleCrossRef" href="#bib0700">48</a> Propericiazine,<a class="elsevierStyleCrossRef" href="#bib0685">45</a> Propoxyphene,<a class="elsevierStyleCrossRef" href="#tblfn0020">§</a><a class="elsevierStyleCrossRef" href="#bib0555">19</a> Prothipendyl,<a class="elsevierStyleCrossRef" href="#bib0725">53</a> Succinylcholine,<a class="elsevierStyleCrossRef" href="#bib0555">19</a> Verapamil,<a class="elsevierStyleCrossRef" href="#bib0655">39</a> Zuclopenthixol<a class="elsevierStyleCrossRef" href="#bib0725">53</a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Non-therapeutic drugs \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Not applicable<a class="elsevierStyleCrossRef" href="#tblfn0005">*</a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Alcohol,<a class="elsevierStyleCrossRef" href="#bib0870">82</a><a class="elsevierStyleCrossRef" href="#tblfn0025">**</a> Ginseng,<a class="elsevierStyleCrossRef" href="#bib0875">83</a> Licorice root compounds (glycyrrhizin, flavones)<a class="elsevierStyleCrossRef" href="#bib0880">84</a> \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab1768152.png" ] ] ] "notaPie" => array:6 [ 0 => array:3 [ "identificador" => "tblfn0005" "etiqueta" => "*" "nota" => "Not included in the original drug list of CredibleMeds." ] 1 => array:3 [ "identificador" => "tblfn0010" "etiqueta" => "†" "nota" => "Only in Overdose." ] 2 => array:3 [ "identificador" => "tblfn0015" "etiqueta" => "‡" "nota" => "Concomitant use of QT-prolonging drugs." ] 3 => array:3 [ "identificador" => "tblfn0020" "etiqueta" => "§" "nota" => "Removed from market." ] 4 => array:3 [ "identificador" => "tblfn0025" "etiqueta" => "**" "nota" => "Only in binge drinking (i.e., ≥5 alcoholic beverages in one day, during the previous 12 months)." ] 5 => array:3 [ "identificador" => "tblfn0030" "etiqueta" => "***" "nota" => "TdP risk categories." ] ] ] "descripcion" => array:1 [ "en" => "Agents implicated in drug-induced QT prolongation and/or torsades de pointes." ] ] 1 => array:8 [ "identificador" => "tbl0010" "etiqueta" => "Table 2" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at2" "detalle" => "Table " "rol" => "short" ] ] "tabla" => array:2 [ "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Drug class \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Generic name \t\t\t\t\t\t\n \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Antiarrhythmics \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Digitalis<a class="elsevierStyleCrossRef" href="#bib0555">19</a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Antiepileptics \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Rufinamide,<a class="elsevierStyleCrossRefs" href="#bib0510">10,86</a> Lamotrigine,<a class="elsevierStyleCrossRef" href="#bib0890">86</a><a class="elsevierStyleCrossRef" href="#tblfn0035">*</a> Valproic acid<a class="elsevierStyleCrossRef" href="#bib0890">86</a><a class="elsevierStyleCrossRef" href="#tblfn0035">*</a> \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab1768151.png" ] ] ] "notaPie" => array:1 [ 0 => array:3 [ "identificador" => "tblfn0035" "etiqueta" => "*" "nota" => "Combined with rufinamide." ] ] ] "descripcion" => array:1 [ "en" => "Agents implicated in drug-induced QT shortening and/or life-threatening arrhythmias." ] ] 2 => array:8 [ "identificador" => "tbl0015" "etiqueta" => "Table 3" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at3" "detalle" => "Table " "rol" => "short" ] ] "tabla" => array:3 [ "leyenda" => "Adapted from the website <a class="elsevierStyleInterRef" target="_blank" id="intr0015" href="http://www.brugadadrugs.org/">www.brugadadrugs.org</a><a class="elsevierStyleCrossRef" href="#bib0590">26</a> (accessed January 12, 2017). For an extensive and systematically updated list of all available evidence about the offending drugs, corresponding risk categories and classes of recommendation, please visit <a class="elsevierStyleInterRef" target="_blank" id="intr0020" href="http://www.brugadadrugs.org/">www.brugadadrugs.org</a>.Abbreviations: SSRI: selective serotonin reuptake inhibitors." "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Drug class \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Risk category<a class="elsevierStyleCrossRef" href="#tblfn0040">*</a> \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Generic name \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Class \t\t\t\t\t\t\n \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="table-entry " rowspan="2" align="left" valign="top">Anesthetics/analgesics</td><td class="td" title="table-entry " align="left" valign="top">To be avoided \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Bupivacaine,<a class="elsevierStyleCrossRefs" href="#bib0510">10,21,23,87</a> Procaine,<a class="elsevierStyleCrossRefs" href="#bib0565">21,23,87</a><a class="elsevierStyleCrossRef" href="#tblfn0045">†</a> Propofol<a class="elsevierStyleCrossRefs" href="#bib0510">10,21,23,87</a><a class="elsevierStyleCrossRef" href="#tblfn0045">†</a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">IIa \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Preferentially avoided \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Ketamine<a class="elsevierStyleCrossRef" href="#bib0895">87</a><a class="elsevierStyleCrossRef" href="#tblfn0045">†</a> Tramadol<a class="elsevierStyleCrossRef" href="#bib0895">87</a><a class="elsevierStyleCrossRef" href="#tblfn0045">†</a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">IIb \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Antianginals \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Not to be avoided \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Diltiazem,<a class="elsevierStyleCrossRef" href="#bib0565">21</a> Nicorandil,<a class="elsevierStyleCrossRef" href="#bib0565">21</a> Nifedipine,<a class="elsevierStyleCrossRef" href="#bib0565">21</a> Nitroglycerine<a class="elsevierStyleCrossRef" href="#bib0565">21</a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">III \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " rowspan="2" align="left" valign="top">Antiarrhythmics, class Ia</td><td class="td" title="table-entry " align="left" valign="top">To be avoided \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Ajmaline,<a class="elsevierStyleCrossRefs" href="#bib0495">7,10,15,21,23,63,87</a> Procainamide<a class="elsevierStyleCrossRefs" href="#bib0495">7,10,15,21,23,87</a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">I \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Preferentially avoided \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Cibenzoline,<a class="elsevierStyleCrossRef" href="#bib0565">21</a> Disopyramide<a class="elsevierStyleCrossRef" href="#bib0565">21</a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">IIb \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " rowspan="2" align="left" valign="top">Antiarrhythmics, class Ic</td><td class="td" title="table-entry " rowspan="2" align="left" valign="top">To be avoided</td><td class="td" title="table-entry " align="left" valign="top">Flecainide,<a class="elsevierStyleCrossRefs" href="#bib0495">7,10,15,21,23,63,87</a> Pilsicainide<a class="elsevierStyleCrossRefs" href="#bib0495">7,10,15,21,23,87</a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">I \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Propafenone<a class="elsevierStyleCrossRefs" href="#bib0510">10,21</a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">IIa \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Antiarrhythmics, class III (also Ia, II and IV effects) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Preferentially avoided \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Amiodarone<a class="elsevierStyleCrossRef" href="#bib0905">89</a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">IIb \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Antiarrhythmics, class IV \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Preferentially avoided \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Verapamil<a class="elsevierStyleCrossRef" href="#bib0565">21</a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">IIb \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Antiemetics \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Preferentially avoided \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Dimenhydrinate,<a class="elsevierStyleCrossRefs" href="#bib0565">21,87</a> Metoclopramide<a class="elsevierStyleCrossRef" href="#bib0895">87</a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">IIb \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " rowspan="2" align="left" valign="top">Antiepileptics</td><td class="td" title="table-entry " align="left" valign="top">To be avoided \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Oxcarbazepine<a class="elsevierStyleCrossRefs" href="#bib0565">21,87</a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">IIa \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Preferentially avoided \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Carbamazepine,<a class="elsevierStyleCrossRef" href="#bib0915">91</a><a class="elsevierStyleCrossRef" href="#tblfn0050">‡</a> Lamotrigine,<a class="elsevierStyleCrossRef" href="#bib0915">91</a><a class="elsevierStyleCrossRef" href="#tblfn0050">‡</a> Phenytoin<a class="elsevierStyleCrossRef" href="#bib0915">91</a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">IIb \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Antihistamines \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Preferentially avoided \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Diphenhydramine,<a class="elsevierStyleCrossRef" href="#bib0895">87</a><a class="elsevierStyleCrossRef" href="#tblfn0045">†</a> Terfenadine/Fexofenadine<a class="elsevierStyleCrossRef" href="#bib0895">87</a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">IIb \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " rowspan="2" align="left" valign="top">Antipsychotics</td><td class="td" title="table-entry " align="left" valign="top">To be avoided \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Loxapine,<a class="elsevierStyleCrossRefs" href="#bib0565">21,87</a> Trifluoperazine<a class="elsevierStyleCrossRefs" href="#bib0565">21,87</a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">IIa \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Preferentially avoided \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Cyamemazine,<a class="elsevierStyleCrossRefs" href="#bib0565">21,38,87</a><a class="elsevierStyleCrossRef" href="#tblfn0045">†</a> Perphenazine,<a class="elsevierStyleCrossRefs" href="#bib0565">21,87</a><a class="elsevierStyleCrossRef" href="#tblfn0045">†</a> Thioridazine<a class="elsevierStyleCrossRef" href="#bib0895">87</a><a class="elsevierStyleCrossRef" href="#tblfn0045">†</a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">IIb \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">SSRI antidepressants \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Preferentially avoided \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Fluoxetine,<a class="elsevierStyleCrossRefs" href="#bib0565">21,38,87</a><a class="elsevierStyleCrossRef" href="#tblfn0045">†</a> Fluvoxamine,<a class="elsevierStyleCrossRef" href="#bib0895">87</a> Paroxetine<a class="elsevierStyleCrossRef" href="#bib0895">87</a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">IIb \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Tetracyclic Antidepressants \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Preferentially avoided \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Maprotiline<a class="elsevierStyleCrossRefs" href="#bib0565">21,38,87</a><a class="elsevierStyleCrossRef" href="#tblfn0045">†</a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">IIb \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " rowspan="2" align="left" valign="top">Tricyclic Antidepressants</td><td class="td" title="table-entry " align="left" valign="top">To be avoided \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Amytriptiline,<a class="elsevierStyleCrossRefs" href="#bib0565">21,87</a><a class="elsevierStyleCrossRef" href="#tblfn0045">†</a> Clomipramine,<a class="elsevierStyleCrossRefs" href="#bib0565">21,38,87</a><a class="elsevierStyleCrossRef" href="#tblfn0045">†</a> Desipramine,<a class="elsevierStyleCrossRefs" href="#bib0565">21,87</a><a class="elsevierStyleCrossRef" href="#tblfn0045">†</a> Nortriptyline<a class="elsevierStyleCrossRefs" href="#bib0485">5,21</a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">IIa \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Preferentially avoided \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Dosulepin,<a class="elsevierStyleCrossRef" href="#bib0895">87</a><a class="elsevierStyleCrossRef" href="#tblfn0045">†</a> Doxepin,<a class="elsevierStyleCrossRef" href="#bib0895">87</a><a class="elsevierStyleCrossRef" href="#tblfn0045">†</a> Imipramine<a class="elsevierStyleCrossRef" href="#bib0895">87</a><a class="elsevierStyleCrossRef" href="#tblfn0045">†</a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">IIb \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Other antidepressants \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">To be avoided \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Lithium<a class="elsevierStyleCrossRefs" href="#bib0510">10,23,38</a><a class="elsevierStyleCrossRef" href="#tblfn0050">‡</a><a class="elsevierStyleCrossRef" href="#bib0895">87</a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">IIb \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " rowspan="3" align="left" valign="top">Substances</td><td class="td" title="table-entry " rowspan="2" align="left" valign="top">To be avoided</td><td class="td" title="table-entry " align="left" valign="top">Acetylcholine,<a class="elsevierStyleCrossRefs" href="#bib0535">15,21,87</a> Cocaine<a class="elsevierStyleCrossRefs" href="#bib0510">10,15,21</a><a class="elsevierStyleCrossRef" href="#tblfn0045">†</a><a class="elsevierStyleCrossRefs" href="#bib0575">23,87</a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">IIa \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Alcohol,<a class="elsevierStyleCrossRef" href="#tblfn0045">†</a><a class="elsevierStyleCrossRefs" href="#bib0535">15,21,23,87</a> Cannabis,<a class="elsevierStyleCrossRefs" href="#bib0565">21,23</a> Ergonovine<a class="elsevierStyleCrossRefs" href="#bib0535">15,21,23,87</a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">IIb \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Preferentially avoided \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Edrophonium<a class="elsevierStyleCrossRef" href="#bib0895">87</a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">IIb \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Other drugs \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Not applicable<a class="elsevierStyleCrossRef" href="#tblfn0040">*</a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Isosorbide dinitrate,<a class="elsevierStyleCrossRef" href="#bib0565">21</a> Nicotine<a class="elsevierStyleCrossRef" href="#bib0920">92</a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Not applicable<a class="elsevierStyleCrossRef" href="#tblfn0040">*</a> \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab1768150.png" ] ] ] "notaPie" => array:3 [ 0 => array:3 [ "identificador" => "tblfn0040" "etiqueta" => "*" "nota" => "Not included in the original drug list." ] 1 => array:3 [ "identificador" => "tblfn0045" "etiqueta" => "†" "nota" => "Only in Overdose." ] 2 => array:3 [ "identificador" => "tblfn0050" "etiqueta" => "‡" "nota" => "Concomitant drug use." ] ] ] "descripcion" => array:1 [ "en" => "Agents implicated in drug-induced Brugada ECG pattern and/or life-threatening arrhythmias in Brugada syndrome patients." ] ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0015" "bibliografiaReferencia" => array:92 [ 0 => array:3 [ "identificador" => "bib0465" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC) Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC)" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ …3] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1093/europace/euv319" "Revista" => array:6 [ "tituloSerie" => "Europace" "fecha" => "2015" "volumen" => "17" "paginaInicial" => "1601" "paginaFinal" => "1687" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0470" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Sudden cardiac death in young adult" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ …3] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s12012-014-9255-1" "Revista" => array:6 [ "tituloSerie" => "Cardiovasc Toxicol" "fecha" => "2014" "volumen" => "14" "paginaInicial" => "379" "paginaFinal" => "386" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0475" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Ventricular arrhythmias and sudden cardiac death" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ …3] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/S0140-6736(12)61413-5" "Revista" => array:6 [ "tituloSerie" => "Lancet" "fecha" => "2012" "volumen" => "380" "paginaInicial" => "1520" "paginaFinal" => "1529" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0480" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Pathophysiology and prevention of sudden cardiac death" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ …3] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1139/cjpp-2015-0366" "Revista" => array:6 [ "tituloSerie" => "Can J Physiol Pharmacol" "fecha" => "2016" "volumen" => "94" "paginaInicial" => "237" "paginaFinal" => "244" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0485" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Sudden cardiac arrest associated with use of a non-cardiac drug that reduces cardiac excitability: evidence from bench, bedside, and community" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ …3] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1093/eurheartj/eht054" "Revista" => array:6 [ "tituloSerie" => "Eur Heart J" "fecha" => "2013" "volumen" => "34" "paginaInicial" => "1506" "paginaFinal" => "1516" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib0490" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Antipsychotic drugs are associated with pulseless electrical activity: the Oregon Sudden Unexpected Death Study" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ …3] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.hrthm.2012.12.002" "Revista" => array:6 [ "tituloSerie" => "Heart Rhythm" "fecha" => "2013" "volumen" => "10" "paginaInicial" => "526" "paginaFinal" => "530" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib0495" "etiqueta" => "7" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Ventricular arrhythmias in the absence of structural heart disease" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ …3] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jacc.2012.01.036" "Revista" => array:6 [ "tituloSerie" => "J Am Coll Cardiol" "fecha" => "2012" "volumen" => "59" "paginaInicial" => "1733" "paginaFinal" => "1744" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bib0500" "etiqueta" => "8" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Antipsychotic medication and QT prolongation" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ …3] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.12669/pjms.315.8998" "Revista" => array:6 [ "tituloSerie" => "Pak J Med Sci" "fecha" => "2015" "volumen" => "31" "paginaInicial" => "1269" "paginaFinal" => "1271" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bib0505" "etiqueta" => "9" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Assessing QT interval prolongation and its associated risks with antipsychotics" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ …3] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.2165/11587800-000000000-00000" "Revista" => array:6 [ "tituloSerie" => "CNS Drugs" "fecha" => "2011" "volumen" => "25" "paginaInicial" => "473" "paginaFinal" => "490" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 9 => array:3 [ "identificador" => "bib0510" "etiqueta" => "10" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Mechanisms of drug-induced proarrhythmia in clinical practice" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ …3] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.4330/wjc.v5.i6.175" "Revista" => array:6 [ "tituloSerie" => "World J Cardiol" "fecha" => "2013" "volumen" => "5" "paginaInicial" => "175" "paginaFinal" => "185" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 10 => array:3 [ "identificador" => "bib0515" "etiqueta" => "11" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ …3] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jacc.2010.01.001" "Revista" => array:6 [ "tituloSerie" => "J Am Coll Cardiol" "fecha" => "2010" "volumen" => "55" "paginaInicial" => "934" "paginaFinal" => "947" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 11 => array:3 [ "identificador" => "bib0520" "etiqueta" => "12" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Drug-induced prolongation of the QT interval" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ …1] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMra032426" "Revista" => array:6 [ "tituloSerie" => "N Engl J Med" "fecha" => "2004" "volumen" => "350" "paginaInicial" => "1013" "paginaFinal" => "1022" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 12 => array:3 [ "identificador" => "bib0525" "etiqueta" => "13" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Unveiling specific triggers and precipitating factors for fatal cardiac events in inherited arrhythmia syndromes" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ …3] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1253/circj.CJ-15-0322" "Revista" => array:6 [ "tituloSerie" => "Circ J" "fecha" => "2015" "volumen" => "79" "paginaInicial" => "1185" "paginaFinal" => "1192" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 13 => array:3 [ "identificador" => "bib0530" "etiqueta" => "14" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Pharmacogenetics of drug-induced QT interval prolongation: an update" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ …3] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s40264-015-0316-6" "Revista" => array:6 [ "tituloSerie" => "Drug Saf" "fecha" => "2015" "volumen" => "38" "paginaInicial" => "855" "paginaFinal" => "867" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 14 => array:3 [ "identificador" => "bib0535" "etiqueta" => "15" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Cardiac sodium channels and inherited electrophysiological disorders: an update on the pharmacotherapy" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ …3] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1517/14656566.2014.936380" "Revista" => array:6 [ "tituloSerie" => "Expert Opin Pharmacother" "fecha" => "2014" "volumen" => "15" "paginaInicial" => "1875" "paginaFinal" => "1887" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 15 => array:3 [ "identificador" => "bib0540" "etiqueta" => "16" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies: this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA)" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ …3] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1093/europace/eur245" "Revista" => array:6 [ "tituloSerie" => "Europace" "fecha" => "2011" "volumen" => "13" "paginaInicial" => "1077" "paginaFinal" => "1109" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 16 => array:3 [ "identificador" => "bib0545" "etiqueta" => "17" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "QTc behavior during exercise and genetic testing for the long-QT syndrome" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ …2] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1161/CIRCULATIONAHA.111.062182" "Revista" => array:6 [ "tituloSerie" => "Circulation" "fecha" => "2011" "volumen" => "124" "paginaInicial" => "2181" "paginaFinal" => "2184" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 17 => array:3 [ "identificador" => "bib0550" "etiqueta" => "18" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Idiopathic short QT interval: a new clinical syndrome?" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ …3] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1159/000047299" "Revista" => array:6 [ "tituloSerie" => "Cardiology" "fecha" => "2000" "volumen" => "94" "paginaInicial" => "99" "paginaFinal" => "102" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 18 => array:3 [ "identificador" => "bib0555" "etiqueta" => "19" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Sudden cardiac death and disorders of the QT interval: anesthetic implications and focus on perioperative management" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ …3] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1053/j.jvca.2015.07.026" "Revista" => array:6 [ "tituloSerie" => "J Cardiothorac Vasc Anesth" "fecha" => "2015" "volumen" => "29" "paginaInicial" => "1723" "paginaFinal" => "1733" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 19 => array:3 [ "identificador" => "bib0560" "etiqueta" => "20" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Right bundle branch block, persistent ST segment elevation and sudden cardiac death: a distinct clinical and electrocardiographic syndrome. A multicenter report" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ …2] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "J Am Coll Cardiol" "fecha" => "1992" "volumen" => "20" "paginaInicial" => "1391" "paginaFinal" => "1396" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 20 => array:3 [ "identificador" => "bib0565" "etiqueta" => "21" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Brugada syndrome: clinical, genetic, molecular, cellular, and ionic aspects" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ …2] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.cpcardiol.2015.06.002" "Revista" => array:6 [ "tituloSerie" => "Curr Probl Cardiol" "fecha" => "2016" "volumen" => "41" "paginaInicial" => "7" "paginaFinal" => "57" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 21 => array:3 [ "identificador" => "bib0570" "etiqueta" => "22" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Genetics of Brugada syndrome" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ …2] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.joa.2016.07.012" "Revista" => array:6 [ "tituloSerie" => "J Arrhythm" "fecha" => "2016" "volumen" => "32" "paginaInicial" => "418" "paginaFinal" => "425" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 22 => array:3 [ "identificador" => "bib0575" "etiqueta" => "23" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "J-Wave syndromes expert consensus conference report: emerging concepts and gaps in knowledge: endorsed by the Asia Pacific Heart Rhythm Society (APHRS), the European Heart Rhythm Association (EHRA), the Heart Rhythm Society (HRS), and the Latin American Society of Cardiac Pacing and Electrophysiology (Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología [SOLAECE])" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ …3] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:2 [ "tituloSerie" => "Europace" "fecha" => "2016" ] ] ] ] ] ] 23 => array:3 [ "identificador" => "bib0580" "etiqueta" => "24" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes: document endorsed by HRS, EHRA, and APHRS in May 2013 and by ACCF, AHA, PACES, and AEPC in June 2013" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ …3] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.hrthm.2013.05.014" "Revista" => array:7 [ "tituloSerie" => "Heart Rhythm" "fecha" => "2013" "volumen" => "10" "paginaInicial" => "1932" "paginaFinal" => "1963" "link" => array:1 [ 0 => array:2 [ …2] ] "itemHostRev" => array:3 [ "pii" => "S0007091217311571" "estado" => "S300" "issn" => "00070912" ] ] ] ] ] ] ] 24 => array:3 [ "identificador" => "bib0585" "etiqueta" => "25" "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Woosley R, Heise CW, Romero KA. QTdrugs List. AZCERT, Inc., 1822 Innovation Park Dr., Oro Valley, AZ 85755. <a id="intr0045" class="elsevierStyleInterRef" href="http://www.crediblemeds.org/">www.CredibleMeds.org</a> [accessed 12.01.17]." ] ] ] 25 => array:3 [ "identificador" => "bib0590" "etiqueta" => "26" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Safe drug use in long QT syndrome and Brugada syndrome: comparison of website statistics" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ …3] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1093/europace/eut018" "Revista" => array:6 [ "tituloSerie" => "Europace" "fecha" => "2013" "volumen" => "15" "paginaInicial" => "1042" "paginaFinal" => "1049" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 26 => array:3 [ "identificador" => "bib0595" "etiqueta" => "27" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Drug-induced proarrhythmia: risk factors and electrophysiological mechanisms" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ …2] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1038/nrcardio.2015.110" "Revista" => array:6 [ "tituloSerie" => "Nat Rev Cardiol" "fecha" => "2016" "volumen" => "13" "paginaInicial" => "36" "paginaFinal" => "47" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 27 => array:3 [ "identificador" => "bib0600" "etiqueta" => "28" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Genetics of congenital and drug-induced long QT syndromes: current evidence and future research perspectives" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ …3] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s10840-013-9779-5" "Revista" => array:6 [ "tituloSerie" => "J Interv Card Electrophysiol" "fecha" => "2013" "volumen" => "37" "paginaInicial" => "9" "paginaFinal" => "19" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 28 => array:3 [ "identificador" => "bib0605" "etiqueta" => "29" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Effect of smoking on Tp-e interval, Tp-e/QT and Tp-e/QTc ratios as indices of ventricular arrhythmogenesis" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ …3] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.hlc.2014.03.016" "Revista" => array:7 [ "tituloSerie" => "Heart Lung Circ" "fecha" => "2014" "volumen" => "23" "paginaInicial" => "827" "paginaFinal" => "832" "link" => array:1 [ 0 => array:2 [ …2] ] "itemHostRev" => array:3 [ "pii" => "S0007091217337686" "estado" => "S300" "issn" => "00070912" ] ] ] ] ] ] ] 29 => array:3 [ "identificador" => "bib0610" "etiqueta" => "30" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The effects of cigarette smoking on the Tp-e interval, Tp-e/QT ratio and Tp-e/QTc ratio" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ …3] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Adv Clin Exp Med" "fecha" => "2015" "volumen" => "24" "paginaInicial" => "973" "paginaFinal" => "978" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 30 => array:3 [ "identificador" => "bib0615" "etiqueta" => "31" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Impact of psychotropic drugs on QT interval dispersion in adult patients" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ …3] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Arq Bras Cardiol" "fecha" => "2014" "volumen" => "102" "paginaInicial" => "465" "paginaFinal" => "472" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 31 => array:3 [ "identificador" => "bib0620" "etiqueta" => "32" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Psychiatric medications and sudden cardiac death: putting the risk in perspective" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ …1] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.3928/02793695-20150527-55" "Revista" => array:6 [ "tituloSerie" => "J Psychosoc Nurs Ment Health Serv" "fecha" => "2015" "volumen" => "53" "paginaInicial" => "23" "paginaFinal" => "25" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 32 => array:3 [ "identificador" => "bib0625" "etiqueta" => "33" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Non-cardiovascular drugs that inhibit hERG-encoded potassium channels and risk of sudden cardiac death" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ …3] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1136/hrt.2009.188367" "Revista" => array:6 [ "tituloSerie" => "Heart" "fecha" => "2011" "volumen" => "97" "paginaInicial" => "215" "paginaFinal" => "220" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 33 => array:3 [ "identificador" => "bib0630" "etiqueta" => "34" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "A possible mechanistic link between the CYP2C19 genotype, the methadone metabolite ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidene (EDDP), and methadone-induced corrected QT interval prolongation in a pilot study" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ …3] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s40291-015-0137-4" "Revista" => array:6 [ "tituloSerie" => "Mol Diagn Ther" "fecha" => "2015" "volumen" => "19" "paginaInicial" => "131" "paginaFinal" => "138" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 34 => array:3 [ "identificador" => "bib0635" "etiqueta" => "35" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "QT interval prolongation: prevalence, risk factors and pharmacovigilance data among methadone-treated patients in France" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ …3] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1472-8206.2010.00871.x" "Revista" => array:6 [ "tituloSerie" => "Fundam Clin Pharmacol" "fecha" => "2011" "volumen" => "25" "paginaInicial" => "503" "paginaFinal" => "510" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 35 => array:3 [ "identificador" => "bib0640" "etiqueta" => "36" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The role of macrolide antibiotics in increasing cardiovascular risk" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ …3] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jacc.2015.09.029" "Revista" => array:6 [ "tituloSerie" => "J Am Coll Cardiol" "fecha" => "2015" "volumen" => "66" "paginaInicial" => "2173" "paginaFinal" => "2184" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 36 => array:3 [ "identificador" => "bib0645" "etiqueta" => "37" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Domperidone in Parkinson's disease: a perilous arrhythmogenic or the gold standard?" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ …3] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Curr Drug Saf" "fecha" => "2013" "volumen" => "8" "paginaInicial" => "63" "paginaFinal" => "68" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 37 => array:3 [ "identificador" => "bib0650" "etiqueta" => "38" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Sudden death of cardiac origin and psychotropic drugs" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ …3] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.3389/fphar.2012.00076" "Revista" => array:5 [ "tituloSerie" => "Front Pharmacol" "fecha" => "2012" "volumen" => "3" "paginaInicial" => "76" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 38 => array:3 [ "identificador" => "bib0655" "etiqueta" => "39" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Nitric oxide synthase 1 adaptor protein, an emerging new genetic marker for QT prolongation and sudden cardiac death" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ …3] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Acta Cardiol Sin" "fecha" => "2013" "volumen" => "29" "paginaInicial" => "217" "paginaFinal" => "225" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 39 => array:3 [ "identificador" => "bib0660" "etiqueta" => "40" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Drug-induced long QT syndrome and fatal arrhythmias in the intensive care unit" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ …3] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/aas.12257" "Revista" => array:7 [ "tituloSerie" => "Acta Anaesthesiol Scand" "fecha" => "2014" "volumen" => "58" "paginaInicial" => "266" "paginaFinal" => "272" "link" => array:1 [ 0 => array:2 [ …2] ] "itemHostRev" => array:3 [ …3] ] ] ] ] ] ] 40 => array:3 [ "identificador" => "bib0665" "etiqueta" => "41" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Impact of age and sex on QT prolongation in patients receiving psychotropics" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1177/070674371506000502" "Revista" => array:6 [ "tituloSerie" => "Can J Psychiatry" "fecha" => "2015" "volumen" => "60" "paginaInicial" => "206" "paginaFinal" => "214" "link" => array:1 [ …1] ] ] ] ] ] ] 41 => array:3 [ "identificador" => "bib0670" "etiqueta" => "42" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Acquired long QT syndrome: frequency, onset, and risk factors in intensive care patients" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.4037/ccn2012900" "Revista" => array:6 [ "tituloSerie" => "Crit Care Nurse" "fecha" => "2012" "volumen" => "32" "paginaInicial" => "32" "paginaFinal" => "41" "link" => array:1 [ …1] ] ] ] ] ] ] 42 => array:3 [ "identificador" => "bib0675" "etiqueta" => "43" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "A case of sudden cardiac death due to pilsicainide-induced torsades de pointes" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.4070/kcj.2014.44.2.122" "Revista" => array:6 [ "tituloSerie" => "Korean Circ J" "fecha" => "2014" "volumen" => "44" "paginaInicial" => "122" "paginaFinal" => "124" "link" => array:1 [ …1] ] ] ] ] ] ] 43 => array:3 [ "identificador" => "bib0680" "etiqueta" => "44" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The risk of sudden cardiac death in patients with non-ST elevation acute coronary syndrome and prolonged QTc interval: effect of ranolazine" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1093/europace/eus400" "Revista" => array:6 [ "tituloSerie" => "Europace" "fecha" => "2013" "volumen" => "15" "paginaInicial" => "429" "paginaFinal" => "436" "link" => array:1 [ …1] ] ] ] ] ] ] 44 => array:3 [ "identificador" => "bib0685" "etiqueta" => "45" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Risk factors for QT prolongation associated with acute psychotropic drug overdose" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.ajem.2014.09.048" "Revista" => array:6 [ "tituloSerie" => "Am J Emerg Med" "fecha" => "2015" "volumen" => "33" "paginaInicial" => "142" "paginaFinal" => "149" "link" => array:1 [ …1] ] ] ] ] ] ] 45 => array:3 [ "identificador" => "bib0690" "etiqueta" => "46" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Cardiac toxicity in selective serotonin reuptake inhibitor users" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1097/PAF.0000000000000205" "Revista" => array:6 [ "tituloSerie" => "Am J Forensic Med Pathol" "fecha" => "2015" "volumen" => "36" "paginaInicial" => "293" "paginaFinal" => "297" "link" => array:1 [ …1] ] ] ] ] ] ] 46 => array:3 [ "identificador" => "bib0695" "etiqueta" => "47" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Meta-analysis of selective serotonin reuptake inhibitor-associated QTc prolongation" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.4088/JCP.13r08672" "Revista" => array:6 [ "tituloSerie" => "J Clin Psychiatry" "fecha" => "2014" "volumen" => "75" "paginaInicial" => "e441" "paginaFinal" => "e449" "link" => array:1 [ …1] ] ] ] ] ] ] 47 => array:3 [ "identificador" => "bib0700" "etiqueta" => "48" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Drug-induced long QT in adult psychiatric inpatients: the 5-year cross-sectional ECG Screening Outcome in Psychiatry study" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1176/appi.ajp.2013.12060860" "Revista" => array:7 [ "tituloSerie" => "Am J Psychiatry" "fecha" => "2013" "volumen" => "170" "paginaInicial" => "1468" "paginaFinal" => "1476" "link" => array:1 [ …1] "itemHostRev" => array:3 [ …3] ] ] ] ] ] ] 48 => array:3 [ "identificador" => "bib0705" "etiqueta" => "49" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Citalopram, QTc interval prolongation, and torsade de pointes. How should we apply the recent FDA ruling?" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.amjmed.2011.12.002" "Revista" => array:6 [ "tituloSerie" => "Am J Med" "fecha" => "2012" "volumen" => "125" "paginaInicial" => "859" "paginaFinal" => "868" "link" => array:1 [ …1] ] ] ] ] ] ] 49 => array:3 [ "identificador" => "bib0710" "etiqueta" => "50" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Risk of QT/QTc prolongation among newer non-SSRI antidepressants" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1177/1060028014550645" "Revista" => array:6 [ "tituloSerie" => "Ann Pharmacother" "fecha" => "2014" "volumen" => "48" "paginaInicial" => "1620" "paginaFinal" => "1628" "link" => array:1 [ …1] ] ] ] ] ] ] 50 => array:3 [ "identificador" => "bib0715" "etiqueta" => "51" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Antidepressants and the risk of sudden cardiac death and ventricular arrhythmia" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/pds.2181" "Revista" => array:6 [ "tituloSerie" => "Pharmacoepidemiol Drug Saf" "fecha" => "2011" "volumen" => "20" "paginaInicial" => "903" "paginaFinal" => "913" "link" => array:1 [ …1] ] ] ] ] ] ] 51 => array:3 [ "identificador" => "bib0720" "etiqueta" => "52" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Antipsychotic drugs and the risk of ventricular arrhythmia and/or sudden cardiac death: a nation-wide case-crossover study" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:3 [ "tituloSerie" => "J Am Heart Assoc" "fecha" => "2015" "volumen" => "4" ] ] ] ] ] ] 52 => array:3 [ "identificador" => "bib0725" "etiqueta" => "53" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Torsadogenic risk of antipsychotics: combining adverse event reports with drug utilization data across Europe" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1371/journal.pone.0081208" "Revista" => array:5 [ "tituloSerie" => "PLoS ONE" "fecha" => "2013" "volumen" => "8" "paginaInicial" => "e81208" "link" => array:1 [ …1] ] ] ] ] ] ] 53 => array:3 [ "identificador" => "bib0730" "etiqueta" => "54" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Antipsychotics and torsadogenic risk: signals emerging from the US FDA Adverse Event Reporting System database" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s40264-013-0032-z" "Revista" => array:6 [ "tituloSerie" => "Drug Saf" "fecha" => "2013" "volumen" => "36" "paginaInicial" => "467" "paginaFinal" => "479" "link" => array:1 [ …1] ] ] ] ] ] ] 54 => array:3 [ "identificador" => "bib0735" "etiqueta" => "55" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Risk of arrhythmia induced by psychotropic medications: a proposal for clinical management" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1093/eurheartj/ehu100" "Revista" => array:6 [ "tituloSerie" => "Eur Heart J" "fecha" => "2014" "volumen" => "35" "paginaInicial" => "1306" "paginaFinal" => "1315" "link" => array:1 [ …1] ] ] ] ] ] ] 55 => array:3 [ "identificador" => "bib0740" "etiqueta" => "56" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The contribution of national spontaneous reporting systems to detect signals of torsadogenicity: issues emerging from the ARITMO project" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s40264-015-0353-1" "Revista" => array:6 [ "tituloSerie" => "Drug Saf" "fecha" => "2016" "volumen" => "39" "paginaInicial" => "59" "paginaFinal" => "68" "link" => array:1 [ …1] ] ] ] ] ] ] 56 => array:3 [ "identificador" => "bib0745" "etiqueta" => "57" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Antipsychotics and the risks of sudden cardiac death and all-cause death: cohort studies in Medicaid and dually-eligible Medicaid-Medicare beneficiaries of five states" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.4172/2155-9880.S10-006" "Revista" => array:7 [ "tituloSerie" => "J Clin Exp Cardiolog" "fecha" => "2013" "volumen" => "10" "numero" => "Suppl" "paginaInicial" => "1" "paginaFinal" => "9" "link" => array:1 [ …1] ] ] ] ] ] ] 57 => array:3 [ "identificador" => "bib0750" "etiqueta" => "58" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "QTc prolongation: is clozapine safe? Study of 82 cases before and after clozapine treatment" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/hup.1221" "Revista" => array:6 [ "tituloSerie" => "Hum Psychopharmacol" "fecha" => "2011" "volumen" => "26" "paginaInicial" => "397" "paginaFinal" => "403" "link" => array:1 [ …1] ] ] ] ] ] ] 58 => array:3 [ "identificador" => "bib0755" "etiqueta" => "59" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Comparative mortality associated with ziprasidone and olanzapine in real-world use among 18,154 patients with schizophrenia: The Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC)" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1176/appi.ajp.2010.08040484" "Revista" => array:6 [ "tituloSerie" => "Am J Psychiatry" "fecha" => "2011" "volumen" => "168" "paginaInicial" => "193" "paginaFinal" => "201" "link" => array:1 [ …1] ] ] ] ] ] ] 59 => array:3 [ "identificador" => "bib0760" "etiqueta" => "60" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Methodological challenges in the coding and adjudication of sudden deaths in a large simple trial with observational follow-up: the ziprasidone observational study of cardiac outcomes (ZODIAC)" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/pds.2185" "Revista" => array:6 [ "tituloSerie" => "Pharmacoepidemiol Drug Saf" "fecha" => "2011" "volumen" => "20" "paginaInicial" => "1192" "paginaFinal" => "1198" "link" => array:1 [ …1] ] ] ] ] ] ] 60 => array:3 [ "identificador" => "bib0765" "etiqueta" => "61" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Drug safety evaluation of ziprasidone" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1517/14740338.2011.560114" "Revista" => array:6 [ "tituloSerie" => "Expert Opin Drug Saf" "fecha" => "2011" "volumen" => "10" "paginaInicial" => "437" "paginaFinal" => "448" "link" => array:1 [ …1] ] ] ] ] ] ] 61 => array:3 [ "identificador" => "bib0770" "etiqueta" => "62" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The cardiac safety of aripiprazole treatment in patients at high risk for torsade: a systematic review with a meta-analytic approach" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Psychopharmacology (Berl)" "fecha" => "2015" "volumen" => "232" "paginaInicial" => "3297" "paginaFinal" => "3308" ] ] ] ] ] ] 62 => array:3 [ "identificador" => "bib0775" "etiqueta" => "63" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Cardiovascular safety of antipsychotics: a clinical overview" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1517/14740338.2016.1161021" "Revista" => array:6 [ "tituloSerie" => "Expert Opin Drug Saf" "fecha" => "2016" "volumen" => "15" "paginaInicial" => "679" "paginaFinal" => "688" "link" => array:1 [ …1] ] ] ] ] ] ] 63 => array:3 [ "identificador" => "bib0780" "etiqueta" => "64" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Quetiapine, QTc interval prolongation, and torsade de pointes: a review of case reports" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1177/2045125313510194" "Revista" => array:6 [ "tituloSerie" => "Ther Adv Psychopharmacol" "fecha" => "2014" "volumen" => "4" "paginaInicial" => "130" "paginaFinal" => "138" "link" => array:1 [ …1] ] ] ] ] ] ] 64 => array:3 [ "identificador" => "bib0785" "etiqueta" => "65" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Increased risk of antipsychotic-related QT prolongation during nighttime: a 24-hour holter electrocardiogram recording study" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1097/JCP.0b013e31823f6f21" "Revista" => array:6 [ "tituloSerie" => "J Clin Psychopharmacol" "fecha" => "2012" "volumen" => "32" "paginaInicial" => "18" "paginaFinal" => "22" "link" => array:1 [ …1] ] ] ] ] ] ] 65 => array:3 [ "identificador" => "bib0790" "etiqueta" => "66" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "QT prolongation of the antipsychotic risperidone is predominantly related to its 9-hydroxy metabolite paliperidone" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/hup.1258" "Revista" => array:6 [ "tituloSerie" => "Hum Psychopharmacol" "fecha" => "2012" "volumen" => "27" "paginaInicial" => "39" "paginaFinal" => "42" "link" => array:1 [ …1] ] ] ] ] ] ] 66 => array:3 [ "identificador" => "bib0795" "etiqueta" => "67" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Prescribing pattern of antipsychotic drugs during the years 1996–2010: a population-based database study in Europe with a focus on torsadogenic drugs" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/bcp.12955" "Revista" => array:6 [ "tituloSerie" => "Br J Clin Pharmacol" "fecha" => "2016" "volumen" => "82" "paginaInicial" => "487" "paginaFinal" => "497" "link" => array:1 [ …1] ] ] ] ] ] ] 67 => array:3 [ "identificador" => "bib0800" "etiqueta" => "68" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "QTc prolongation in patients acutely admitted to hospital for psychosis and treated with second generation antipsychotics" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1155/2013/375020" "Revista" => array:5 [ "tituloSerie" => "Schizophr Res Treatment" "fecha" => "2013" "volumen" => "2013" "paginaInicial" => "375020" "link" => array:1 [ …1] ] ] ] ] ] ] 68 => array:3 [ "identificador" => "bib0805" "etiqueta" => "69" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Antipsychotic drug administration does not correlate with prolonged rate-corrected QT interval in children and adolescents: results from a nested case-control study" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1089/cap.2011.0024" "Revista" => array:6 [ "tituloSerie" => "J Child Adolesc Psychopharmacol" "fecha" => "2011" "volumen" => "21" "paginaInicial" => "365" "paginaFinal" => "368" "link" => array:1 [ …1] ] ] ] ] ] ] 69 => array:3 [ "identificador" => "bib0810" "etiqueta" => "70" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Azithromycin and the risk of cardiovascular death" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMoa1003833" "Revista" => array:6 [ "tituloSerie" => "N Engl J Med" "fecha" => "2012" "volumen" => "366" "paginaInicial" => "1881" "paginaFinal" => "1890" "link" => array:1 [ …1] ] ] ] ] ] ] 70 => array:3 [ "identificador" => "bib0815" "etiqueta" => "71" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Azithromycin and levofloxacin use and increased risk of cardiac arrhythmia and death" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1370/afm.1601" "Revista" => array:6 [ "tituloSerie" => "Ann Fam Med" "fecha" => "2014" "volumen" => "12" "paginaInicial" => "121" "paginaFinal" => "127" "link" => array:1 [ …1] ] ] ] ] ] ] 71 => array:3 [ "identificador" => "bib0820" "etiqueta" => "72" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Sudden cardiac arrest during anesthesia in a 30-month-old boy with syndactyly: a case of genetically proven Timothy syndrome" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.3346/jkms.2013.28.5.788" "Revista" => array:6 [ "tituloSerie" => "J Korean Med Sci" "fecha" => "2013" "volumen" => "28" "paginaInicial" => "788" "paginaFinal" => "791" "link" => array:1 [ …1] ] ] ] ] ] ] 72 => array:3 [ "identificador" => "bib0825" "etiqueta" => "73" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Domperidone and risk of ventricular arrhythmia and cardiac death: a systematic review and meta-analysis" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s40261-015-0360-0" "Revista" => array:6 [ "tituloSerie" => "Clin Drug Investig" "fecha" => "2016" "volumen" => "36" "paginaInicial" => "97" "paginaFinal" => "107" "link" => array:1 [ …1] ] ] ] ] ] ] 73 => array:3 [ "identificador" => "bib0830" "etiqueta" => "74" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Risk of out-of-hospital sudden cardiac death in users of domperidonem proton pump inhibitors, or metoclopramide: a population-based nested case-control study" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s40264-015-0338-0" "Revista" => array:6 [ "tituloSerie" => "Drug Saf" "fecha" => "2015" "volumen" => "38" "paginaInicial" => "1187" "paginaFinal" => "1199" "link" => array:1 [ …1] ] ] ] ] ] ] 74 => array:3 [ "identificador" => "bib0835" "etiqueta" => "75" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Intravenous ondansetron and the QT interval in adult emergency department patients: an observational study" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/acem.12836" "Revista" => array:6 [ "tituloSerie" => "Acad Emerg Med" "fecha" => "2016" "volumen" => "23" "paginaInicial" => "102" "paginaFinal" => "105" "link" => array:1 [ …1] ] ] ] ] ] ] 75 => array:3 [ "identificador" => "bib0840" "etiqueta" => "76" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Pro-arrhythmic potential of oral antihistamines (H1): combining adverse event reports with drug utilization data across Europe" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1371/journal.pone.0119551" "Revista" => array:5 [ "tituloSerie" => "PLOS ONE" "fecha" => "2015" "volumen" => "10" "paginaInicial" => "e0119551" "link" => array:1 [ …1] ] ] ] ] ] ] 76 => array:3 [ "identificador" => "bib0845" "etiqueta" => "77" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Chemotherapy and QT prolongation: overview with clinical perspective" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s11936-014-0303-8" "Revista" => array:5 [ "tituloSerie" => "Curr Treat Options Cardiovasc Med" "fecha" => "2014" "volumen" => "16" "paginaInicial" => "303" "link" => array:1 [ …1] ] ] ] ] ] ] 77 => array:3 [ "identificador" => "bib0850" "etiqueta" => "78" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "What links BRAF to the heart function? New insights from the cardiotoxicity of BRAF inhibitors in cancer treatment" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.18632/oncotarget.5853" "Revista" => array:6 [ "tituloSerie" => "Oncotarget" "fecha" => "2015" "volumen" => "6" "paginaInicial" => "35589" "paginaFinal" => "35601" "link" => array:1 [ …1] ] ] ] ] ] ] 78 => array:3 [ "identificador" => "bib0855" "etiqueta" => "79" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Risk of serious cardiovascular problems with medications for attention-deficit hyperactivity disorder" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s40263-012-0019-9" "Revista" => array:6 [ "tituloSerie" => "CNS Drugs" "fecha" => "2013" "volumen" => "27" "paginaInicial" => "15" "paginaFinal" => "30" "link" => array:1 [ …1] ] ] ] ] ] ] 79 => array:3 [ "identificador" => "bib0860" "etiqueta" => "80" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Do prescription stimulants increase the risk of adverse cardiovascular events?: A systematic review" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1186/1471-2261-12-41" "Revista" => array:5 [ "tituloSerie" => "BMC Cardiovasc Disord" "fecha" => "2012" "volumen" => "12" "paginaInicial" => "41" "link" => array:1 [ …1] ] ] ] ] ] ] 80 => array:3 [ "identificador" => "bib0865" "etiqueta" => "81" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Methylphenidate and risk of serious cardiovascular events in adults" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1176/appi.ajp.2011.11010125" "Revista" => array:6 [ "tituloSerie" => "Am J Psychiatry" "fecha" => "2012" "volumen" => "169" "paginaInicial" => "178" "paginaFinal" => "185" "link" => array:1 [ …1] ] ] ] ] ] ] 81 => array:3 [ "identificador" => "bib0870" "etiqueta" => "82" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Coffee, alcohol, smoking, physical activity and QT interval duration: results from the Third National Health and Nutrition Examination Survey" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1371/journal.pone.0017584" "Revista" => array:5 [ "tituloSerie" => "PLoS ONE" "fecha" => "2011" "volumen" => "6" "paginaInicial" => "e17584" "link" => array:1 [ …1] ] ] ] ] ] ] 82 => array:3 [ "identificador" => "bib0875" "etiqueta" => "83" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Ginseng: a potential cause of long QT" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jelectrocard.2010.08.007" "Revista" => array:6 [ "tituloSerie" => "J Electrocardiol" "fecha" => "2011" "volumen" => "44" "paginaInicial" => "357" "paginaFinal" => "358" "link" => array:1 [ …1] ] ] ] ] ] ] 83 => array:3 [ "identificador" => "bib0880" "etiqueta" => "84" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Polymorphic ventricular tachycardia (Torsades de pointes) due to licorice root tea" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Turk Kardiyol Dern Ars" "fecha" => "2013" "volumen" => "41" "paginaInicial" => "241" "paginaFinal" => "244" "link" => array:1 [ …1] ] ] ] ] ] ] 84 => array:3 [ "identificador" => "bib0885" "etiqueta" => "85" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Drug-induced QT interval shortening: potential harbinger of proarrhythmia and regulatory perspectives" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1476-5381.2009.00191.x" "Revista" => array:6 [ "tituloSerie" => "Br J Pharmacol" "fecha" => "2010" "volumen" => "159" "paginaInicial" => "58" "paginaFinal" => "69" "link" => array:1 [ …1] ] ] ] ] ] ] 85 => array:3 [ "identificador" => "bib0890" "etiqueta" => "86" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Drug-induced QT-interval shortening following antiepileptic treatment with oral rufinamide" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.hrthm.2012.01.006" "Revista" => array:6 [ "tituloSerie" => "Heart Rhythm" "fecha" => "2012" "volumen" => "9" "paginaInicial" => "776" "paginaFinal" => "781" "link" => array:1 [ …1] ] ] ] ] ] ] 86 => array:3 [ "identificador" => "bib0895" "etiqueta" => "87" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Drug-induced Brugada syndrome by noncardiac agents" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/pace.12234" "Revista" => array:6 [ "tituloSerie" => "Pacing Clin Electrophysiol" "fecha" => "2013" "volumen" => "36" "paginaInicial" => "1570" "paginaFinal" => "1577" "link" => array:1 [ …1] ] ] ] ] ] ] 87 => array:3 [ "identificador" => "bib0900" "etiqueta" => "88" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The safety of flecainide treatment of atrial fibrillation: long-term incidence of sudden cardiac death and proarrhythmic events" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1365-2796.2011.02395.x" "Revista" => array:7 [ "tituloSerie" => "J Intern Med" "fecha" => "2011" "volumen" => "270" "paginaInicial" => "281" "paginaFinal" => "290" "link" => array:1 [ …1] "itemHostRev" => array:3 [ …3] ] ] ] ] ] ] 88 => array:3 [ "identificador" => "bib0905" "etiqueta" => "89" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Brugada electrocardiogram pattern “unmasked” by amiodarone infusion" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1097/01.mjt.0000433948.16654.91" "Revista" => array:6 [ "tituloSerie" => "Am J Ther" "fecha" => "2014" "volumen" => "21" "paginaInicial" => "540" "paginaFinal" => "541" "link" => array:1 [ …1] ] ] ] ] ] ] 89 => array:3 [ "identificador" => "bib0910" "etiqueta" => "90" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Sudden cardiac death is associated both with epilepsy and with use of antiepileptic medications" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1136/heartjnl-2014-305664" "Revista" => array:6 [ "tituloSerie" => "Heart" "fecha" => "2015" "volumen" => "101" "paginaInicial" => "17" "paginaFinal" => "22" "link" => array:1 [ …1] ] ] ] ] ] ] 90 => array:3 [ "identificador" => "bib0915" "etiqueta" => "91" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Polytherapy with sodium channel-blocking antiepileptic drugs is associated with arrhythmogenic ST-T abnormality in patients with epilepsy" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.seizure.2016.06.004" "Revista" => array:7 [ "tituloSerie" => "Seizure" "fecha" => "2016" "volumen" => "40" "paginaInicial" => "81" "paginaFinal" => "87" "link" => array:1 [ …1] "itemHostRev" => array:3 [ …3] ] ] ] ] ] ] 91 => array:3 [ "identificador" => "bib0920" "etiqueta" => "92" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Type 1 Brugada pattern associated with nicotine toxicity" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jemermed.2015.08.008" "Revista" => array:6 [ "tituloSerie" => "J Emerg Med" "fecha" => "2015" "volumen" => "49" "paginaInicial" => "e183" "paginaFinal" => "e186" "link" => array:1 [ …1] ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/21742049/0000003700000005/v1_201806100418/S2174204918301685/v1_201806100418/en/main.assets" "Apartado" => array:4 [ "identificador" => "9924" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Review Article" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/21742049/0000003700000005/v1_201806100418/S2174204918301685/v1_201806100418/en/main.pdf?idApp=UINPBA00004E&text.app=https://revportcardiol.org/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2174204918301685?idApp=UINPBA00004E"]

Statistics

Review Article

Drug-induced life-threatening arrhythmias and sudden cardiac death: A clinical perspective of long QT, short QT and Brugada syndromes

Arritmias potencialmente fatais e morte súbita cardíaca induzidas por fármacos: uma perspetiva clínica das síndromes do QT longo, QT curto e Brugada

Diogo Ramalhoa,

Corresponding author

silva.josediogo@gmail.com

Corresponding author.

, João Freitasb

a Departamento de Medicina, Faculdade de Medicina, Universidade do Porto, Porto, Portugal

b Serviço de Cardiologia, Centro Hospitalar de São João EPE, Porto, Portugal

Read

8395

Times
was read the article

2320

Total PDF

6075

Total HTML

Share statistics

 array:25 [
  "pii" => "S2174204918301685"
  "issn" => "21742049"
  "doi" => "10.1016/j.repce.2017.07.010"
  "estado" => "S300"
  "fechaPublicacion" => "2018-05-01"
  "aid" => "1184"
  "copyright" => "Sociedade Portuguesa de Cardiologia"
  "copyrightAnyo" => "2018"
  "documento" => "article"
  "crossmark" => 1
  "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/"
  "subdocumento" => "rev"
  "cita" => "Rev Port Cardiol. 2018;37:435-46"
  "abierto" => array:3 [
    "ES" => true
    "ES2" => true
    "LATM" => true
  ]
  "gratuito" => true
  "lecturas" => array:2 [
    "total" => 1985
    "formatos" => array:3 [
      "EPUB" => 101
      "HTML" => 1573
      "PDF" => 311
    ]
  ]
  "Traduccion" => array:1 [
    "en" => array:20 [
      "pii" => "S0870255117300586"
      "issn" => "08702551"
      "doi" => "10.1016/j.repc.2017.07.010"
      "estado" => "S300"
      "fechaPublicacion" => "2018-05-01"
      "aid" => "1184"
      "copyright" => "Sociedade Portuguesa de Cardiologia"
      "documento" => "article"
      "crossmark" => 1
      "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/"
      "subdocumento" => "rev"
      "cita" => "Rev Port Cardiol. 2018;37:435-46"
      "abierto" => array:3 [
        "ES" => true
        "ES2" => true
        "LATM" => true
      ]
      "gratuito" => true
      "lecturas" => array:2 [
        "total" => 3507
        "formatos" => array:3 [
          "EPUB" => 145
          "HTML" => 2821
          "PDF" => 541
        ]
      ]
      "en" => array:12 [
        "idiomaDefecto" => true
        "cabecera" => "<span class="elsevierStyleTextfn">Review Article</span>"
        "titulo" => "Drug-induced life-threatening arrhythmias and sudden cardiac death&#58; A clinical perspective of long QT&#44; short QT and Brugada syndromes"
        "tienePdf" => "en"
        "tieneTextoCompleto" => "en"
        "tieneResumen" => array:2 [
          0 => "en"
          1 => "pt"
        ]
        "paginas" => array:1 [
          0 => array:2 [
            "paginaInicial" => "435"
            "paginaFinal" => "446"
          ]
        ]
        "titulosAlternativos" => array:1 [
          "pt" => array:1 [
            "titulo" => "Arritmias potencialmente fatais e morte s&#250;bita card&#237;aca induzidas por f&#225;rmacos&#58; uma perspetiva cl&#237;nica das s&#237;ndromes do QT longo&#44; QT curto e Brugada"
          ]
        ]
        "contieneResumen" => array:2 [
          "en" => true
          "pt" => true
        ]
        "contieneTextoCompleto" => array:1 [
          "en" => true
        ]
        "contienePdf" => array:1 [
          "en" => true
        ]
        "autores" => array:1 [
          0 => array:2 [
            "autoresLista" => "Diogo Ramalho, Jo&#227;o Freitas"
            "autores" => array:2 [
              0 => array:2 [
                "nombre" => "Diogo"
                "apellidos" => "Ramalho"
              ]
              1 => array:2 [
                "nombre" => "Jo&#227;o"
                "apellidos" => "Freitas"
              ]
            ]
          ]
        ]
      ]
      "idiomaDefecto" => "en"
      "Traduccion" => array:1 [
        "en" => array:9 [
          "pii" => "S2174204918301685"
          "doi" => "10.1016/j.repce.2017.07.010"
          "estado" => "S300"
          "subdocumento" => ""
          "abierto" => array:3 [
            "ES" => true
            "ES2" => true
            "LATM" => true
          ]
          "gratuito" => true
          "lecturas" => array:1 [
            "total" => 0
          ]
          "idiomaDefecto" => "en"
          "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2174204918301685?idApp=UINPBA00004E"
        ]
      ]
      "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0870255117300586?idApp=UINPBA00004E"
      "url" => "/08702551/0000003700000005/v1_201805250945/S0870255117300586/v1_201805250945/en/main.assets"
    ]
  ]
  "itemSiguiente" => array:20 [
    "pii" => "S2174204918301697"
    "issn" => "21742049"
    "doi" => "10.1016/j.repce.2017.02.019"
    "estado" => "S300"
    "fechaPublicacion" => "2018-05-01"
    "aid" => "1185"
    "copyright" => "Sociedade Portuguesa de Cardiologia"
    "documento" => "simple-article"
    "crossmark" => 1
    "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/"
    "subdocumento" => "crp"
    "cita" => "Rev Port Cardiol. 2018;37:447&#46;e1-6"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 1515
      "formatos" => array:3 [
        "EPUB" => 120
        "HTML" => 1170
        "PDF" => 225
      ]
    ]
    "en" => array:13 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Case report</span>"
      "titulo" => "Massive organ embolization from primary aortic thrombosis"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "tieneResumen" => array:2 [
        0 => "en"
        1 => "pt"
      ]
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "447&#46;e1"
          "paginaFinal" => "447&#46;e6"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "pt" => array:1 [
          "titulo" => "Emboliza&#231;&#227;o org&#226;nica maci&#231;a de trombose prim&#225;ria da aorta"
        ]
      ]
      "contieneResumen" => array:2 [
        "en" => true
        "pt" => true
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 0
        "multimedia" => array:7 [
          "identificador" => "fig0010"
          "etiqueta" => "Figure 2"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => true
          "mostrarDisplay" => false
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "gr2.jpeg"
              "Alto" => 1773
              "Ancho" => 2501
              "Tamanyo" => 477028
            ]
          ]
          "descripcion" => array:1 [
            "en" => "<p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">CT scan of the abdomen&#47;pelvis showing total hypodensity of the spleen representing a complete infarct&#44; without contrast enhancement except for a fine capsule&#46; Splenic artery occlusion&#46; Hypodense ill-defined lesion in the pancreas tail&#44; measuring 55&#215;38&#160;mm with adjacent fat densification&#44; but without contrast enhancement leading to a differential diagnosis between ischemic infarct and malignant neoplasm&#46; Heterogeneous contrast enhancement of both kidneys&#44; with triangular parenchymal areas of lower attenuation&#44; suggestive of ischemic renal foci&#46; Heterogeneous hepatomegaly with areas of non-contrast enhancement&#44; the biggest one in segments VII and VIII&#59; similar area on the liver border and smaller hypodense areas that&#44; in this context&#44; can represent occlusive arterial conditions&#46; Small parietal thrombus &#40;9<span class="elsevierStyleHsp" style=""></span>mm&#41; in the left lateral aortic wall&#44; in the axial plane of the celiac trunk&#44; with no evident atheromatous lesions&#46;</p>"
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "Catarina Patr&#237;cio, Mariana Marques Silva, Pedro Eduardo Silva, Jo&#227;o Oliveira, Lu&#237;s Bagulho"
          "autores" => array:5 [
            0 => array:2 [
              "nombre" => "Catarina"
              "apellidos" => "Patr&#237;cio"
            ]
            1 => array:2 [
              "nombre" => "Mariana Marques"
              "apellidos" => "Silva"
            ]
            2 => array:2 [
              "nombre" => "Pedro Eduardo"
              "apellidos" => "Silva"
            ]
            3 => array:2 [
              "nombre" => "Jo&#227;o"
              "apellidos" => "Oliveira"
            ]
            4 => array:2 [
              "nombre" => "Lu&#237;s"
              "apellidos" => "Bagulho"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "Traduccion" => array:1 [
      "en" => array:9 [
        "pii" => "S0870255116302888"
        "doi" => "10.1016/j.repc.2017.02.020"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => true
          "ES2" => true
          "LATM" => true
        ]
        "gratuito" => true
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "en"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0870255116302888?idApp=UINPBA00004E"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2174204918301697?idApp=UINPBA00004E"
    "url" => "/21742049/0000003700000005/v1_201806100418/S2174204918301697/v1_201806100418/en/main.assets"
  ]
  "itemAnterior" => array:20 [
    "pii" => "S2174204918301673"
    "issn" => "21742049"
    "doi" => "10.1016/j.repce.2018.05.007"
    "estado" => "S300"
    "fechaPublicacion" => "2018-05-01"
    "aid" => "1208"
    "copyright" => "Sociedade Portuguesa de Cardiologia"
    "documento" => "simple-article"
    "crossmark" => 1
    "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/"
    "subdocumento" => "dis"
    "cita" => "Rev Port Cardiol. 2018;37:433-4"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 1035
      "formatos" => array:3 [
        "EPUB" => 105
        "HTML" => 684
        "PDF" => 246
      ]
    ]
    "en" => array:10 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Editorial comment</span>"
      "titulo" => "Obesity and hypertension in children&#58; A worldwide problem"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "433"
          "paginaFinal" => "434"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "pt" => array:1 [
          "titulo" => "Obesidade e hipertens&#227;o arterial nas crian&#231;as&#58; um problema &#224; escala mundial"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "Sofia Ferreira"
          "autores" => array:1 [
            0 => array:2 [
              "nombre" => "Sofia"
              "apellidos" => "Ferreira"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "Traduccion" => array:1 [
      "en" => array:9 [
        "pii" => "S0870255118302841"
        "doi" => "10.1016/j.repc.2018.04.006"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => true
          "ES2" => true
          "LATM" => true
        ]
        "gratuito" => true
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "en"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0870255118302841?idApp=UINPBA00004E"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2174204918301673?idApp=UINPBA00004E"
    "url" => "/21742049/0000003700000005/v1_201806100418/S2174204918301673/v1_201806100418/en/main.assets"
  ]
  "en" => array:16 [
    "idiomaDefecto" => true
    "cabecera" => "<span class="elsevierStyleTextfn">Review Article</span>"
    "titulo" => "Drug-induced life-threatening arrhythmias and sudden cardiac death&#58; A clinical perspective of long QT&#44; short QT and Brugada syndromes"
    "tieneTextoCompleto" => true
    "paginas" => array:1 [
      0 => array:2 [
        "paginaInicial" => "435"
        "paginaFinal" => "446"
      ]
    ]
    "autores" => array:1 [
      0 => array:4 [
        "autoresLista" => "Diogo Ramalho, Jo&#227;o Freitas"
        "autores" => array:2 [
          0 => array:4 [
            "nombre" => "Diogo"
            "apellidos" => "Ramalho"
            "email" => array:1 [
              0 => "silva&#46;josediogo&#64;gmail&#46;com"
            ]
            "referencia" => array:2 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "aff0005"
              ]
              1 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">&#42;</span>"
                "identificador" => "cor0005"
              ]
            ]
          ]
          1 => array:3 [
            "nombre" => "Jo&#227;o"
            "apellidos" => "Freitas"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "aff0010"
              ]
            ]
          ]
        ]
        "afiliaciones" => array:2 [
          0 => array:3 [
            "entidad" => "Departamento de Medicina&#44; Faculdade de Medicina&#44; Universidade do Porto&#44; Porto&#44; Portugal"
            "etiqueta" => "a"
            "identificador" => "aff0005"
          ]
          1 => array:3 [
            "entidad" => "Servi&#231;o de Cardiologia&#44; Centro Hospitalar de S&#227;o Jo&#227;o EPE&#44; Porto&#44; Portugal"
            "etiqueta" => "b"
            "identificador" => "aff0010"
          ]
        ]
        "correspondencia" => array:1 [
          0 => array:3 [
            "identificador" => "cor0005"
            "etiqueta" => "&#8270;"
            "correspondencia" => "Corresponding author&#46;"
          ]
        ]
      ]
    ]
    "titulosAlternativos" => array:1 [
      "pt" => array:1 [
        "titulo" => "Arritmias potencialmente fatais e morte s&#250;bita card&#237;aca induzidas por f&#225;rmacos&#58; uma perspetiva cl&#237;nica das s&#237;ndromes do QT longo&#44; QT curto e Brugada"
      ]
    ]
    "textoCompleto" => "<span class="elsevierStyleSections"><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0025">Introduction</span><span id="sec0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0030">Sudden cardiac death</span><p id="par0005" class="elsevierStylePara elsevierViewall">Remarkably&#44; sudden cardiac death &#40;SCD&#41; accounts for about a quarter of the 17 million deaths attributable to cardiovascular diseases every year worldwide&#46;<a class="elsevierStyleCrossRef" href="#bib0465"><span class="elsevierStyleSup">1</span></a></p><p id="par0010" class="elsevierStylePara elsevierViewall">Coronary artery disease &#40;CAD&#41; is still the leading cause of these deaths&#44; particularly in the elderly&#46; However&#44; primary cardiac arrhythmias and cardiomyopathies are the most common causes of SCD in young people&#46;<a class="elsevierStyleCrossRefs" href="#bib0470"><span class="elsevierStyleSup">2&#44;3</span></a> Ventricular fibrillation &#40;VF&#41; is the most common arrhythmia in SCD&#46;<a class="elsevierStyleCrossRef" href="#bib0480"><span class="elsevierStyleSup">4</span></a> In fact&#44; around 50&#37; of SCD cases are due to VF and&#47;or ventricular tachycardia &#40;VT&#41;&#46;<a class="elsevierStyleCrossRef" href="#bib0475"><span class="elsevierStyleSup">3</span></a> They predominantly occur out-of-hospital&#44; explaining the low survival rates &#40;i&#46;e&#46;&#44; &#60;10&#37;&#41; of patients with VF&#46;<a class="elsevierStyleCrossRef" href="#bib0485"><span class="elsevierStyleSup">5</span></a> Conversely&#44; asystole and pulseless electrical activity &#40;PEA&#41; have been emerging in SCD for indefinite reasons&#46;<a class="elsevierStyleCrossRef" href="#bib0475"><span class="elsevierStyleSup">3</span></a> Interestingly&#44; in patients with reported out-of-hospital sudden cardiac arrest &#40;SCA&#41;&#44; antipsychotic drugs have shown to be significant predictors of PEA versus VF&#47;VT&#46;<a class="elsevierStyleCrossRef" href="#bib0490"><span class="elsevierStyleSup">6</span></a></p><p id="par0015" class="elsevierStylePara elsevierViewall">SCD can be caused by an acquired and&#47;or a genetic background of susceptibility&#44; arising from either electrophysiological &#40;e&#46;g&#46;&#44; inherited channelopathies&#41; or structural cardiac abnormalities &#40;e&#46;g&#46;&#44; CAD&#41;&#46;<a class="elsevierStyleCrossRef" href="#bib0465"><span class="elsevierStyleSup">1</span></a></p></span><span id="sec0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0035">Inherited channelopathies</span><p id="par0020" class="elsevierStylePara elsevierViewall">Long QT syndrome &#40;LQTS&#41;&#44; Brugada syndrome &#40;BrS&#41; and short QT syndrome &#40;SQTS&#41; are rare inherited arrhythmia disorders arising from ion channel abnormalities&#44; which in turn are termed channelopathies&#46; These syndromes are highly concerning&#44; particularly in young people&#44; due to their high propensity to suffer severe ventricular arrhythmias and sudden cardiac death&#46;<a class="elsevierStyleCrossRef" href="#bib0495"><span class="elsevierStyleSup">7</span></a></p><p id="par0025" class="elsevierStylePara elsevierViewall">Since the overwhelming majority of patients with inherited channelopathies have no structural heart diseases&#44; an electrocardiogram &#40;ECG&#41; is a valuable tool both in detecting features of these syndromes and in early SCD risk stratification&#46;<a class="elsevierStyleCrossRefs" href="#bib0465"><span class="elsevierStyleSup">1&#44;7</span></a></p></span><span id="sec0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0040">QT prolongation&#44; torsades de pointes and congenital long QT syndrome</span><p id="par0030" class="elsevierStylePara elsevierViewall">The QT interval represents the electrocardiographic index of ventricular repolarization and depolarization&#46;<a class="elsevierStyleCrossRef" href="#bib0500"><span class="elsevierStyleSup">8</span></a> Because the QT interval varies inversely with heart rate&#44; several correction formulas &#40;e&#46;g&#46;&#44; Bazett&#44; Fridericia&#41; allow us to determine a heart rate-corrected QT &#40;QTc&#41; interval&#46; Fridericia&#39;s formula provides a more accurate assessment at extremes of heart rate than Bazett&#39;s formula and&#44; therefore&#44; it is preferred in such cases&#46;<a class="elsevierStyleCrossRefs" href="#bib0505"><span class="elsevierStyleSup">9&#44;10</span></a></p><p id="par0035" class="elsevierStylePara elsevierViewall">The expert group from the American College of Cardiology Foundation and the American Heart Association &#40;ACCF&#47;AHA&#41; gives an upper limit of normal &#40;i&#46;e&#46;&#44; estimated 99th percentile&#41; for abnormally prolonged QTc intervals of 470 ms and 480 ms in otherwise healthy post-pubertal males and females&#44; respectively&#46;<a class="elsevierStyleCrossRef" href="#bib0515"><span class="elsevierStyleSup">11</span></a> Patients with an absolute QTc interval of &#62;500 ms are considered to be at risk for developing torsades de Pointes &#40;TdP&#41;&#44; a polymorphic ventricular tachycardia that may shift into VF and lead to SCD&#46;<a class="elsevierStyleCrossRefs" href="#bib0515"><span class="elsevierStyleSup">11&#44;12</span></a></p><p id="par0040" class="elsevierStylePara elsevierViewall">Congenital QT prolongation is due to various genetically based LQTSs&#46; Thirteen congenital types of LQTS have been reported thus far&#46; The KCNQ1 &#40;LQTS 1&#41;&#44; KCNH2 &#40;LQTS 2&#41; and SCN5A &#40;LQTS 3&#41; genes encompass approximately 90&#37; of all genotype-positive cases&#46;<a class="elsevierStyleCrossRefs" href="#bib0465"><span class="elsevierStyleSup">1&#44;3</span></a> LQTS types 1 and 2 are caused by the loss-of-function mutations of the KCNQ1 and KCNH2 genes encoding the <span class="elsevierStyleItalic">&#945;</span>-subunit of slow &#40;I<span class="elsevierStyleInf">Ks</span>&#41; and rapid &#40;I<span class="elsevierStyleInf">Kr</span>&#41; components of the delayed rectifier potassium currents&#44; respectively&#46;<a class="elsevierStyleCrossRefs" href="#bib0495"><span class="elsevierStyleSup">7&#44;13&#44;14</span></a> Gain-of-function mutations of the SCN5A gene encoding the &#945;-subunit of the cardiac voltage-gated sodium channels are responsible for LQTS type 3&#46;<a class="elsevierStyleCrossRef" href="#bib0535"><span class="elsevierStyleSup">15</span></a> Genetic testing identifies a disease-causing mutation in about 75&#37; of clinically definite LQTS&#44; which proves its diagnostic significance&#46;<a class="elsevierStyleCrossRef" href="#bib0540"><span class="elsevierStyleSup">16</span></a></p><p id="par0045" class="elsevierStylePara elsevierViewall">TdP may clinically present as syncope&#44; SCA or SD&#44;<a class="elsevierStyleCrossRefs" href="#bib0475"><span class="elsevierStyleSup">3&#44;13</span></a> beginning on average at the age of 12&#46;<a class="elsevierStyleCrossRef" href="#bib0495"><span class="elsevierStyleSup">7</span></a></p><p id="par0050" class="elsevierStylePara elsevierViewall">The Schwartz risk score is still a widely used diagnostic tool&#44; and is based on clinical presentation&#44; family history and ECG characteristics&#46; The authors currently consider a cut-off value of &#8805;3&#46;5 to be highly accurate in showing a high probability of having LQTS&#46;<a class="elsevierStyleCrossRef" href="#bib0545"><span class="elsevierStyleSup">17</span></a> Additionally&#44; the panel of experts for the latest guidelines from the European Society of Cardiology proposed a QTc &#8805;480 ms in repeated 12-lead ECG as diagnostic criteria&#44; or detection of at least one unequivocally gene culprit mutation&#44; regardless of QT interval duration&#46; A QTc &#8805;460 ms can also be diagnostic in a scenario of unexplained syncope&#46; In all the above-mentioned criteria&#44; other causes for QT prolongation should previously be ruled out&#46;<a class="elsevierStyleCrossRef" href="#bib0465"><span class="elsevierStyleSup">1</span></a></p></span><span id="sec0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0045">Short QT syndrome</span><p id="par0055" class="elsevierStylePara elsevierViewall">A rare inheritable channelopathy&#44; called Short QT Syndrome &#40;SQTS&#41;&#44; was first clinically described in 2000&#44; in three members of one family who presented with abnormally short QT intervals and tall peaked T-waves in the precordial ECG leads&#46;<a class="elsevierStyleCrossRef" href="#bib0550"><span class="elsevierStyleSup">18</span></a></p><p id="par0060" class="elsevierStylePara elsevierViewall">Gain-of-function mutations in genes encoding cardiac repolarizing K<span class="elsevierStyleSup">&#43;</span> channels &#40;i&#46;e&#46;&#44; KCNH2&#44; KCNQ1 and KCNJ2&#41; and loss-of-function mutations of calcium channel <span class="elsevierStyleItalic">CACNA1C</span>&#44; <span class="elsevierStyleItalic">CACNB2</span> and <span class="elsevierStyleItalic">CACNA2D1</span> genes have been associated with SQTS&#46;<a class="elsevierStyleCrossRefs" href="#bib0465"><span class="elsevierStyleSup">1&#44;7&#44;10</span></a> However&#44; the diagnostic yield of genetic testing remains low &#40;i&#46;e&#46;&#44; about 20&#37;&#41;&#46;<a class="elsevierStyleCrossRef" href="#bib0540"><span class="elsevierStyleSup">16</span></a></p><p id="par0065" class="elsevierStylePara elsevierViewall">SQTS is diagnosed when QTc interval is &#8804;340 ms or&#44; alternatively&#44; should be considered if QTc interval is &#8804;360 ms along with one or more of the following&#58; &#40;1&#41; survival from a VT&#47;VF episode&#44; in the absence of cardiac disease&#59; &#40;2&#41; a confirmed pathogenic mutation&#59; &#40;3&#41; a family history of SQTS&#44; or &#40;4&#41; a family history of sudden death at the age of &#60;40 years&#46;<a class="elsevierStyleCrossRef" href="#bib0465"><span class="elsevierStyleSup">1</span></a></p><p id="par0070" class="elsevierStylePara elsevierViewall">Apart from congenital SQTS&#44; other clinical scenarios&#44; such as electrolyte disturbances &#40;e&#46;g&#46;&#44; hypercalcemia&#44; hyperkalemia&#41;&#44; acidosis&#44; increased heart rate and increased levels of acetylcholine or catecholamine can shorten QT interval&#46;</p><p id="par0075" class="elsevierStylePara elsevierViewall">QT shortening can degenerate into paroxysmal atrial fibrillation &#40;AF&#41; and&#47;or VT and potentially lead to SCD&#46;<a class="elsevierStyleCrossRefs" href="#bib0550"><span class="elsevierStyleSup">18&#44;19</span></a></p></span><span id="sec0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0050">Brugada syndrome</span><p id="par0080" class="elsevierStylePara elsevierViewall">Brugada syndrome &#40;BrS&#41; is a relatively recent clinical entity&#44; first described in 1992 by a set of distinctive ECG features&#44; especially right bundle branch block and ST-segment elevation in right precordial leads &#40;i&#46;e&#46;&#44; V<span class="elsevierStyleInf">1</span> to V<span class="elsevierStyleInf">3</span>&#41;&#44; in the absence of other concurrent factors &#40;e&#46;g&#46;&#44; ischemia&#44; structural heart disease or electrolyte imbalance&#41;&#46;<a class="elsevierStyleCrossRef" href="#bib0560"><span class="elsevierStyleSup">20</span></a></p><p id="par0085" class="elsevierStylePara elsevierViewall">BrS is inherited through an autosomal dominant mode of transmission&#46; Approximately 20 culprit genes have been reported thus far&#46;<a class="elsevierStyleCrossRef" href="#bib0565"><span class="elsevierStyleSup">21</span></a> The pathogenesis of congenital BrS is more commonly due to loss-of-function mutations in the <span class="elsevierStyleItalic">SCN5A</span> gene&#46; Currently&#44; over 300 <span class="elsevierStyleItalic">SCN5A</span> gene mutations have been described&#44; accounting for the vast majority &#40;i&#46;e&#46;&#44; approximately 75&#37;&#41; of genotype-positive cases&#46;<a class="elsevierStyleCrossRef" href="#bib0570"><span class="elsevierStyleSup">22</span></a> Nevertheless&#44; genetic testing identifies such mutations in only about 20-25&#37; of BrS patients&#46;<a class="elsevierStyleCrossRef" href="#bib0540"><span class="elsevierStyleSup">16</span></a> The increase in the transient outward potassium current &#40;I<span class="elsevierStyleInf">to</span>&#41; and the decrease in the L-type Ca<span class="elsevierStyleSup">2&#43;</span> current &#40;I<span class="elsevierStyleInf">Ca&#44;L</span>&#41; have also been postulated to contribute to the pathogenesis of BrS&#46;<a class="elsevierStyleCrossRefs" href="#bib0535"><span class="elsevierStyleSup">15&#44;21</span></a></p><p id="par0090" class="elsevierStylePara elsevierViewall">Patients with a BrS ECG pattern are often clinically concealed at the time of diagnosis&#44; which in turn is often incidental&#46;<a class="elsevierStyleCrossRef" href="#bib0565"><span class="elsevierStyleSup">21</span></a> In fact&#44; patients may persist asymptomatically for life&#44; but a subgroup of BrS patients can experience syncope&#44; nocturnal agonal respiration and palpitations associated with high risk of fatal arrhythmias &#40;e&#46;g&#46;&#44; VT&#47;VF&#41; and SCD&#44; which generally occur in the third or fourth decades of life&#44; mainly at rest or during sleep&#46;<a class="elsevierStyleCrossRefs" href="#bib0525"><span class="elsevierStyleSup">13&#44;15&#44;21</span></a> Although BrS affects both males and women&#44; the condition appears to be 8 to 10 times more common in males&#46;<a class="elsevierStyleCrossRef" href="#bib0510"><span class="elsevierStyleSup">10</span></a></p><p id="par0095" class="elsevierStylePara elsevierViewall">BrS ECG patterns have been categorized as type 1&#44; 2 or 3 according to detailed characteristics of surface ECGs&#46; A coved ST-segment elevation &#8805;2 mm followed by a negative T wave is representative of a type 1 ECG pattern&#46; Type 2 comprises a saddleback ST-segment elevation of &#8805;0&#46;5 mm &#40;i&#46;e&#46;&#44; usually &#8805;2 mm in V<span class="elsevierStyleInf">2</span>&#41; in at least 1 right precordial lead &#40;i&#46;e&#46;&#44; V<span class="elsevierStyleInf">1</span>-V<span class="elsevierStyleInf">3</span>&#41;&#44; followed by a convex shape&#46; T-wave morphology differs in V<span class="elsevierStyleInf">1</span> and it is characteristically positive in V<span class="elsevierStyleInf">2</span>&#46; Type 3 pattern is characterized by either a coved or a saddleback appearance with an ST-segment elevation &#60;1 mm&#46;<a class="elsevierStyleCrossRef" href="#bib0575"><span class="elsevierStyleSup">23</span></a> Nonetheless&#44; only type 1 is recognized as diagnostic&#46; Type 2 and type 3 are not specific to BrS and&#44; therefore&#44; it is currently uncertain whether or not they should be considered BrS patterns&#46; However&#44; physicians should be aware and recognize these patterns as they can be an electrocardiographical presentation of some genuine BrS patients&#46;<a class="elsevierStyleCrossRef" href="#bib0565"><span class="elsevierStyleSup">21</span></a></p><p id="par0100" class="elsevierStylePara elsevierViewall">The diagnostic criteria of BrS were recently updated in the 2016 expert consensus conference on J-wave syndromes&#44;<a class="elsevierStyleCrossRef" href="#bib0575"><span class="elsevierStyleSup">23</span></a> since the criteria proposed in the 2015 guidelines<a class="elsevierStyleCrossRef" href="#bib0465"><span class="elsevierStyleSup">1</span></a> and in the previous 2013 consensus statement<a class="elsevierStyleCrossRef" href="#bib0580"><span class="elsevierStyleSup">24</span></a> tend to overdiagnose cases of the type 1 ECG pattern&#46; Overdiagnosis is unmasked after intravenous sodium-channel blocker challenge with ajmaline&#44; flecainide&#44; pilsicainide or procainamide&#46; In such patients&#44; BrS diagnosis should require that the patient also present with at least 1 of the following&#58; &#40;1&#41; nocturnal agonal respiration&#44; &#40;2&#41; syncope of probable arrhythmic cause&#44; &#40;3&#41; family history of SCD at less than 45 years old with negative autopsy&#44; &#40;4&#41; documented polymorphic VT or VF&#44; or &#40;5&#41; coved-type ECGs in family members&#46; A spontaneous type 1 ECG pattern in at least 1 right precordial lead &#40;i&#46;e&#46;&#44; V<span class="elsevierStyleInf">1</span>&#44; V<span class="elsevierStyleInf">2</span> and V<span class="elsevierStyleInf">3</span>&#44; placed in the 2nd&#44; 3rd and 4th intercostal spaces&#44; respectively&#41; is an independent BrS diagnostic criterion&#46;<a class="elsevierStyleCrossRef" href="#bib0575"><span class="elsevierStyleSup">23</span></a></p><p id="par0105" class="elsevierStylePara elsevierViewall">Since other acute &#40;e&#46;g&#46;&#44; coronary events&#44; metabolic disorders&#44; electrolyte disturbances&#41; and chronic &#40;e&#46;g&#46;&#44; ventricular hypertrophy&#44; autonomic nervous system disorders&#41; conditions can bring about ST-segment elevation patterns&#44; diagnosis of BrS is feasible only after these scenarios are ruled out&#46;<a class="elsevierStyleCrossRefs" href="#bib0565"><span class="elsevierStyleSup">21&#44;23</span></a></p></span></span><span id="sec0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0055">Aim</span><p id="par0110" class="elsevierStylePara elsevierViewall">The aim of this article is to comprehensively and critically review the recently published evidence with regard to drug-induced life-threatening arrhythmias and sudden cardiac death&#46; It will take into account the provision of data to physicians that are useful in the identification of the culprit drugs&#44; and thus&#44; contribute to the prompt recognition and management of these serious clinical conditions&#46;</p></span><span id="sec0040" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0060">Methods</span><p id="par0115" class="elsevierStylePara elsevierViewall">A comprehensive search was carried out through PubMed to identify human-based studies published in English and&#47;or Portuguese&#44; between January 1&#44; 2011 and January 12&#44; 2017&#46; The following keywords were used in combination&#44; both as Medical Subject Headings &#40;MeSH&#41; terms and text words&#58; &#8220;sudden cardiac death&#8221;&#44; &#8220;cardiac arrhythmias&#8221;&#44; &#8220;long QT syndrome&#8221;&#44; &#8220;torsades de pointes&#8221;&#44; &#8220;Brugada syndrome&#8221;&#44; &#8220;drug-related side effects and adverse reactions&#8221; and &#8220;pharmaceutical preparations&#8221;&#46; Additionally&#44; the text words &#8220;arrhythmias&#8221;&#44; &#8220;proarrhythmia&#8221;&#44; &#8220;torsade de pointes&#8221;&#44; &#8220;short QT syndrome&#8221;&#44; &#8220;adverse effects&#8221;&#44; &#8220;drugs&#8221; and &#8220;drug-induced&#8221; were combined with the abovementioned search terms&#46; The literature search encompassed relevant studies regarding drug-induced proarrhythmia and SCD&#44; especially those which aimed to address the so-called congenital and acquired arrhythmia syndromes LQTS&#44; SQTS or BrS&#46; A clinical perspective was chosen due to the wide range of data within this field&#46; Case reports were excluded&#44; unless they displayed original evidence or were the only source of a causal relationship&#46; Papers that only aimed to address detailed therapeutic strategies were not considered&#46;</p><p id="par0120" class="elsevierStylePara elsevierViewall">A total of 496 studies were identified&#46; Titles and abstracts were initially screened&#44; and full-text articles were retrieved&#46; The reference list of the identified articles was checked for potentially relevant papers&#46; Two reviewers &#40;i&#46;e&#46;&#44; first and last author&#41; independently analyzed each study to minimize bias&#46;</p><p id="par0125" class="elsevierStylePara elsevierViewall">The final review ended up comprising a total of 90 articles&#46; Two additional websites &#40;i&#46;e&#46;&#44; <a id="intr0025" class="elsevierStyleInterRef" href="http://www.crediblemeds.org/">www&#46;crediblemeds&#46;org</a><a class="elsevierStyleCrossRef" href="#bib0585"><span class="elsevierStyleSup">25</span></a>&#59; <a id="intr0030" class="elsevierStyleInterRef" href="http://www.brugadadrugs.org/">www&#46;brugadadrugs&#46;org</a><a class="elsevierStyleCrossRef" href="#bib0590"><span class="elsevierStyleSup">26</span></a>&#41; were included as they provide useful information regarding the aim of this review&#46;</p></span><span id="sec0045" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0065">Drug-induced proarrhythmia and SCD</span><p id="par0130" class="elsevierStylePara elsevierViewall">Drug-induced proarrhythmia is the outcome of prior or concomitant use of any drug with life-threatening proarrhythmic effects and SCD risk&#46;<a class="elsevierStyleCrossRefs" href="#bib0510"><span class="elsevierStyleSup">10&#44;27</span></a> Growing evidence suggests the implication of an increasing number of drugs in acquired forms of long QT &#40;<a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>&#41;&#44; short QT to a lesser extent &#40;<a class="elsevierStyleCrossRef" href="#tbl0010">Table 2</a>&#41; and Brugada syndrome &#40;<a class="elsevierStyleCrossRef" href="#tbl0015">Table 3</a>&#41;&#46;<a class="elsevierStyleCrossRef" href="#bib0510"><span class="elsevierStyleSup">10</span></a></p><elsevierMultimedia ident="tbl0005"></elsevierMultimedia><elsevierMultimedia ident="tbl0010"></elsevierMultimedia><elsevierMultimedia ident="tbl0015"></elsevierMultimedia><span id="sec0050" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0070">Drug-induced LQTS</span><p id="par0135" class="elsevierStylePara elsevierViewall">Acquired LQTS is undoubtedly more common than inherited LQTS&#46;<a class="elsevierStyleCrossRef" href="#bib0505"><span class="elsevierStyleSup">9</span></a> Drugs are undeniably the leading cause of acquired LQTS&#46;<a class="elsevierStyleCrossRef" href="#bib0600"><span class="elsevierStyleSup">28</span></a> Notably&#44; in the last decade&#44; drug-induced TdP was the single most common cause of the withdrawal or restriction of the use of drugs that have already been marketed&#46;<a class="elsevierStyleCrossRef" href="#bib0520"><span class="elsevierStyleSup">12</span></a></p><p id="par0140" class="elsevierStylePara elsevierViewall">The ACCF&#47;AHA scientific statement recognized a QTc interval of &#62;500 ms&#44; or an increase after drug administration of QTc &#62;60 ms from the pre-drug baseline&#44; as alarming signals that should warrant prompt management and correction&#46;<a class="elsevierStyleCrossRef" href="#bib0515"><span class="elsevierStyleSup">11</span></a> In fact&#44; the majority of drug-induced TdP cases has been reported with QTc intervals of &#62;500 ms&#46;<a class="elsevierStyleCrossRef" href="#bib0510"><span class="elsevierStyleSup">10</span></a></p><p id="par0145" class="elsevierStylePara elsevierViewall">However&#44; data suggests that the magnitude of QTc prolongation does not directly correlate with the risk of developing TdP&#46; Amiodarone and ranolazine are two paradigmatic cases&#44; which undoubtedly cause QT prolongation&#44; but with few reported cases of TdP&#46; Apparently&#44; these agents attenuate the dispersion of ventricular repolarization&#44; which balance out with the QT prolongation effect&#46;<a class="elsevierStyleCrossRef" href="#bib0510"><span class="elsevierStyleSup">10</span></a> Although not yet proven in congenital forms of LQTS&#44; indirect assessment of transmural dispersion of ventricular repolarization using Tpeak-end interval and the Tpeak-Tend&#47;QT ratio &#40;e&#46;g&#46;&#44; significantly increased in cigarette smokers&#41; has been demonstrated to properly predict the risk of potentially life-threatening arrhythmias in drug-induced LQTS&#46;<a class="elsevierStyleCrossRefs" href="#bib0505"><span class="elsevierStyleSup">9&#44;10&#44;29&#44;30</span></a> QT dispersion &#40;i&#46;e&#46;&#44; difference between the longest and shortest QT interval in the 12 ECG leads&#41;&#44; is another potential surrogate marker for ventricular repolarization heterogeneity&#44; which was shown to increase with the use of psychotropic drugs&#46;<a class="elsevierStyleCrossRef" href="#bib0615"><span class="elsevierStyleSup">31</span></a></p><p id="par0150" class="elsevierStylePara elsevierViewall">Nevertheless&#44; the QT interval is still widely used in clinical practice to assess the risk of TdP and SCD&#44; notwithstanding its poor predictive value&#46;<a class="elsevierStyleCrossRefs" href="#bib0505"><span class="elsevierStyleSup">9&#44;32</span></a></p><p id="par0155" class="elsevierStylePara elsevierViewall">Drug interactions with cardiac ion channels are the main mechanisms involved in potentially life-threatening arrhythmias&#46;<a class="elsevierStyleCrossRef" href="#bib0595"><span class="elsevierStyleSup">27</span></a> Theoretically&#44; almost all drugs associated with QT prolongation and TdP block the rapid delayed rectifier potassium current&#44; I<span class="elsevierStyleInf">Kr</span>&#44; but not all I<span class="elsevierStyleInf">Kr</span> inhibitors prolong the QT interval and cause TdP&#46;<a class="elsevierStyleCrossRefs" href="#bib0520"><span class="elsevierStyleSup">12&#44;14</span></a> However&#44; the use of these channel blockers in the general population has been associated with high risk of SCD&#46;<a class="elsevierStyleCrossRef" href="#bib0625"><span class="elsevierStyleSup">33</span></a></p><p id="par0160" class="elsevierStylePara elsevierViewall">Various drugs are metabolized by intestinal or hepatic cytochrome P450 &#40;CYP450&#41; enzymes&#46;<a class="elsevierStyleCrossRefs" href="#bib0530"><span class="elsevierStyleSup">14&#44;27</span></a> Methadone &#40;i&#46;e&#46;&#44; CYP2C19&#44; notably&#44; the &#42;2 variant that is associated with QTc prolongation&#44;<a class="elsevierStyleCrossRef" href="#bib0630"><span class="elsevierStyleSup">34</span></a> CYP3A4 and to a lesser extent the CYP2D6&#44; CYP2B6 and CYP1A2 enzymes<a class="elsevierStyleCrossRef" href="#bib0635"><span class="elsevierStyleSup">35</span></a>&#41;&#44; clarithromycin and erythromycin &#40;CYP3A enzymes&#41;&#44;<a class="elsevierStyleCrossRef" href="#bib0640"><span class="elsevierStyleSup">36</span></a> domperidone &#40;CYP3A4&#41;<a class="elsevierStyleCrossRef" href="#bib0645"><span class="elsevierStyleSup">37</span></a> and clozapine &#40;CYP2D6&#41;<a class="elsevierStyleCrossRef" href="#bib0650"><span class="elsevierStyleSup">38</span></a> are examples of such drugs&#46; If those pathways are more prone to be inhibited by the concurrent use of other drugs or their activity is impaired by certain gene polymorphisms&#44; extremely elevated drug serum levels and fatal outcomes are expected to occur&#46;<a class="elsevierStyleCrossRef" href="#bib0595"><span class="elsevierStyleSup">27</span></a></p><p id="par0165" class="elsevierStylePara elsevierViewall">Recently&#44; the nitric oxide synthase 1 adaptor protein &#40;NOS1AP&#41; genetic variation has been identified as a new genetic marker in modulating QT prolongation and SCD&#44; both in congenital and drug-induced LQTS&#46;<a class="elsevierStyleCrossRefs" href="#bib0600"><span class="elsevierStyleSup">28&#44;39</span></a> In fact&#44; along with P-glycoprotein&#44; a transmembrane efflux pump &#40;i&#46;e&#46;&#44; domperidone is one of its substrates<a class="elsevierStyleCrossRef" href="#bib0645"><span class="elsevierStyleSup">37</span></a>&#41;&#44; the NOS1AP gene appears to be implicated in the bioavailability of various QT-prolonging drugs&#44; especially calcium channel inhibitors &#40;e&#46;g&#46;&#44; verapamil and diltiazem&#41;&#44; since it is involved in the inhibition of L-type Ca<span class="elsevierStyleSup">2&#43;</span> channels&#46;<a class="elsevierStyleCrossRef" href="#bib0530"><span class="elsevierStyleSup">14</span></a></p><p id="par0170" class="elsevierStylePara elsevierViewall">Apart from subclinical congenital LQTS&#44; drug-induced TdP depends on a multitude of risk factors&#44; which comprise female gender&#44; advanced age and common clinical conditions&#44; such as bradycardia&#44; hypertension&#44; structural heart diseases &#40;e&#46;g&#46;&#44; congestive heart failure&#44; hypertrophic cardiomyopathy&#41; and electrolyte imbalances &#40;e&#46;g&#46;&#44; hypokalemia&#44; hypomagnesemia&#44; hypocalcemia&#41;&#46;<a class="elsevierStyleCrossRefs" href="#bib0515"><span class="elsevierStyleSup">11&#44;12&#44;38&#44;40&#44;41</span></a></p><p id="par0175" class="elsevierStylePara elsevierViewall">An up-to-date list of cardiovascular and non-cardiovascular drugs &#40;i&#46;e&#46;&#44; mainly psychotropics and antimicrobials<a class="elsevierStyleCrossRef" href="#bib0510"><span class="elsevierStyleSup">10</span></a>&#41; implicated in QT prolongation and&#47;or TdP is currently available at <a id="intr0035" class="elsevierStyleInterRef" href="http://www.crediblemeds.org/">www&#46;crediblemeds&#46;org</a>&#46;<a class="elsevierStyleCrossRef" href="#bib0585"><span class="elsevierStyleSup">25</span></a></p></span><span id="sec0055" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0075">Antiarrhythmic drugs</span><p id="par0180" class="elsevierStylePara elsevierViewall">Antiarrhythmic drugs are among the most harmful regarding their high risk of life-threatening arrhythmias&#46; Vaughan Williams class III drugs &#40;e&#46;g&#46;&#44; sotalol&#44; dofetilide&#44; ibutilide&#41; lead to the greatest concern for TdP within antiarrhythmics&#46;<a class="elsevierStyleCrossRef" href="#bib0595"><span class="elsevierStyleSup">27</span></a> Apart from the well-known QTc prolongation effect&#44; amiodarone exhibits a low risk of TdP&#44; when used alone&#46;<a class="elsevierStyleCrossRefs" href="#bib0505"><span class="elsevierStyleSup">9&#44;10&#44;42</span></a> Nevertheless&#44; TdP has already been reported with concomitant use &#40;e&#46;g&#46;&#44; erythromycin and haloperidol&#41;&#46;<a class="elsevierStyleCrossRef" href="#bib0660"><span class="elsevierStyleSup">40</span></a> Therefore&#44; ECG monitoring is required in all intensive care unit &#40;ICU&#41; patients receiving amiodarone&#44; since this subset of patients has a high incidence of concomitant use of other QT-prolonging drugs&#46;<a class="elsevierStyleCrossRef" href="#bib0670"><span class="elsevierStyleSup">42</span></a></p><p id="par0185" class="elsevierStylePara elsevierViewall">Notably&#44; pilsicainide&#44; a class Ic antiarrhythmic drug&#44; triggered TdP in an elderly patient who ended up dying suddenly&#44; two days after receiving it to convert his paroxysmal AF to sinus rhythm&#46;<a class="elsevierStyleCrossRef" href="#bib0675"><span class="elsevierStyleSup">43</span></a></p></span><span id="sec0060" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0080">Antianginal drugs</span><p id="par0190" class="elsevierStylePara elsevierViewall">In spite of its known QT-prolonging effect&#44; low risk of TdP and SCD have been reported with ranolazine&#44;<a class="elsevierStyleCrossRefs" href="#bib0510"><span class="elsevierStyleSup">10&#44;27</span></a> including when it is used to treat non-ST elevation acute coronary syndrome in patients with prolonged baseline QTc intervals&#46;<a class="elsevierStyleCrossRef" href="#bib0680"><span class="elsevierStyleSup">44</span></a></p></span><span id="sec0065" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0085">Antidepressant and antipsychotic drugs</span><p id="par0195" class="elsevierStylePara elsevierViewall">Tricyclic antidepressants are well-known risk factors for QT prolongation and TdP&#44; especially in overdose cases&#46;<a class="elsevierStyleCrossRefs" href="#bib0595"><span class="elsevierStyleSup">27&#44;45</span></a></p><p id="par0200" class="elsevierStylePara elsevierViewall">Overall&#44; selective serotonin-reuptake inhibitors &#40;SSRIs&#41; increase the QTc interval&#44; but citalopram and escitalopram seem to incite a more pronounced QTc prolongation in a dose-dependent fashion&#46;<a class="elsevierStyleCrossRefs" href="#bib0690"><span class="elsevierStyleSup">46&#8211;48</span></a> Nevertheless&#44; the role of citalopram as a trigger of TdP and SCD remains controversial&#44; as there are no concomitant risk factors for QT prolongation and TdP&#46;<a class="elsevierStyleCrossRef" href="#bib0705"><span class="elsevierStyleSup">49</span></a></p><p id="par0205" class="elsevierStylePara elsevierViewall">Although bupropion and venlafaxine prolong the QTc interval almost exclusively in overdose scenarios&#44; generally&#44; newer non-SSRIs pose a low risk of such effect at therapeutic doses&#46; Their shorter market life may explain the limited data&#46;<a class="elsevierStyleCrossRef" href="#bib0710"><span class="elsevierStyleSup">50</span></a></p><p id="par0210" class="elsevierStylePara elsevierViewall">In a cohort study&#44; no considerable differences regarding sudden death and ventricular arrhythmia &#40;SD&#47;VA&#41; risks were detected among 11 antidepressants and paroxetine&#46; High risk of SD&#47;VA was only reported with mirtazapine&#44; but the authors reminded us that such outcome was biased by confounding factors&#46; Therefore&#44; cardiac safety was considered similar among antidepressants&#46;<a class="elsevierStyleCrossRef" href="#bib0715"><span class="elsevierStyleSup">51</span></a></p><p id="par0215" class="elsevierStylePara elsevierViewall">Given the numerous adverse effects of antipsychotics&#44; drug-induced LQTS is truly one of the most dangerous&#46;<a class="elsevierStyleCrossRef" href="#bib0595"><span class="elsevierStyleSup">27</span></a> Overall&#44; first-generation antipsychotics are considered to be more likely to prolong QT interval and have higher risks of ventricular arrhythmias &#40;VAs&#41; and SCD than second-generation antipsychotics&#46;<a class="elsevierStyleCrossRefs" href="#bib0500"><span class="elsevierStyleSup">8&#44;52</span></a></p><p id="par0220" class="elsevierStylePara elsevierViewall">The Food and Drug Administration Adverse Event Reporting System &#40;FAERS&#41; database has been systematically analyzed to detect signals of torsadogenicity&#46;<a class="elsevierStyleCrossRefs" href="#bib0725"><span class="elsevierStyleSup">53&#44;54</span></a> In this regard&#44; detecting new potential signals of torsadogenicity &#40;e&#46;g&#46;&#44; with amisulpride&#44; cyamemazine and olanzapine&#41; provided new insights for pharmacovigilance in antipsychotics&#46; This is because it allowed updating the Arizona Center for Education and Research on Therapeutics &#40;AZCERT<a class="elsevierStyleCrossRef" href="#bib0585"><span class="elsevierStyleSup">25</span></a>&#41; drug list&#46;<a class="elsevierStyleCrossRef" href="#bib0730"><span class="elsevierStyleSup">54</span></a> One year later&#44; Fanoe et al&#46; combined pharmacovigilance data from various international databases&#46; Only haloperidol&#44; pimozide&#44; sertindole and ziprasidone were considered to be class B&#42; drugs &#40;i&#46;e&#46;&#44; &#8220;a drug with pronounced QT prolongation&#44; documented cases of TdP&#44; or other serious arrhythmias&#8221;&#41;&#46;<a class="elsevierStyleCrossRef" href="#bib0735"><span class="elsevierStyleSup">55</span></a> Alternatively&#44; the data analysis of three national spontaneous reporting systems &#40;i&#46;e&#46;&#44; France&#44; Germany and Italy&#41; demonstrated that in all of the national databases studied&#44; TdP events were reported only with amisulpride&#44; aripiprazole&#44; haloperidol&#44; olanzapine and risperidone&#46;<a class="elsevierStyleCrossRef" href="#bib0740"><span class="elsevierStyleSup">56</span></a></p><p id="par0225" class="elsevierStylePara elsevierViewall">Therefore&#44; available data on haloperidol have consistently favored its marked QT prolongation effect and high risk for TdP and SCD&#44;<a class="elsevierStyleCrossRefs" href="#bib0725"><span class="elsevierStyleSup">53&#8211;57</span></a> but such outcomes have been disparate for clozapine &#40;low risk of QTc prolongation<a class="elsevierStyleCrossRef" href="#bib0750"><span class="elsevierStyleSup">58</span></a>&#59; &#8220;very strong signals of torsadogenicity&#8221;<a class="elsevierStyleCrossRefs" href="#bib0725"><span class="elsevierStyleSup">53&#44;54</span></a>&#41; and olanzapine &#40;&#8220;a drug considered to be without any risk of QT prolongation or TdP&#8221;<a class="elsevierStyleCrossRef" href="#bib0735"><span class="elsevierStyleSup">55</span></a>&#59; &#8220;potential signal of torsadogenicity&#8221;<a class="elsevierStyleCrossRef" href="#bib0730"><span class="elsevierStyleSup">54</span></a>&#59; &#8220;very strong signal of torsadogenicity&#8221;<a class="elsevierStyleCrossRef" href="#bib0725"><span class="elsevierStyleSup">53</span></a>&#41;&#46; Despite ziprasidone having QT-prolonging and torsadogenic effects&#44;<a class="elsevierStyleCrossRefs" href="#bib0725"><span class="elsevierStyleSup">53&#8211;55</span></a> studies have failed to prove an increased risk of SD&#44; SCD or nonsuicide mortality&#46;<a class="elsevierStyleCrossRefs" href="#bib0755"><span class="elsevierStyleSup">59&#8211;61</span></a> Aripiprazole has a low risk of TdP and SCD&#44; at least in otherwise healthy patients&#46; However&#44; in patients at risk for TdP&#44; it may represent a safety concern&#44; since few studies have been carried in these vulnerable subsets&#46;<a class="elsevierStyleCrossRefs" href="#bib0770"><span class="elsevierStyleSup">62&#44;63</span></a> Cases of QTc prolongation&#44; TdP and SCD have been reported with quetiapine&#44; but only with concomitant risk factors for QT prolongation or TdP&#46;<a class="elsevierStyleCrossRef" href="#bib0780"><span class="elsevierStyleSup">64</span></a> Increased QTc prolongation and higher risk of SCD have been documented with risperidone during nighttime&#44; when compared to olanzapine users&#46;<a class="elsevierStyleCrossRef" href="#bib0785"><span class="elsevierStyleSup">65</span></a> These perilous effects are likely due to the increased serum levels of risperidone&#39;s active metabolite paliperidone in a dose-dependent manner and not to risperidone alone&#46;<a class="elsevierStyleCrossRef" href="#bib0790"><span class="elsevierStyleSup">66</span></a> Two retrospective cohort studies also made a comparison with olanzapine&#44; but both risperidone and quetiapine were not implicated in higher risk of SD or VAs&#46; According to the authors&#44; olanzapine was chosen as the referent&#44; since it is not linked to substantive QT prolongation&#46;<a class="elsevierStyleCrossRef" href="#bib0745"><span class="elsevierStyleSup">57</span></a></p><p id="par0230" class="elsevierStylePara elsevierViewall">Exposure to phenothiazine antipsychotics also carries a risk of QTc prolongation and TdP both in therapeutic and overdose settings&#44; particularly with levomepromazine&#44; chlorpromazine and promethazine&#46;<a class="elsevierStyleCrossRef" href="#bib0685"><span class="elsevierStyleSup">45</span></a></p><p id="par0235" class="elsevierStylePara elsevierViewall">Despite increasing safety concerns&#44; widespread use of antipsychotics with torsadogenic potential has been reported in some European countries in recent years&#44; mostly with haloperidol and thioridazine&#46;<a class="elsevierStyleCrossRef" href="#bib0795"><span class="elsevierStyleSup">67</span></a></p><p id="par0240" class="elsevierStylePara elsevierViewall">ECG monitoring is strongly recommended at hospital admission in patients with acute psychosis &#40;i&#46;e&#46;&#44; recently treated with antipsychotics&#41;&#44; due to the increased risk of QTc prolongation&#46;<a class="elsevierStyleCrossRef" href="#bib0800"><span class="elsevierStyleSup">68</span></a> Conversely&#44; Correll et al&#46; affirmed that&#44; unless other comorbidities are present &#40;e&#46;g&#46;&#44; cardiac diseases&#44; obesity&#44; hypokalemia&#41;&#44; ECG monitoring could potentially be restricted in young people treated with antipsychotics&#44; as significantly prolonged QTc interval was not demonstrated in this subset of patients&#46; Nevertheless&#44; the authors reinforced the idea that larger studies are required in this regard&#46;<a class="elsevierStyleCrossRef" href="#bib0805"><span class="elsevierStyleSup">69</span></a></p></span><span id="sec0070" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0090">Antimicrobial drugs</span><p id="par0245" class="elsevierStylePara elsevierViewall">Macrolide antibiotics are one of the most prescribed non-cardiovascular QT-prolonging agents&#44; and exhibit increased risk of fatal ventricular arrhythmias or SCD&#46;<a class="elsevierStyleCrossRefs" href="#bib0595"><span class="elsevierStyleSup">27&#44;36</span></a> Azithromycin was once considered to be relatively free of adverse cardiac effects&#46; However&#44; new data has been emerging regarding its cardiac safety&#46;<a class="elsevierStyleCrossRefs" href="#bib0810"><span class="elsevierStyleSup">70&#44;71</span></a></p><p id="par0250" class="elsevierStylePara elsevierViewall">Quinolones are broad-spectrum antimicrobials with known risk of QT prolongation&#46;<a class="elsevierStyleCrossRefs" href="#bib0595"><span class="elsevierStyleSup">27&#44;42</span></a> It is noteworthy that in a United States veterans study&#44;<a class="elsevierStyleCrossRef" href="#bib0815"><span class="elsevierStyleSup">71</span></a> levofloxacin was significantly associated with serious arrhythmias and death&#44; throughout the 10-day course of therapy&#46;</p><p id="par0255" class="elsevierStylePara elsevierViewall">QT prolongation and TdP have also been reported with antifungal agents&#44; mainly fluconazole&#46;<a class="elsevierStyleCrossRef" href="#bib0595"><span class="elsevierStyleSup">27</span></a></p></span><span id="sec0075" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0095">Anesthetic drugs</span><p id="par0260" class="elsevierStylePara elsevierViewall">Overall&#44; inhaled anesthetics can prolong the QTc interval or increase dispersion of ventricular repolarization to variable degrees&#46; However&#44; only sevoflurane has been associated with TdP risk&#44; though most likely with concomitant risk factors&#46;<a class="elsevierStyleCrossRef" href="#bib0555"><span class="elsevierStyleSup">19</span></a></p><p id="par0265" class="elsevierStylePara elsevierViewall">An ICU population-based study revealed that a flurane agent had been administered during anesthesia in the overwhelming majority of postoperative patients with QT interval prolongation&#46; Therefore&#44; the authors emphasized the need for QTc interval monitoring in all postoperative ICU patients&#46;<a class="elsevierStyleCrossRef" href="#bib0670"><span class="elsevierStyleSup">42</span></a></p><p id="par0270" class="elsevierStylePara elsevierViewall">A case of SCA following documented QTc interval prolongation &#40;i&#46;e&#46;&#44; 580-600 ms&#41; was reported in a 30-month-old boy during anesthesia induction with sevoflurane and nitric oxide before undergoing plastic surgery for bilateral cutaneous syndactyly&#46; Timothy Syndrome&#44; LQTS type 8 with typical features&#44; including syndactyly&#44; was established by detecting the p&#46;Gly406Arg mutation in the <span class="elsevierStyleItalic">CACNA1C</span> gene encoding Cav1&#46;2 L-type calcium channel&#46;<a class="elsevierStyleCrossRef" href="#bib0820"><span class="elsevierStyleSup">72</span></a></p><p id="par0275" class="elsevierStylePara elsevierViewall">Anticholinergic drugs &#40;e&#46;g&#46;&#44; atropine&#44; glycopyrronium bromide&#41; can prolong the QT interval when simultaneously used with anticholinesterases in healthy patients&#44; but TdP may occur when used alone in LQTS patients&#46;<a class="elsevierStyleCrossRef" href="#bib0555"><span class="elsevierStyleSup">19</span></a></p></span><span id="sec0080" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0100">Antiemetic drugs</span><p id="par0280" class="elsevierStylePara elsevierViewall">Domperidone can prolong the QTc interval and increase the risk of serious VAs and SCD&#46;<a class="elsevierStyleCrossRefs" href="#bib0645"><span class="elsevierStyleSup">37&#44;73</span></a> SCD risk seems to be higher in the first two weeks of treatment&#44; in patients older than 60 years and those with doses over 30 mg&#47;day&#46;<a class="elsevierStyleCrossRef" href="#bib0830"><span class="elsevierStyleSup">74</span></a></p><p id="par0285" class="elsevierStylePara elsevierViewall">Serotonin-receptor antagonists &#40;e&#46;g&#46;&#44; dolasetron&#44; granisetron and ondansetron&#41; are also known QT-prolonging drugs&#44; but their clinical significance remains unclear&#44; due to few reported cases of fatal cardiac arrhythmias and SCD&#46;<a class="elsevierStyleCrossRefs" href="#bib0555"><span class="elsevierStyleSup">19&#44;75</span></a></p></span><span id="sec0085" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0105">Antihistaminic drugs</span><p id="par0290" class="elsevierStylePara elsevierViewall">Apart from not appearing at the forefront of the most common events&#44; adverse cardiac effects are one of the most serious events for patients using first- or second-generation antihistamines&#46;<a class="elsevierStyleCrossRef" href="#bib0840"><span class="elsevierStyleSup">76</span></a></p><p id="par0295" class="elsevierStylePara elsevierViewall">The low number of antihistamines on the AZCERT drugs list<a class="elsevierStyleCrossRef" href="#bib0585"><span class="elsevierStyleSup">25</span></a> demonstrates the scarcity of pharmacovigilance data reporting TdP events&#46; An analysis of safety reports from the FAERS database revealed new evidence on torsadogenic activity for loratadine&#44; desloratadine&#44; cetirizine and fexofenadine&#44; in addition to diphenhydramine&#44;<a class="elsevierStyleCrossRef" href="#bib0840"><span class="elsevierStyleSup">76</span></a> which was already on the AZCERT list&#46;<a class="elsevierStyleCrossRef" href="#bib0585"><span class="elsevierStyleSup">25</span></a></p></span><span id="sec0090" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0110">Antineoplastic drugs</span><p id="par0300" class="elsevierStylePara elsevierViewall">High TdP event rates are almost exclusively reported with arsenic trioxide&#46; However&#44; BRAF inhibitor vemurafenib&#44; histone deacetylase inhibitors &#40;e&#46;g&#46;&#44; depsipeptide and vorinostat&#41; and tyrosine kinase inhibitors &#40;e&#46;g&#46;&#44; dasatinib&#44; nilotinib&#44; lapatinib&#44; sunitinib&#44; vandetinib&#41; are also commonly linked to QTc prolongation to varying degrees&#46;<a class="elsevierStyleCrossRefs" href="#bib0845"><span class="elsevierStyleSup">77&#44;78</span></a></p></span><span id="sec0095" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0115">Opioid replacement drug therapy</span><p id="par0305" class="elsevierStylePara elsevierViewall">Although more commonly reported at high doses &#40;&#62;200 mg&#47;day&#41;&#44; QT prolongation&#44; TdP and SD can occur even at lower doses of methadone &#40;&#60;100 mg&#47;day&#41;&#46; This is predominantly in early periods of treatment and&#47;or during concomitant use of either QT-prolonging agents or those which impair methadone metabolism&#46;<a class="elsevierStyleCrossRef" href="#bib0635"><span class="elsevierStyleSup">35</span></a></p></span><span id="sec0100" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0120">Attention deficit hyperactivity disorder drug therapy</span><p id="par0310" class="elsevierStylePara elsevierViewall">QT prolongation is associated with atomoxetine use in overdose&#46;<a class="elsevierStyleCrossRef" href="#bib0855"><span class="elsevierStyleSup">79</span></a> Nevertheless&#44; there is scarce evidence regarding the involvement of stimulants in fatal arrhythmias and SCD&#46;<a class="elsevierStyleCrossRefs" href="#bib0855"><span class="elsevierStyleSup">79&#44;80</span></a></p><p id="par0315" class="elsevierStylePara elsevierViewall">In a non-randomized cohort study conducted in adults&#44; the risk of VA or SD was significantly associated with methylphenidate use&#46; However&#44; the authors argued that the lack of a dose-response effect did not suggest a causal relationship&#46;<a class="elsevierStyleCrossRef" href="#bib0865"><span class="elsevierStyleSup">81</span></a></p></span><span id="sec0105" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0125">Non-therapeutic drugs</span><p id="par0320" class="elsevierStylePara elsevierViewall">Data collected from a large sample representative of the general US population revealed that binge drinkers displayed substantially prolonged QT intervals&#44; compared to non-binge drinkers or non-drinkers&#46;<a class="elsevierStyleCrossRef" href="#bib0870"><span class="elsevierStyleSup">82</span></a></p><p id="par0325" class="elsevierStylePara elsevierViewall">TdP was reported in a previously healthy 43-year-old woman who presented with syncope after excessive intake of ginseng for 6 months&#46;<a class="elsevierStyleCrossRef" href="#bib0875"><span class="elsevierStyleSup">83</span></a></p><p id="par0330" class="elsevierStylePara elsevierViewall">Ozturk S et al&#46; described the case of a 59-year-old woman who developed TdP after two days of drinking 5-6 glasses of licorice root tea for constipation&#46; The authors hypothesized that glycyrrhizin was the culprit compound due to its known effects on both cardiac depolarization and repolarization&#46;<a class="elsevierStyleCrossRef" href="#bib0880"><span class="elsevierStyleSup">84</span></a></p></span><span id="sec0110" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0130">Drug-induced SQTS</span><p id="par0335" class="elsevierStylePara elsevierViewall">Drug-induced SQTS is still a rarely reported condition&#46;<a class="elsevierStyleCrossRef" href="#bib0885"><span class="elsevierStyleSup">85</span></a> Therefore&#44; its clinical significance is still unclear&#44; since few fatal arrhythmias and SCD cases have been described thus far&#46;<a class="elsevierStyleCrossRef" href="#bib0890"><span class="elsevierStyleSup">86</span></a></p></span><span id="sec0115" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0135">Antiepileptic drugs</span><p id="par0340" class="elsevierStylePara elsevierViewall">Rufinamide has been reported as a QT shortening agent&#46; In patients receiving rufinamide&#44; the concomitant use of lamotrigine and valproic acid has been associated with a significant decrease in the QT interval&#46;<a class="elsevierStyleCrossRef" href="#bib0890"><span class="elsevierStyleSup">86</span></a></p></span><span id="sec0120" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0140">Drug-induced BrS</span><p id="par0345" class="elsevierStylePara elsevierViewall">Evidence suggests that a rising number of drugs universally used in daily clinical practice can reveal the typical ECG pattern of BrS and&#44; thus&#44; potentially lead to fatal arrhythmias&#46;<a class="elsevierStyleCrossRef" href="#bib0895"><span class="elsevierStyleSup">87</span></a></p><p id="par0350" class="elsevierStylePara elsevierViewall">Aside from drugs&#44; other clinical scenarios&#44; including febrile state &#40;e&#46;g&#46;&#44; hyperthermia&#44; hypothermia&#41; and electrolyte disturbances &#40;e&#46;g&#46;&#44; hyperkalemia&#44; hypokalemia&#44; hypercalcemia&#44; hyponatremia&#41;&#44; can trigger a type 1 pattern and modulate the occurrence of potentially life-threatening arrhythmias&#46; Some refer to these modifying factors as &#8220;phenocopies&#8221;&#46; However&#44; at least for now&#44; it is not proper to do so&#44; due to the lack of data regarding genetic predisposition&#46;<a class="elsevierStyleCrossRefs" href="#bib0565"><span class="elsevierStyleSup">21&#44;23</span></a> These conditions are actually more suitably designated as acquired forms of Brugada ECG pattern or BrS&#46;<a class="elsevierStyleCrossRef" href="#bib0575"><span class="elsevierStyleSup">23</span></a></p><p id="par0355" class="elsevierStylePara elsevierViewall">Psychotropic and anesthetic drugs are the most common non-cardiovascular agents involved in BrS ECG phenotype&#46;<a class="elsevierStyleCrossRef" href="#bib0895"><span class="elsevierStyleSup">87</span></a> Postema et al&#46; founded the website <a id="intr0040" class="elsevierStyleInterRef" href="http://www.brugadadrugs.org/">www&#46;brugadadrugs&#46;org</a> to guarantee the worldwide availability of cardiac safety information regarding drug prescription in BrS patients&#46;<a class="elsevierStyleCrossRef" href="#bib0590"><span class="elsevierStyleSup">26</span></a></p></span><span id="sec0125" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0145">Antiarrhythmic drugs</span><p id="par0360" class="elsevierStylePara elsevierViewall">Type 1 BrS ECG pattern is aggravated by drugs that block the cardiac Na<span class="elsevierStyleSup">&#43;</span> channel&#46; Corroborating this finding&#44; some of them &#40;i&#46;e&#46;&#44; ajmaline&#44; flecainide&#44; pilsicainide and procainamide&#41; are currently used for diagnostic purposes to unmask such a typical pattern in concealed BrS patients&#46;<a class="elsevierStyleCrossRef" href="#bib0535"><span class="elsevierStyleSup">15</span></a> Nevertheless&#44; it is noteworthy that flecainide has demonstrated an increased risk of SCD when administered to treat AF&#46;<a class="elsevierStyleCrossRef" href="#bib0900"><span class="elsevierStyleSup">88</span></a></p><p id="par0365" class="elsevierStylePara elsevierViewall">BrS ECG type 1 and type 3 patterns were reported while amiodarone was prophylactically used for AF&#44; following coronary artery bypass grafting&#46;<a class="elsevierStyleCrossRef" href="#bib0905"><span class="elsevierStyleSup">89</span></a></p></span><span id="sec0130" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0150">Antidepressants and antipsychotic drugs</span><p id="par0370" class="elsevierStylePara elsevierViewall">Some tricyclic and SSRI antidepressants and antipsychotics &#40;e&#46;g&#46;&#44; lithium&#41; can induce a BrS ECG phenotype by blocking I<span class="elsevierStyleInf">Na</span> currents&#46;<a class="elsevierStyleCrossRefs" href="#bib0650"><span class="elsevierStyleSup">38&#44;87</span></a></p><p id="par0375" class="elsevierStylePara elsevierViewall">In a population-based study&#44; nortriptyline&#44; an example of such a drug&#44; was associated with a significant 4&#46;5-fold increase in the risk for SCA&#46;<a class="elsevierStyleCrossRef" href="#bib0485"><span class="elsevierStyleSup">5</span></a></p><p id="par0380" class="elsevierStylePara elsevierViewall">Although fluvoxamine and paroxetine at therapeutic doses and fluoxetine in overdose can trigger a BrS ECG pattern&#44; no severe VAs have been reported thus far&#46; Similarly&#44; phenothiazine antipsychotics &#40;including cyamemazine&#44; perphenazine and thioridazine&#41; are well-known culprit agents in drug-induced BrS&#44; but without causing fatal VAs&#46;<a class="elsevierStyleCrossRef" href="#bib0895"><span class="elsevierStyleSup">87</span></a></p></span><span id="sec0135" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0155">Epilepsy and antiepileptic drug therapy</span><p id="par0385" class="elsevierStylePara elsevierViewall">Epilepsy is considered to be an independent risk factor for life-threatening arrhythmias and SCD&#46; In fact&#44; epilepsy has been associated with a two- to three-fold higher risk for SCD than in the general population and with a six-fold higher risk in poorly controlled patients&#46;<a class="elsevierStyleCrossRef" href="#bib0910"><span class="elsevierStyleSup">90</span></a></p><p id="par0390" class="elsevierStylePara elsevierViewall">Recently&#44; Ishizue et al&#46; concluded that the concomitant use of sodium channel-blocking antiepileptic drugs&#44; including carbamazepine&#44; phenytoin and lamotrigine&#44; significantly caused a BrS type 1 pattern&#46; Conversely&#44; the authors admitted the inability to assess the 12-lead ECGs of a large proportion of epilepsy patients&#44; before and after antiepileptic therapy&#46; As a result&#44; epilepsy as a confounding factor cannot be ruled out&#46;<a class="elsevierStyleCrossRef" href="#bib0915"><span class="elsevierStyleSup">91</span></a></p><p id="par0395" class="elsevierStylePara elsevierViewall">Bardai et al&#46; revealed the increased risk of SCD with the use of sodium channel-blocking antiepileptics in epilepsy patients &#40;i&#46;e&#46;&#44; carbamazepine and gabapentin&#41; that was independent from the underlying epileptic condition&#46; In addition&#44; off-label drug use in non-epileptic patients has also been correlated with increased risk for SCD&#44; similarly to epilepsy per se&#46; If we transfer these conclusions to clinical practice&#44; measures involving seizure control with antiepileptic drugs are required&#44; but the risk of SCD must always be taken into account&#46;<a class="elsevierStyleCrossRef" href="#bib0910"><span class="elsevierStyleSup">90</span></a></p></span><span id="sec0140" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0160">Anesthetic drugs</span><p id="par0400" class="elsevierStylePara elsevierViewall">Despite having one of the safest profiles within modern anesthetics&#44; high doses of propofol can lead to SCD&#44; a condition termed &#8220;propofol infusion syndrome&#8221;&#46; A Brugada ECG pattern is commonly seen before &#8220;propofol infusion syndrome&#8221; occurs&#46; Thus BrS is&#44; until proven otherwise&#44; an underlying mechanism for potentially life-threatening arrhythmias and SCD&#46;<a class="elsevierStyleCrossRefs" href="#bib0510"><span class="elsevierStyleSup">10&#44;87</span></a></p></span><span id="sec0145" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0165">Antiemetic drugs</span><p id="par0405" class="elsevierStylePara elsevierViewall">Metoclopramide has been reported to trigger typical BrS ECG features at therapeutic doses&#44; without being involved in serious arrhythmias&#46;<a class="elsevierStyleCrossRef" href="#bib0895"><span class="elsevierStyleSup">87</span></a></p><p id="par0410" class="elsevierStylePara elsevierViewall">In a population-based nested case-control study&#44; oral exposure to metoclopramide demonstrated higher risk for developing SCD than oral exposure to domperidone&#46; However&#44; the authors alleged that this was an unexpected outcome and thus recommended further research in this regard&#46;<a class="elsevierStyleCrossRef" href="#bib0830"><span class="elsevierStyleSup">74</span></a></p></span><span id="sec0150" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0170">Antihistaminic drugs</span><p id="par0415" class="elsevierStylePara elsevierViewall">Both first- and second-generation antihistamines &#40;e&#46;g&#46;&#44; diphenhydramine almost exclusively in overdose and terfenadine&#41; have been involved in drug-induced BrS&#46;<a class="elsevierStyleCrossRef" href="#bib0895"><span class="elsevierStyleSup">87</span></a></p></span><span id="sec0155" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0175">Non-therapeutic drugs</span><p id="par0420" class="elsevierStylePara elsevierViewall">Type 1 Brugada ECG pattern was documented in a woman with a family history of SCD&#44; who used topical nicotine patches for smoking cessation at high doses&#46;<a class="elsevierStyleCrossRef" href="#bib0920"><span class="elsevierStyleSup">92</span></a></p><p id="par0425" class="elsevierStylePara elsevierViewall">Cocaine and alcohol are two well-known triggers of BrS-like ECG pattern and VF&#44; both alone or with cocaethylene&#44; the ensuing metabolite of their combined use&#46;<a class="elsevierStyleCrossRefs" href="#bib0535"><span class="elsevierStyleSup">15&#44;87</span></a></p></span></span><span id="sec0160" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0180">Discussion and conclusions</span><p id="par0430" class="elsevierStylePara elsevierViewall">An increasing number of cardiovascular and non-cardiovascular drugs have been broadly associated with proarrhythmia and SCD&#46; In fact&#44; drug-induced proarrhythmia should always be viewed as a prelude to SCD&#46;<a class="elsevierStyleCrossRef" href="#bib0510"><span class="elsevierStyleSup">10</span></a> Hence&#44; it has been a growing challenge for physicians&#44; the regulatory agencies responsible for assessing drug safety and the pharmaceutical industry due to the pressure to create newer and safer agents&#46;<a class="elsevierStyleCrossRef" href="#bib0895"><span class="elsevierStyleSup">87</span></a></p><p id="par0435" class="elsevierStylePara elsevierViewall">Physicians should weigh the risks of potentially fatal outcomes against therapeutic benefits when making decisions about drug prescriptions&#46; In the event of a suspicious drug-induced proarrhythmia&#44; withdrawal of the offending drugs is recommended&#44; but only after ruling out other concomitant risk factors&#46;<a class="elsevierStyleCrossRef" href="#bib0520"><span class="elsevierStyleSup">12</span></a></p><p id="par0440" class="elsevierStylePara elsevierViewall">Physicians who are aware of inherited arrhythmia syndrome should provide a letter or a similar useful tool to their patients and family members&#46;<a class="elsevierStyleCrossRef" href="#bib0535"><span class="elsevierStyleSup">15</span></a> Postema et al&#46; provide an example of such a letter&#44; available in various languages on their website&#44; which contains drugs that should be avoided or contraindicated in BrS patients&#46;<a class="elsevierStyleCrossRef" href="#bib0590"><span class="elsevierStyleSup">26</span></a></p><p id="par0445" class="elsevierStylePara elsevierViewall">The uncertainty regarding the correlation between the magnitude of QT interval prolongation and the risk of TdP events should lead to a search for more knowledge on risk stratification of drug-induced TdP&#44; given the possible devastating consequences&#46;</p><p id="par0450" class="elsevierStylePara elsevierViewall">Post-approval safety studies provide reliable data for physicians about drug safety&#46; Given the tremendous significance in clinical practice&#44; this review highlights the need for synergy among physicians&#44; regulatory agencies and drug manufacturers&#44; and the need for routine spontaneous reporting and drug utilization analyses&#46;</p><p id="par0455" class="elsevierStylePara elsevierViewall">Future studies to obtain further knowledge and a better understanding of genetic variants related to pharmacokinetics and pharmacodynamics are crucial to more accurately predict drug-induced fatal outcomes for at-risk patients and to clarify which drugs can be administrated more safely&#46; This may avoid the inappropriate withdrawal of certain drugs from the market&#46; Undoubtedly&#44; the field of genetics is growing faster than expected&#44; and it will surely play a key role in this major health concern&#46;</p></span></span>"
    "textoCompletoSecciones" => array:1 [
      "secciones" => array:10 [
        0 => array:3 [
          "identificador" => "xres1041011"
          "titulo" => "Abstract"
          "secciones" => array:1 [
            0 => array:1 [
              "identificador" => "abst0005"
            ]
          ]
        ]
        1 => array:2 [
          "identificador" => "xpalclavsec994073"
          "titulo" => "Keywords"
        ]
        2 => array:3 [
          "identificador" => "xres1041012"
          "titulo" => "Resumo"
          "secciones" => array:1 [
            0 => array:1 [
              "identificador" => "abst0010"
            ]
          ]
        ]
        3 => array:2 [
          "identificador" => "xpalclavsec994072"
          "titulo" => "Palavras-chave"
        ]
        4 => array:3 [
          "identificador" => "sec0005"
          "titulo" => "Introduction"
          "secciones" => array:5 [
            0 => array:2 [
              "identificador" => "sec0010"
              "titulo" => "Sudden cardiac death"
            ]
            1 => array:2 [
              "identificador" => "sec0015"
              "titulo" => "Inherited channelopathies"
            ]
            2 => array:2 [
              "identificador" => "sec0020"
              "titulo" => "QT prolongation&#44; torsades de pointes and congenital long QT syndrome"
            ]
            3 => array:2 [
              "identificador" => "sec0025"
              "titulo" => "Short QT syndrome"
            ]
            4 => array:2 [
              "identificador" => "sec0030"
              "titulo" => "Brugada syndrome"
            ]
          ]
        ]
        5 => array:2 [
          "identificador" => "sec0035"
          "titulo" => "Aim"
        ]
        6 => array:2 [
          "identificador" => "sec0040"
          "titulo" => "Methods"
        ]
        7 => array:3 [
          "identificador" => "sec0045"
          "titulo" => "Drug-induced proarrhythmia and SCD"
          "secciones" => array:22 [
            0 => array:2 [
              "identificador" => "sec0050"
              "titulo" => "Drug-induced LQTS"
            ]
            1 => array:2 [
              "identificador" => "sec0055"
              "titulo" => "Antiarrhythmic drugs"
            ]
            2 => array:2 [
              "identificador" => "sec0060"
              "titulo" => "Antianginal drugs"
            ]
            3 => array:2 [
              "identificador" => "sec0065"
              "titulo" => "Antidepressant and antipsychotic drugs"
            ]
            4 => array:2 [
              "identificador" => "sec0070"
              "titulo" => "Antimicrobial drugs"
            ]
            5 => array:2 [
              "identificador" => "sec0075"
              "titulo" => "Anesthetic drugs"
            ]
            6 => array:2 [
              "identificador" => "sec0080"
              "titulo" => "Antiemetic drugs"
            ]
            7 => array:2 [
              "identificador" => "sec0085"
              "titulo" => "Antihistaminic drugs"
            ]
            8 => array:2 [
              "identificador" => "sec0090"
              "titulo" => "Antineoplastic drugs"
            ]
            9 => array:2 [
              "identificador" => "sec0095"
              "titulo" => "Opioid replacement drug therapy"
            ]
            10 => array:2 [
              "identificador" => "sec0100"
              "titulo" => "Attention deficit hyperactivity disorder drug therapy"
            ]
            11 => array:2 [
              "identificador" => "sec0105"
              "titulo" => "Non-therapeutic drugs"
            ]
            12 => array:2 [
              "identificador" => "sec0110"
              "titulo" => "Drug-induced SQTS"
            ]
            13 => array:2 [
              "identificador" => "sec0115"
              "titulo" => "Antiepileptic drugs"
            ]
            14 => array:2 [
              "identificador" => "sec0120"
              "titulo" => "Drug-induced BrS"
            ]
            15 => array:2 [
              "identificador" => "sec0125"
              "titulo" => "Antiarrhythmic drugs"
            ]
            16 => array:2 [
              "identificador" => "sec0130"
              "titulo" => "Antidepressants and antipsychotic drugs"
            ]
            17 => array:2 [
              "identificador" => "sec0135"
              "titulo" => "Epilepsy and antiepileptic drug therapy"
            ]
            18 => array:2 [
              "identificador" => "sec0140"
              "titulo" => "Anesthetic drugs"
            ]
            19 => array:2 [
              "identificador" => "sec0145"
              "titulo" => "Antiemetic drugs"
            ]
            20 => array:2 [
              "identificador" => "sec0150"
              "titulo" => "Antihistaminic drugs"
            ]
            21 => array:2 [
              "identificador" => "sec0155"
              "titulo" => "Non-therapeutic drugs"
            ]
          ]
        ]
        8 => array:2 [
          "identificador" => "sec0160"
          "titulo" => "Discussion and conclusions"
        ]
        9 => array:1 [
          "titulo" => "References"
        ]
      ]
    ]
    "pdfFichero" => "main.pdf"
    "tienePdf" => true
    "PalabrasClave" => array:2 [
      "en" => array:1 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Keywords"
          "identificador" => "xpalclavsec994073"
          "palabras" => array:6 [
            0 => "Sudden cardiac death"
            1 => "Long QT syndrome"
            2 => "Torsades de pointes"
            3 => "Short QT syndrome"
            4 => "Brugada syndrome"
            5 => "Pharmaceutical preparations"
          ]
        ]
      ]
      "pt" => array:1 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Palavras-chave"
          "identificador" => "xpalclavsec994072"
          "palabras" => array:6 [
            0 => "Morte s&#250;bita card&#237;aca"
            1 => "S&#237;ndrome do QT longo"
            2 => "<span class="elsevierStyleItalic">Torsades de pointes</span>"
            3 => "S&#237;ndrome do QT curto"
            4 => "S&#237;ndrome de Brugada"
            5 => "Prepara&#231;&#245;es farmac&#234;uticas"
          ]
        ]
      ]
    ]
    "tieneResumen" => true
    "resumen" => array:2 [
      "en" => array:2 [
        "titulo" => "Abstract"
        "resumen" => "<span id="abst0005" class="elsevierStyleSection elsevierViewall"><p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Sudden cardiac death is a major public health challenge&#44; which can be caused by genetic or acquired structural or electrophysiological abnormalities&#46; These abnormalities include hereditary channelopathies&#58; long QT&#44; short QT and Brugada syndromes&#46; These syndromes are a notable concern&#44; particularly in young people&#44; due to their high propensity for severe ventricular arrhythmias and sudden cardiac death&#46;</p><p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">Current evidence suggests the involvement of an increasing number of drugs in acquired forms of long QT and Brugada syndromes&#46; However&#44; drug-induced short QT syndrome is still a rarely reported condition&#46; Therefore&#44; there has been speculation on its clinical significance&#44; since few fatal arrhythmias and sudden cardiac death cases have been described so far&#46;</p><p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">Drug-induced proarrhythmia is a growing challenge for physicians&#44; regulatory agencies and the pharmaceutical industry&#46; Physicians should weigh the risks of potentially fatal outcomes against the therapeutic benefits&#44; when making decisions about drug prescriptions&#46; Growing concerns about its safety and the need for more accurate predictive models for drug-induced fatal outcomes justify further research in these fields&#46;</p><p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">The aim of this article is to comprehensively and critically review the recently published evidence with regard to drug-induced life-threatening arrhythmias and sudden cardiac death&#46; This article will take into account the provision of data to physicians that are useful in the identification of the culprit drugs&#44; and thus&#44; contribute to the prompt recognition and management of these serious clinical conditions&#46;</p></span>"
      ]
      "pt" => array:2 [
        "titulo" => "Resumo"
        "resumen" => "<span id="abst0010" class="elsevierStyleSection elsevierViewall"><p id="spar0025" class="elsevierStyleSimplePara elsevierViewall">A morte s&#250;bita card&#237;aca &#233; um desafio significativo para a sa&#250;de p&#250;blica&#44; pode desencadear-se de anormalidades estruturais ou eletrofisiol&#243;gicas&#44; tanto gen&#233;ticas como adquiridas&#44; e abranger as assim chamadas canalopatias heredit&#225;rias&#58; s&#237;ndromes do QT longo&#44; QT curto e Brugada&#46; Essas s&#237;ndromes s&#227;o um problema consider&#225;vel&#44; particularmente para os jovens&#44; pela sua elevada propens&#227;o para arritmias ventriculares graves e morte s&#250;bita card&#237;aca&#46;</p><p id="spar0030" class="elsevierStyleSimplePara elsevierViewall">A evid&#234;ncia atual sugere o envolvimento de um n&#250;mero crescente de f&#225;rmacos nas formas adquiridas das s&#237;ndromes do QT longo e Brugada&#46; No entanto&#44; a s&#237;ndrome do QT curto induzida por f&#225;rmacos &#233; ainda uma condi&#231;&#227;o raramente reportada&#46; Consequentemente&#44; especula&#231;&#227;o tem surgido sobre o seu significado cl&#237;nico&#44; uma vez que poucos casos de arritmias fatais e de morte s&#250;bita card&#237;aca foram descritos at&#233; ao momento&#46;</p><p id="spar0035" class="elsevierStyleSimplePara elsevierViewall">A pr&#243;-arritmia induzida por f&#225;rmacos &#233; um desafio crescente tanto para m&#233;dicos como para entidades reguladoras e ind&#250;stria farmac&#234;utica&#46; Os m&#233;dicos devem pesar o risco de desfechos potencialmente fatais com os benef&#237;cios terap&#234;uticos&#44; aquando da tomada de decis&#245;es na prescri&#231;&#227;o de f&#225;rmacos&#46; As preocupa&#231;&#245;es crescentes sobre a sua seguran&#231;a e a necessidade de modelos preditivos mais precisos para desfechos fatais induzidos por f&#225;rmacos justificam pesquisas adicionais nesses dom&#237;nios&#46;</p><p id="spar0040" class="elsevierStyleSimplePara elsevierViewall">O objetivo deste artigo foi rever&#44; de forma abrangente e cr&#237;tica&#44; a evid&#234;ncia publicada recentemente&#44; no que diz respeito &#224;s arritmias potencialmente fatais e morte s&#250;bita card&#237;aca induzidas por f&#225;rmacos&#44; tendo em considera&#231;&#227;o o fornecimento de dados &#250;teis para m&#233;dicos na identifica&#231;&#227;o dos f&#225;rmacos respons&#225;veis e&#44; assim&#44; contribuir para o pronto reconhecimento e gest&#227;o desses quadros cl&#237;nicos graves&#46;</p></span>"
      ]
    ]
    "multimedia" => array:3 [
      0 => array:8 [
        "identificador" => "tbl0005"
        "etiqueta" => "Table 1"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at1"
            "detalle" => "Table "
            "rol" => "short"
          ]
        ]
        "tabla" => array:3 [
          "leyenda" => "<p id="spar0050" class="elsevierStyleSimplePara elsevierViewall">Adapted from the website <a class="elsevierStyleInterRef" target="_blank" id="intr0005" href="http://www.crediblemeds.org/">www&#46;crediblemeds&#46;org</a><a class="elsevierStyleCrossRef" href="#bib0585"><span class="elsevierStyleSup">25</span></a> &#40;accessed January 12&#44; 2017&#41;&#46; For an extensive and systematically updated list of all available evidence about the offending drugs and corresponding TdP risk categories&#44; please visit <a class="elsevierStyleInterRef" target="_blank" id="intr0010" href="http://www.crediblemeds.org/">www&#46;crediblemeds&#46;org</a>&#46;</p><p id="spar0055" class="elsevierStyleSimplePara elsevierViewall"><span class="elsevierStyleItalic">Abbreviations</span>&#58; GI&#58; gastrointestinal&#59; SNRI&#58; serotonin and norepinephrine reuptake inhibitors&#59; SSRI&#58; selective serotonin reuptake inhibitors&#59; TdP&#58; torsades de pointes&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Drug Class&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Risk category<a class="elsevierStyleCrossRef" href="#tblfn0030"><span class="elsevierStyleSup">&#42;&#42;&#42;</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Generic name&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="table-entry  " rowspan="2" align="left" valign="top">Antianginals</td><td class="td" title="table-entry  " align="left" valign="top">Known&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Bepridil<a class="elsevierStyleCrossRef" href="#tblfn0020"><span class="elsevierStyleSup">&#167;</span></a><a class="elsevierStyleCrossRefs" href="#bib0510"><span class="elsevierStyleSup">10&#44;38</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Conditional&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Ranolazine<a class="elsevierStyleCrossRef" href="#bib0510"><span class="elsevierStyleSup">10</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Antiarrhythmics&#44; class Ia&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Known&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Disopyramide&#44;<a class="elsevierStyleCrossRefs" href="#bib0555"><span class="elsevierStyleSup">19&#44;38</span></a> Procainamide&#44;<a class="elsevierStyleCrossRef" href="#bib0555"><span class="elsevierStyleSup">19</span></a> Quinidine<a class="elsevierStyleCrossRefs" href="#bib0525"><span class="elsevierStyleSup">13&#44;14&#44;19&#44;27</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Antiarrhythmics&#44; class III&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Known&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Amiodarone&#44;<a class="elsevierStyleCrossRefs" href="#bib0465"><span class="elsevierStyleSup">1&#44;10&#44;14&#44;19&#44;27&#44;38&#44;40&#44;42</span></a><a class="elsevierStyleCrossRef" href="#tblfn0015"><span class="elsevierStyleSup">&#8225;</span></a> Dofetilide&#44;<a class="elsevierStyleCrossRefs" href="#bib0530"><span class="elsevierStyleSup">14&#44;19&#44;27</span></a> Ibutilide<a class="elsevierStyleCrossRefs" href="#bib0555"><span class="elsevierStyleSup">19&#44;27&#44;38</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Antiarrhythmics&#47;Beta blockers&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Known&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Sotalol<a class="elsevierStyleCrossRefs" href="#bib0465"><span class="elsevierStyleSup">1&#44;10&#44;13&#44;14&#44;19&#44;27&#44;38</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Antibiotics&#44; macrolides&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Known&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Azithromycin&#44;<a class="elsevierStyleCrossRefs" href="#bib0640"><span class="elsevierStyleSup">36&#44;42&#44;71</span></a> Clarithromycin&#44;<a class="elsevierStyleCrossRefs" href="#bib0465"><span class="elsevierStyleSup">1&#44;27&#44;36</span></a> Erythromycin<a class="elsevierStyleCrossRefs" href="#bib0465"><span class="elsevierStyleSup">1&#44;27&#44;36&#44;38&#44;40</span></a><a class="elsevierStyleCrossRef" href="#tblfn0015"><span class="elsevierStyleSup">&#8225;</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Antibiotics&#44; quinolones&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Known&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Ciprofloxacin&#44;<a class="elsevierStyleCrossRef" href="#bib0670"><span class="elsevierStyleSup">42</span></a> Grepafloxacin&#44;<a class="elsevierStyleCrossRef" href="#tblfn0020"><span class="elsevierStyleSup">&#167;</span></a><a class="elsevierStyleCrossRef" href="#bib0595"><span class="elsevierStyleSup">27</span></a> Levofloxacin&#44;<a class="elsevierStyleCrossRefs" href="#bib0670"><span class="elsevierStyleSup">42&#44;71</span></a> Moxifloxacin&#44;<a class="elsevierStyleCrossRef" href="#bib0530"><span class="elsevierStyleSup">14</span></a> Sparfloxacin<a class="elsevierStyleCrossRef" href="#tblfn0020"><span class="elsevierStyleSup">&#167;</span></a><a class="elsevierStyleCrossRef" href="#bib0595"><span class="elsevierStyleSup">27</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " rowspan="2" align="left" valign="top">Antiemetics</td><td class="td" title="table-entry  " align="left" valign="top">Known&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Domperidone&#44;<a class="elsevierStyleCrossRefs" href="#bib0645"><span class="elsevierStyleSup">37&#44;73</span></a> Ondansetron<a class="elsevierStyleCrossRefs" href="#bib0555"><span class="elsevierStyleSup">19&#44;42&#44;75</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Possible&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Dolasetron&#44;<a class="elsevierStyleCrossRef" href="#bib0555"><span class="elsevierStyleSup">19</span></a> Granisetron<a class="elsevierStyleCrossRef" href="#bib0555"><span class="elsevierStyleSup">19</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " rowspan="2" align="left" valign="top">Antifungals</td><td class="td" title="table-entry  " align="left" valign="top">Known&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Fluconazole&#44;<a class="elsevierStyleCrossRef" href="#bib0595"><span class="elsevierStyleSup">27</span></a> Pentamidine<a class="elsevierStyleCrossRef" href="#bib0650"><span class="elsevierStyleSup">38</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Conditional&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Voriconazole<a class="elsevierStyleCrossRef" href="#bib0595"><span class="elsevierStyleSup">27</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Antihistamines&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Conditional&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Diphenhydramine<a class="elsevierStyleCrossRef" href="#bib0840"><span class="elsevierStyleSup">76</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Antimania&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Possible&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Lithium<a class="elsevierStyleCrossRefs" href="#bib0505"><span class="elsevierStyleSup">9&#44;38&#44;55&#44;87</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " rowspan="2" align="left" valign="top">Antimalarials</td><td class="td" title="table-entry  " align="left" valign="top">Known&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Halofantrine<a class="elsevierStyleCrossRef" href="#bib0650"><span class="elsevierStyleSup">38</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Conditional&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Quinine sulfate<a class="elsevierStyleCrossRef" href="#bib0650"><span class="elsevierStyleSup">38</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " rowspan="2" align="left" valign="top">Antineoplastics</td><td class="td" title="table-entry  " align="left" valign="top">Known&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Arsenic trioxide&#44;<a class="elsevierStyleCrossRef" href="#bib0845"><span class="elsevierStyleSup">77</span></a> Vandetanib<a class="elsevierStyleCrossRef" href="#bib0845"><span class="elsevierStyleSup">77</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Possible&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Dasatinib&#44;<a class="elsevierStyleCrossRef" href="#bib0845"><span class="elsevierStyleSup">77</span></a> Lapatinib&#44;<a class="elsevierStyleCrossRef" href="#bib0845"><span class="elsevierStyleSup">77</span></a> Nilotinib&#44;<a class="elsevierStyleCrossRef" href="#bib0845"><span class="elsevierStyleSup">77</span></a> Sunitinib&#44;<a class="elsevierStyleCrossRef" href="#bib0845"><span class="elsevierStyleSup">77</span></a> Vemurafenib&#44;<a class="elsevierStyleCrossRefs" href="#bib0845"><span class="elsevierStyleSup">77&#44;78</span></a> Vorinostat<a class="elsevierStyleCrossRef" href="#bib0845"><span class="elsevierStyleSup">77</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " rowspan="2" align="left" valign="top">Antipsychotics</td><td class="td" title="table-entry  " align="left" valign="top">Known&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Haloperidol&#44;<a class="elsevierStyleCrossRefs" href="#bib0500"><span class="elsevierStyleSup">8&#44;9&#44;14&#44;27&#44;38&#44;40&#44;41&#44;48&#44;53&#8211;56&#44;63&#44;67</span></a> Levomepromazine&#44;<a class="elsevierStyleCrossRefs" href="#bib0500"><span class="elsevierStyleSup">8&#44;45&#44;48&#44;53&#44;55&#44;63</span></a> Mesoridazine&#44;<a class="elsevierStyleCrossRef" href="#tblfn0020"><span class="elsevierStyleSup">&#167;</span></a><a class="elsevierStyleCrossRef" href="#bib0650"><span class="elsevierStyleSup">38</span></a> Pimozide&#44;<a class="elsevierStyleCrossRef" href="#bib0735"><span class="elsevierStyleSup">55</span></a> Thioridazine<a class="elsevierStyleCrossRefs" href="#bib0500"><span class="elsevierStyleSup">8&#44;9&#44;14&#44;38&#44;41&#44;67</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Possible&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Cyamemazine &#40;cyamepromazine&#41;&#44;<a class="elsevierStyleCrossRefs" href="#bib0725"><span class="elsevierStyleSup">53&#44;54&#44;63</span></a> Flupentixol&#44;<a class="elsevierStyleCrossRefs" href="#bib0735"><span class="elsevierStyleSup">55&#44;56</span></a> Perphenazine<a class="elsevierStyleCrossRef" href="#bib0685"><span class="elsevierStyleSup">45</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " rowspan="3" align="left" valign="top">Antipsychotics&#44; atypical</td><td class="td" title="table-entry  " align="left" valign="top">Known&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Sulpiride<a class="elsevierStyleCrossRef" href="#bib0735"><span class="elsevierStyleSup">55</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Possible&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Aripiprazole&#44;<a class="elsevierStyleCrossRef" href="#bib0740"><span class="elsevierStyleSup">56</span></a> Clozapine&#44;<a class="elsevierStyleCrossRefs" href="#bib0650"><span class="elsevierStyleSup">38&#44;41&#44;53&#8211;55&#44;63</span></a> Iloperidone&#44;<a class="elsevierStyleCrossRef" href="#bib0530"><span class="elsevierStyleSup">14</span></a> Paliperidone&#44;<a class="elsevierStyleCrossRefs" href="#bib0650"><span class="elsevierStyleSup">38&#44;55&#44;66</span></a> Risperidone&#44;<a class="elsevierStyleCrossRefs" href="#bib0530"><span class="elsevierStyleSup">14&#44;38&#44;41&#44;53&#8211;56&#44;63&#44;65</span></a> Sertindole&#44;<a class="elsevierStyleCrossRefs" href="#bib0505"><span class="elsevierStyleSup">9&#44;38&#44;63</span></a> Tiapride<a class="elsevierStyleCrossRef" href="#bib0740"><span class="elsevierStyleSup">56</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Conditional&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Amisulpride&#44;<a class="elsevierStyleCrossRefs" href="#bib0725"><span class="elsevierStyleSup">53&#8211;56&#44;63</span></a> Olanzapine&#44;<a class="elsevierStyleCrossRefs" href="#bib0530"><span class="elsevierStyleSup">14&#44;41&#44;53&#44;54&#44;56&#44;63</span></a> Quetiapine&#44;<a class="elsevierStyleCrossRefs" href="#bib0530"><span class="elsevierStyleSup">14&#44;27&#44;38&#44;39&#44;41&#44;53&#8211;55&#44;63&#44;64</span></a> Ziprasidone<a class="elsevierStyleCrossRefs" href="#bib0500"><span class="elsevierStyleSup">8&#44;9&#44;14&#44;38&#44;41&#44;53&#8211;55&#44;63</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " rowspan="2" align="left" valign="top">Antipsychotics&#47;antiemetics</td><td class="td" title="table-entry  " align="left" valign="top">Known&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Chlorpromazine&#44;<a class="elsevierStyleCrossRefs" href="#bib0500"><span class="elsevierStyleSup">8&#44;38&#44;45&#44;53&#44;54&#44;63</span></a> Droperidol<a class="elsevierStyleCrossRefs" href="#bib0555"><span class="elsevierStyleSup">19&#44;53&#44;54</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Possible&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Promethazine<a class="elsevierStyleCrossRef" href="#bib0685"><span class="elsevierStyleSup">45</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">GI stimulants&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Known&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Cisapride&#44;<a class="elsevierStyleCrossRef" href="#tblfn0020"><span class="elsevierStyleSup">&#167;</span></a><a class="elsevierStyleCrossRef" href="#bib0510"><span class="elsevierStyleSup">10</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">General anesthetics&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Known&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Sevoflurane<a class="elsevierStyleCrossRefs" href="#bib0555"><span class="elsevierStyleSup">19&#44;72</span></a><a class="elsevierStyleCrossRef" href="#tblfn0015"><span class="elsevierStyleSup">&#8225;</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Opioid agonists&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Known&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Levomethadyl acetate&#44;<a class="elsevierStyleCrossRef" href="#tblfn0020"><span class="elsevierStyleSup">&#167;</span></a><a class="elsevierStyleCrossRef" href="#bib0555"><span class="elsevierStyleSup">19</span></a> Methadone<a class="elsevierStyleCrossRefs" href="#bib0505"><span class="elsevierStyleSup">9&#44;14&#44;19&#44;34&#44;35&#44;55</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Opioid receptor modulator&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Possible&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Buprenorphine<a class="elsevierStyleCrossRef" href="#bib0555"><span class="elsevierStyleSup">19</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Psychostimulants&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Possible&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Atomoxetine<a class="elsevierStyleCrossRef" href="#bib0855"><span class="elsevierStyleSup">79</span></a><a class="elsevierStyleCrossRef" href="#tblfn0010"><span class="elsevierStyleSup">&#8224;</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">SNRI antidepressants&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Possible&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Venlafaxine<a class="elsevierStyleCrossRefs" href="#bib0650"><span class="elsevierStyleSup">38&#44;41&#44;50&#44;55</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " rowspan="2" align="left" valign="top">SSRI antidepressants</td><td class="td" title="table-entry  " align="left" valign="top">Known&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Citalopram&#44;<a class="elsevierStyleCrossRefs" href="#bib0500"><span class="elsevierStyleSup">8&#44;27&#44;41&#44;46&#8211;48&#44;55</span></a> Escitalopram<a class="elsevierStyleCrossRefs" href="#bib0500"><span class="elsevierStyleSup">8&#44;27&#44;38&#44;41&#44;46&#44;48&#44;55</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Conditional&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Fluoxetine&#44;<a class="elsevierStyleCrossRef" href="#bib0665"><span class="elsevierStyleSup">41</span></a> Sertraline<a class="elsevierStyleCrossRef" href="#bib0665"><span class="elsevierStyleSup">41</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " rowspan="2" align="left" valign="top">Tricyclic antidepressants</td><td class="td" title="table-entry  " align="left" valign="top">Possible&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Clomipramine&#44;<a class="elsevierStyleCrossRefs" href="#bib0685"><span class="elsevierStyleSup">45&#44;55</span></a> Desipramine&#44;<a class="elsevierStyleCrossRef" href="#bib0685"><span class="elsevierStyleSup">45</span></a> Imipramine &#40;melipramine&#41;&#44;<a class="elsevierStyleCrossRefs" href="#bib0665"><span class="elsevierStyleSup">41&#44;45&#44;55</span></a> Nortriptyline<a class="elsevierStyleCrossRefs" href="#bib0665"><span class="elsevierStyleSup">41&#44;45&#44;55</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Conditional&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Amitriptyline&#44;<a class="elsevierStyleCrossRefs" href="#bib0685"><span class="elsevierStyleSup">45&#44;55</span></a> Doxepin<a class="elsevierStyleCrossRef" href="#bib0735"><span class="elsevierStyleSup">55</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Other therapeutic drugs&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Not applicable<a class="elsevierStyleCrossRef" href="#tblfn0005"><span class="elsevierStyleSup">&#42;</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Amoxapine&#44;<a class="elsevierStyleCrossRef" href="#bib0685"><span class="elsevierStyleSup">45</span></a> Atropine&#44;<a class="elsevierStyleCrossRef" href="#bib0555"><span class="elsevierStyleSup">19</span></a> Bromperidol&#44;<a class="elsevierStyleCrossRef" href="#bib0725"><span class="elsevierStyleSup">53</span></a> Bupropion&#44;<a class="elsevierStyleCrossRef" href="#bib0710"><span class="elsevierStyleSup">50</span></a><a class="elsevierStyleCrossRef" href="#tblfn0010"><span class="elsevierStyleSup">&#8224;</span></a> Cetirizine&#44;<a class="elsevierStyleCrossRef" href="#bib0840"><span class="elsevierStyleSup">76</span></a> Chlorprothixene&#44;<a class="elsevierStyleCrossRefs" href="#bib0725"><span class="elsevierStyleSup">53&#44;55&#44;63</span></a> Clotiapine&#44;<a class="elsevierStyleCrossRef" href="#bib0700"><span class="elsevierStyleSup">48</span></a> Depsipeptide&#44;<a class="elsevierStyleCrossRef" href="#bib0845"><span class="elsevierStyleSup">77</span></a> Desflurane&#44;<a class="elsevierStyleCrossRef" href="#bib0555"><span class="elsevierStyleSup">19</span></a> Desloratadine&#44;<a class="elsevierStyleCrossRef" href="#bib0840"><span class="elsevierStyleSup">76</span></a> Enflurane&#44;<a class="elsevierStyleCrossRef" href="#bib0555"><span class="elsevierStyleSup">19</span></a> Fexofenadine&#44;<a class="elsevierStyleCrossRef" href="#bib0840"><span class="elsevierStyleSup">76</span></a> Fluphenazine&#44;<a class="elsevierStyleCrossRefs" href="#bib0725"><span class="elsevierStyleSup">53&#44;63</span></a> Ganciclovir&#44;<a class="elsevierStyleCrossRef" href="#bib0740"><span class="elsevierStyleSup">56</span></a> Glycopyrrolate&#44;<a class="elsevierStyleCrossRef" href="#bib0555"><span class="elsevierStyleSup">19</span></a> Halothane&#44;<a class="elsevierStyleCrossRef" href="#bib0555"><span class="elsevierStyleSup">19</span></a> Hydroquinidine&#44;<a class="elsevierStyleCrossRef" href="#bib0650"><span class="elsevierStyleSup">38</span></a> Isoflurane&#44;<a class="elsevierStyleCrossRef" href="#bib0555"><span class="elsevierStyleSup">19</span></a> Levocetirizine&#44;<a class="elsevierStyleCrossRef" href="#bib0740"><span class="elsevierStyleSup">56</span></a> Loratadine&#44;<a class="elsevierStyleCrossRef" href="#bib0840"><span class="elsevierStyleSup">76</span></a> Mizolastine&#44;<a class="elsevierStyleCrossRef" href="#bib0650"><span class="elsevierStyleSup">38</span></a> Moclobemide&#44;<a class="elsevierStyleCrossRef" href="#bib0735"><span class="elsevierStyleSup">55</span></a> Nitric oxide&#44;<a class="elsevierStyleCrossRef" href="#bib0820"><span class="elsevierStyleSup">72</span></a><a class="elsevierStyleCrossRef" href="#tblfn0015"><span class="elsevierStyleSup">&#8225;</span></a> Oxatomide&#44;<a class="elsevierStyleCrossRef" href="#bib0740"><span class="elsevierStyleSup">56</span></a> Oxycodone&#44;<a class="elsevierStyleCrossRef" href="#bib0555"><span class="elsevierStyleSup">19</span></a> Pentobarbital&#44;<a class="elsevierStyleCrossRef" href="#bib0510"><span class="elsevierStyleSup">10</span></a> Pilsicainide&#44;<a class="elsevierStyleCrossRef" href="#bib0675"><span class="elsevierStyleSup">43</span></a> Promazine&#44;<a class="elsevierStyleCrossRef" href="#bib0700"><span class="elsevierStyleSup">48</span></a> Propericiazine&#44;<a class="elsevierStyleCrossRef" href="#bib0685"><span class="elsevierStyleSup">45</span></a> Propoxyphene&#44;<a class="elsevierStyleCrossRef" href="#tblfn0020"><span class="elsevierStyleSup">&#167;</span></a><a class="elsevierStyleCrossRef" href="#bib0555"><span class="elsevierStyleSup">19</span></a> Prothipendyl&#44;<a class="elsevierStyleCrossRef" href="#bib0725"><span class="elsevierStyleSup">53</span></a> Succinylcholine&#44;<a class="elsevierStyleCrossRef" href="#bib0555"><span class="elsevierStyleSup">19</span></a> Verapamil&#44;<a class="elsevierStyleCrossRef" href="#bib0655"><span class="elsevierStyleSup">39</span></a> Zuclopenthixol<a class="elsevierStyleCrossRef" href="#bib0725"><span class="elsevierStyleSup">53</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Non-therapeutic drugs&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Not applicable<a class="elsevierStyleCrossRef" href="#tblfn0005"><span class="elsevierStyleSup">&#42;</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Alcohol&#44;<a class="elsevierStyleCrossRef" href="#bib0870"><span class="elsevierStyleSup">82</span></a><a class="elsevierStyleCrossRef" href="#tblfn0025"><span class="elsevierStyleSup">&#42;&#42;</span></a> Ginseng&#44;<a class="elsevierStyleCrossRef" href="#bib0875"><span class="elsevierStyleSup">83</span></a><br>Licorice root compounds &#40;glycyrrhizin&#44; flavones&#41;<a class="elsevierStyleCrossRef" href="#bib0880"><span class="elsevierStyleSup">84</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab1768152.png"
              ]
            ]
          ]
          "notaPie" => array:6 [
            0 => array:3 [
              "identificador" => "tblfn0005"
              "etiqueta" => "&#42;"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0005">Not included in the original drug list of CredibleMeds&#46;</p>"
            ]
            1 => array:3 [
              "identificador" => "tblfn0010"
              "etiqueta" => "&#8224;"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0010">Only in Overdose&#46;</p>"
            ]
            2 => array:3 [
              "identificador" => "tblfn0015"
              "etiqueta" => "&#8225;"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0015">Concomitant use of QT-prolonging drugs&#46;</p>"
            ]
            3 => array:3 [
              "identificador" => "tblfn0020"
              "etiqueta" => "&#167;"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0020">Removed from market&#46;</p>"
            ]
            4 => array:3 [
              "identificador" => "tblfn0025"
              "etiqueta" => "&#42;&#42;"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0025">Only in binge drinking &#40;i&#46;e&#46;&#44; &#8805;5 alcoholic beverages in one day&#44; during the previous 12 months&#41;&#46;</p>"
            ]
            5 => array:3 [
              "identificador" => "tblfn0030"
              "etiqueta" => "&#42;&#42;&#42;"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0030">TdP risk categories&#46;</p>"
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0045" class="elsevierStyleSimplePara elsevierViewall">Agents implicated in drug-induced QT prolongation and&#47;or torsades de pointes&#46;</p>"
        ]
      ]
      1 => array:8 [
        "identificador" => "tbl0010"
        "etiqueta" => "Table 2"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at2"
            "detalle" => "Table "
            "rol" => "short"
          ]
        ]
        "tabla" => array:2 [
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Drug class&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Generic name&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Antiarrhythmics&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Digitalis<a class="elsevierStyleCrossRef" href="#bib0555"><span class="elsevierStyleSup">19</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Antiepileptics&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Rufinamide&#44;<a class="elsevierStyleCrossRefs" href="#bib0510"><span class="elsevierStyleSup">10&#44;86</span></a> Lamotrigine&#44;<a class="elsevierStyleCrossRef" href="#bib0890"><span class="elsevierStyleSup">86</span></a><a class="elsevierStyleCrossRef" href="#tblfn0035"><span class="elsevierStyleSup">&#42;</span></a> Valproic acid<a class="elsevierStyleCrossRef" href="#bib0890"><span class="elsevierStyleSup">86</span></a><a class="elsevierStyleCrossRef" href="#tblfn0035"><span class="elsevierStyleSup">&#42;</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab1768151.png"
              ]
            ]
          ]
          "notaPie" => array:1 [
            0 => array:3 [
              "identificador" => "tblfn0035"
              "etiqueta" => "&#42;"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0035">Combined with rufinamide&#46;</p>"
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0060" class="elsevierStyleSimplePara elsevierViewall">Agents implicated in drug-induced QT shortening and&#47;or life-threatening arrhythmias&#46;</p>"
        ]
      ]
      2 => array:8 [
        "identificador" => "tbl0015"
        "etiqueta" => "Table 3"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at3"
            "detalle" => "Table "
            "rol" => "short"
          ]
        ]
        "tabla" => array:3 [
          "leyenda" => "<p id="spar0070" class="elsevierStyleSimplePara elsevierViewall">Adapted from the website <a class="elsevierStyleInterRef" target="_blank" id="intr0015" href="http://www.brugadadrugs.org/">www&#46;brugadadrugs&#46;org</a><a class="elsevierStyleCrossRef" href="#bib0590"><span class="elsevierStyleSup">26</span></a> &#40;accessed January 12&#44; 2017&#41;&#46; For an extensive and systematically updated list of all available evidence about the offending drugs&#44; corresponding risk categories and classes of recommendation&#44; please visit <a class="elsevierStyleInterRef" target="_blank" id="intr0020" href="http://www.brugadadrugs.org/">www&#46;brugadadrugs&#46;org</a>&#46;</p><p id="spar0075" class="elsevierStyleSimplePara elsevierViewall"><span class="elsevierStyleItalic">Abbreviations</span>&#58; SSRI&#58; selective serotonin reuptake inhibitors&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Drug class&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Risk category<a class="elsevierStyleCrossRef" href="#tblfn0040"><span class="elsevierStyleSup">&#42;</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Generic name&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Class&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="table-entry  " rowspan="2" align="left" valign="top">Anesthetics&#47;analgesics</td><td class="td" title="table-entry  " align="left" valign="top">To be avoided&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Bupivacaine&#44;<a class="elsevierStyleCrossRefs" href="#bib0510"><span class="elsevierStyleSup">10&#44;21&#44;23&#44;87</span></a> Procaine&#44;<a class="elsevierStyleCrossRefs" href="#bib0565"><span class="elsevierStyleSup">21&#44;23&#44;87</span></a><a class="elsevierStyleCrossRef" href="#tblfn0045"><span class="elsevierStyleSup">&#8224;</span></a> Propofol<a class="elsevierStyleCrossRefs" href="#bib0510"><span class="elsevierStyleSup">10&#44;21&#44;23&#44;87</span></a><a class="elsevierStyleCrossRef" href="#tblfn0045"><span class="elsevierStyleSup">&#8224;</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">IIa&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Preferentially avoided&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Ketamine<a class="elsevierStyleCrossRef" href="#bib0895"><span class="elsevierStyleSup">87</span></a><a class="elsevierStyleCrossRef" href="#tblfn0045"><span class="elsevierStyleSup">&#8224;</span></a> Tramadol<a class="elsevierStyleCrossRef" href="#bib0895"><span class="elsevierStyleSup">87</span></a><a class="elsevierStyleCrossRef" href="#tblfn0045"><span class="elsevierStyleSup">&#8224;</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">IIb&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Antianginals&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Not to be avoided&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Diltiazem&#44;<a class="elsevierStyleCrossRef" href="#bib0565"><span class="elsevierStyleSup">21</span></a> Nicorandil&#44;<a class="elsevierStyleCrossRef" href="#bib0565"><span class="elsevierStyleSup">21</span></a> Nifedipine&#44;<a class="elsevierStyleCrossRef" href="#bib0565"><span class="elsevierStyleSup">21</span></a> Nitroglycerine<a class="elsevierStyleCrossRef" href="#bib0565"><span class="elsevierStyleSup">21</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">III&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " rowspan="2" align="left" valign="top">Antiarrhythmics&#44; class Ia</td><td class="td" title="table-entry  " align="left" valign="top">To be avoided&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Ajmaline&#44;<a class="elsevierStyleCrossRefs" href="#bib0495"><span class="elsevierStyleSup">7&#44;10&#44;15&#44;21&#44;23&#44;63&#44;87</span></a> Procainamide<a class="elsevierStyleCrossRefs" href="#bib0495"><span class="elsevierStyleSup">7&#44;10&#44;15&#44;21&#44;23&#44;87</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">I&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Preferentially avoided&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Cibenzoline&#44;<a class="elsevierStyleCrossRef" href="#bib0565"><span class="elsevierStyleSup">21</span></a> Disopyramide<a class="elsevierStyleCrossRef" href="#bib0565"><span class="elsevierStyleSup">21</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">IIb&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " rowspan="2" align="left" valign="top">Antiarrhythmics&#44; class Ic</td><td class="td" title="table-entry  " rowspan="2" align="left" valign="top">To be avoided</td><td class="td" title="table-entry  " align="left" valign="top">Flecainide&#44;<a class="elsevierStyleCrossRefs" href="#bib0495"><span class="elsevierStyleSup">7&#44;10&#44;15&#44;21&#44;23&#44;63&#44;87</span></a> Pilsicainide<a class="elsevierStyleCrossRefs" href="#bib0495"><span class="elsevierStyleSup">7&#44;10&#44;15&#44;21&#44;23&#44;87</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">I&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Propafenone<a class="elsevierStyleCrossRefs" href="#bib0510"><span class="elsevierStyleSup">10&#44;21</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">IIa&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Antiarrhythmics&#44; class III &#40;also Ia&#44; II and IV effects&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Preferentially avoided&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Amiodarone<a class="elsevierStyleCrossRef" href="#bib0905"><span class="elsevierStyleSup">89</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">IIb&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Antiarrhythmics&#44; class IV&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Preferentially avoided&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Verapamil<a class="elsevierStyleCrossRef" href="#bib0565"><span class="elsevierStyleSup">21</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">IIb&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Antiemetics&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Preferentially avoided&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Dimenhydrinate&#44;<a class="elsevierStyleCrossRefs" href="#bib0565"><span class="elsevierStyleSup">21&#44;87</span></a> Metoclopramide<a class="elsevierStyleCrossRef" href="#bib0895"><span class="elsevierStyleSup">87</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">IIb&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " rowspan="2" align="left" valign="top">Antiepileptics</td><td class="td" title="table-entry  " align="left" valign="top">To be avoided&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Oxcarbazepine<a class="elsevierStyleCrossRefs" href="#bib0565"><span class="elsevierStyleSup">21&#44;87</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">IIa&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Preferentially avoided&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Carbamazepine&#44;<a class="elsevierStyleCrossRef" href="#bib0915"><span class="elsevierStyleSup">91</span></a><a class="elsevierStyleCrossRef" href="#tblfn0050"><span class="elsevierStyleSup">&#8225;</span></a> Lamotrigine&#44;<a class="elsevierStyleCrossRef" href="#bib0915"><span class="elsevierStyleSup">91</span></a><a class="elsevierStyleCrossRef" href="#tblfn0050"><span class="elsevierStyleSup">&#8225;</span></a> Phenytoin<a class="elsevierStyleCrossRef" href="#bib0915"><span class="elsevierStyleSup">91</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">IIb&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Antihistamines&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Preferentially avoided&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Diphenhydramine&#44;<a class="elsevierStyleCrossRef" href="#bib0895"><span class="elsevierStyleSup">87</span></a><a class="elsevierStyleCrossRef" href="#tblfn0045"><span class="elsevierStyleSup">&#8224;</span></a> Terfenadine&#47;Fexofenadine<a class="elsevierStyleCrossRef" href="#bib0895"><span class="elsevierStyleSup">87</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">IIb&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " rowspan="2" align="left" valign="top">Antipsychotics</td><td class="td" title="table-entry  " align="left" valign="top">To be avoided&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Loxapine&#44;<a class="elsevierStyleCrossRefs" href="#bib0565"><span class="elsevierStyleSup">21&#44;87</span></a> Trifluoperazine<a class="elsevierStyleCrossRefs" href="#bib0565"><span class="elsevierStyleSup">21&#44;87</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">IIa&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Preferentially avoided&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Cyamemazine&#44;<a class="elsevierStyleCrossRefs" href="#bib0565"><span class="elsevierStyleSup">21&#44;38&#44;87</span></a><a class="elsevierStyleCrossRef" href="#tblfn0045"><span class="elsevierStyleSup">&#8224;</span></a> Perphenazine&#44;<a class="elsevierStyleCrossRefs" href="#bib0565"><span class="elsevierStyleSup">21&#44;87</span></a><a class="elsevierStyleCrossRef" href="#tblfn0045"><span class="elsevierStyleSup">&#8224;</span></a> Thioridazine<a class="elsevierStyleCrossRef" href="#bib0895"><span class="elsevierStyleSup">87</span></a><a class="elsevierStyleCrossRef" href="#tblfn0045"><span class="elsevierStyleSup">&#8224;</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">IIb&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">SSRI antidepressants&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Preferentially avoided&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Fluoxetine&#44;<a class="elsevierStyleCrossRefs" href="#bib0565"><span class="elsevierStyleSup">21&#44;38&#44;87</span></a><a class="elsevierStyleCrossRef" href="#tblfn0045"><span class="elsevierStyleSup">&#8224;</span></a> Fluvoxamine&#44;<a class="elsevierStyleCrossRef" href="#bib0895"><span class="elsevierStyleSup">87</span></a> Paroxetine<a class="elsevierStyleCrossRef" href="#bib0895"><span class="elsevierStyleSup">87</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">IIb&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Tetracyclic Antidepressants&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Preferentially avoided&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Maprotiline<a class="elsevierStyleCrossRefs" href="#bib0565"><span class="elsevierStyleSup">21&#44;38&#44;87</span></a><a class="elsevierStyleCrossRef" href="#tblfn0045"><span class="elsevierStyleSup">&#8224;</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">IIb&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " rowspan="2" align="left" valign="top">Tricyclic Antidepressants</td><td class="td" title="table-entry  " align="left" valign="top">To be avoided&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Amytriptiline&#44;<a class="elsevierStyleCrossRefs" href="#bib0565"><span class="elsevierStyleSup">21&#44;87</span></a><a class="elsevierStyleCrossRef" href="#tblfn0045"><span class="elsevierStyleSup">&#8224;</span></a> Clomipramine&#44;<a class="elsevierStyleCrossRefs" href="#bib0565"><span class="elsevierStyleSup">21&#44;38&#44;87</span></a><a class="elsevierStyleCrossRef" href="#tblfn0045"><span class="elsevierStyleSup">&#8224;</span></a> Desipramine&#44;<a class="elsevierStyleCrossRefs" href="#bib0565"><span class="elsevierStyleSup">21&#44;87</span></a><a class="elsevierStyleCrossRef" href="#tblfn0045"><span class="elsevierStyleSup">&#8224;</span></a> Nortriptyline<a class="elsevierStyleCrossRefs" href="#bib0485"><span class="elsevierStyleSup">5&#44;21</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">IIa&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Preferentially avoided&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Dosulepin&#44;<a class="elsevierStyleCrossRef" href="#bib0895"><span class="elsevierStyleSup">87</span></a><a class="elsevierStyleCrossRef" href="#tblfn0045"><span class="elsevierStyleSup">&#8224;</span></a> Doxepin&#44;<a class="elsevierStyleCrossRef" href="#bib0895"><span class="elsevierStyleSup">87</span></a><a class="elsevierStyleCrossRef" href="#tblfn0045"><span class="elsevierStyleSup">&#8224;</span></a> Imipramine<a class="elsevierStyleCrossRef" href="#bib0895"><span class="elsevierStyleSup">87</span></a><a class="elsevierStyleCrossRef" href="#tblfn0045"><span class="elsevierStyleSup">&#8224;</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">IIb&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Other antidepressants&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">To be avoided&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Lithium<a class="elsevierStyleCrossRefs" href="#bib0510"><span class="elsevierStyleSup">10&#44;23&#44;38</span></a><a class="elsevierStyleCrossRef" href="#tblfn0050"><span class="elsevierStyleSup">&#8225;</span></a><a class="elsevierStyleCrossRef" href="#bib0895"><span class="elsevierStyleSup">87</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">IIb&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " rowspan="3" align="left" valign="top">Substances</td><td class="td" title="table-entry  " rowspan="2" align="left" valign="top">To be avoided</td><td class="td" title="table-entry  " align="left" valign="top">Acetylcholine&#44;<a class="elsevierStyleCrossRefs" href="#bib0535"><span class="elsevierStyleSup">15&#44;21&#44;87</span></a> Cocaine<a class="elsevierStyleCrossRefs" href="#bib0510"><span class="elsevierStyleSup">10&#44;15&#44;21</span></a><a class="elsevierStyleCrossRef" href="#tblfn0045"><span class="elsevierStyleSup">&#8224;</span></a><a class="elsevierStyleCrossRefs" href="#bib0575"><span class="elsevierStyleSup">23&#44;87</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">IIa&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Alcohol&#44;<a class="elsevierStyleCrossRef" href="#tblfn0045"><span class="elsevierStyleSup">&#8224;</span></a><a class="elsevierStyleCrossRefs" href="#bib0535"><span class="elsevierStyleSup">15&#44;21&#44;23&#44;87</span></a> Cannabis&#44;<a class="elsevierStyleCrossRefs" href="#bib0565"><span class="elsevierStyleSup">21&#44;23</span></a> Ergonovine<a class="elsevierStyleCrossRefs" href="#bib0535"><span class="elsevierStyleSup">15&#44;21&#44;23&#44;87</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">IIb&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Preferentially avoided&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Edrophonium<a class="elsevierStyleCrossRef" href="#bib0895"><span class="elsevierStyleSup">87</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">IIb&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Other drugs&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Not applicable<a class="elsevierStyleCrossRef" href="#tblfn0040"><span class="elsevierStyleSup">&#42;</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Isosorbide dinitrate&#44;<a class="elsevierStyleCrossRef" href="#bib0565"><span class="elsevierStyleSup">21</span></a> Nicotine<a class="elsevierStyleCrossRef" href="#bib0920"><span class="elsevierStyleSup">92</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Not applicable<a class="elsevierStyleCrossRef" href="#tblfn0040"><span class="elsevierStyleSup">&#42;</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab1768150.png"
              ]
            ]
          ]
          "notaPie" => array:3 [
            0 => array:3 [
              "identificador" => "tblfn0040"
              "etiqueta" => "&#42;"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0040">Not included in the original drug list&#46;</p>"
            ]
            1 => array:3 [
              "identificador" => "tblfn0045"
              "etiqueta" => "&#8224;"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0045">Only in Overdose&#46;</p>"
            ]
            2 => array:3 [
              "identificador" => "tblfn0050"
              "etiqueta" => "&#8225;"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0050">Concomitant drug use&#46;</p>"
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0065" class="elsevierStyleSimplePara elsevierViewall">Agents implicated in drug-induced Brugada ECG pattern and&#47;or life-threatening arrhythmias in Brugada syndrome patients&#46;</p>"
        ]
      ]
    ]
    "bibliografia" => array:2 [
      "titulo" => "References"
      "seccion" => array:1 [
        0 => array:2 [
          "identificador" => "bibs0015"
          "bibliografiaReferencia" => array:92 [
            0 => array:3 [
              "identificador" => "bib0465"
              "etiqueta" => "1"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death&#58; The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology &#40;ESC&#41; Endorsed by&#58; Association for European Paediatric and Congenital Cardiology &#40;AEPC&#41;"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:3 [ …3]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1093/europace/euv319"
                      "Revista" => array:6 [
                        "tituloSerie" => "Europace"
                        "fecha" => "2015"
                        "volumen" => "17"
                        "paginaInicial" => "1601"
                        "paginaFinal" => "1687"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            1 => array:3 [
              "identificador" => "bib0470"
              "etiqueta" => "2"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Sudden cardiac death in young adult"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:3 [ …3]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1007/s12012-014-9255-1"
                      "Revista" => array:6 [
                        "tituloSerie" => "Cardiovasc Toxicol"
                        "fecha" => "2014"
                        "volumen" => "14"
                        "paginaInicial" => "379"
                        "paginaFinal" => "386"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            2 => array:3 [
              "identificador" => "bib0475"
              "etiqueta" => "3"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Ventricular arrhythmias and sudden cardiac death"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:3 [ …3]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/S0140-6736(12)61413-5"
                      "Revista" => array:6 [
                        "tituloSerie" => "Lancet"
                        "fecha" => "2012"
                        "volumen" => "380"
                        "paginaInicial" => "1520"
                        "paginaFinal" => "1529"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            3 => array:3 [
              "identificador" => "bib0480"
              "etiqueta" => "4"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Pathophysiology and prevention of sudden cardiac death"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [ …3]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1139/cjpp-2015-0366"
                      "Revista" => array:6 [
                        "tituloSerie" => "Can J Physiol Pharmacol"
                        "fecha" => "2016"
                        "volumen" => "94"
                        "paginaInicial" => "237"
                        "paginaFinal" => "244"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            4 => array:3 [
              "identificador" => "bib0485"
              "etiqueta" => "5"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Sudden cardiac arrest associated with use of a non-cardiac drug that reduces cardiac excitability&#58; evidence from bench&#44; bedside&#44; and community"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:3 [ …3]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1093/eurheartj/eht054"
                      "Revista" => array:6 [
                        "tituloSerie" => "Eur Heart J"
                        "fecha" => "2013"
                        "volumen" => "34"
                        "paginaInicial" => "1506"
                        "paginaFinal" => "1516"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            5 => array:3 [
              "identificador" => "bib0490"
              "etiqueta" => "6"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Antipsychotic drugs are associated with pulseless electrical activity&#58; the Oregon Sudden Unexpected Death Study"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:3 [ …3]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.hrthm.2012.12.002"
                      "Revista" => array:6 [
                        "tituloSerie" => "Heart Rhythm"
                        "fecha" => "2013"
                        "volumen" => "10"
                        "paginaInicial" => "526"
                        "paginaFinal" => "530"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            6 => array:3 [
              "identificador" => "bib0495"
              "etiqueta" => "7"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Ventricular arrhythmias in the absence of structural heart disease"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:3 [ …3]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jacc.2012.01.036"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Am Coll Cardiol"
                        "fecha" => "2012"
                        "volumen" => "59"
                        "paginaInicial" => "1733"
                        "paginaFinal" => "1744"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            7 => array:3 [
              "identificador" => "bib0500"
              "etiqueta" => "8"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Antipsychotic medication and QT prolongation"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [ …3]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.12669/pjms.315.8998"
                      "Revista" => array:6 [
                        "tituloSerie" => "Pak J Med Sci"
                        "fecha" => "2015"
                        "volumen" => "31"
                        "paginaInicial" => "1269"
                        "paginaFinal" => "1271"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            8 => array:3 [
              "identificador" => "bib0505"
              "etiqueta" => "9"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Assessing QT interval prolongation and its associated risks with antipsychotics"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:3 [ …3]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.2165/11587800-000000000-00000"
                      "Revista" => array:6 [
                        "tituloSerie" => "CNS Drugs"
                        "fecha" => "2011"
                        "volumen" => "25"
                        "paginaInicial" => "473"
                        "paginaFinal" => "490"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            9 => array:3 [
              "identificador" => "bib0510"
              "etiqueta" => "10"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Mechanisms of drug-induced proarrhythmia in clinical practice"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:3 [ …3]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.4330/wjc.v5.i6.175"
                      "Revista" => array:6 [
                        "tituloSerie" => "World J Cardiol"
                        "fecha" => "2013"
                        "volumen" => "5"
                        "paginaInicial" => "175"
                        "paginaFinal" => "185"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            10 => array:3 [
              "identificador" => "bib0515"
              "etiqueta" => "11"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Prevention of torsade de pointes in hospital settings&#58; a scientific statement from the American Heart Association and the American College of Cardiology Foundation"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:3 [ …3]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jacc.2010.01.001"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Am Coll Cardiol"
                        "fecha" => "2010"
                        "volumen" => "55"
                        "paginaInicial" => "934"
                        "paginaFinal" => "947"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            11 => array:3 [
              "identificador" => "bib0520"
              "etiqueta" => "12"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Drug-induced prolongation of the QT interval"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:1 [ …1]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1056/NEJMra032426"
                      "Revista" => array:6 [
                        "tituloSerie" => "N Engl J Med"
                        "fecha" => "2004"
                        "volumen" => "350"
                        "paginaInicial" => "1013"
                        "paginaFinal" => "1022"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            12 => array:3 [
              "identificador" => "bib0525"
              "etiqueta" => "13"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Unveiling specific triggers and precipitating factors for fatal cardiac events in inherited arrhythmia syndromes"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [ …3]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1253/circj.CJ-15-0322"
                      "Revista" => array:6 [
                        "tituloSerie" => "Circ J"
                        "fecha" => "2015"
                        "volumen" => "79"
                        "paginaInicial" => "1185"
                        "paginaFinal" => "1192"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            13 => array:3 [
              "identificador" => "bib0530"
              "etiqueta" => "14"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Pharmacogenetics of drug-induced QT interval prolongation&#58; an update"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:3 [ …3]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1007/s40264-015-0316-6"
                      "Revista" => array:6 [
                        "tituloSerie" => "Drug Saf"
                        "fecha" => "2015"
                        "volumen" => "38"
                        "paginaInicial" => "855"
                        "paginaFinal" => "867"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            14 => array:3 [
              "identificador" => "bib0535"
              "etiqueta" => "15"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Cardiac sodium channels and inherited electrophysiological disorders&#58; an update on the pharmacotherapy"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [ …3]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1517/14656566.2014.936380"
                      "Revista" => array:6 [
                        "tituloSerie" => "Expert Opin Pharmacother"
                        "fecha" => "2014"
                        "volumen" => "15"
                        "paginaInicial" => "1875"
                        "paginaFinal" => "1887"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            15 => array:3 [
              "identificador" => "bib0540"
              "etiqueta" => "16"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "HRS&#47;EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies&#58; this document was developed as a partnership between the Heart Rhythm Society &#40;HRS&#41; and the European Heart Rhythm Association &#40;EHRA&#41;"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:3 [ …3]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1093/europace/eur245"
                      "Revista" => array:6 [
                        "tituloSerie" => "Europace"
                        "fecha" => "2011"
                        "volumen" => "13"
                        "paginaInicial" => "1077"
                        "paginaFinal" => "1109"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            16 => array:3 [
              "identificador" => "bib0545"
              "etiqueta" => "17"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "QTc behavior during exercise and genetic testing for the long-QT syndrome"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1161/CIRCULATIONAHA.111.062182"
                      "Revista" => array:6 [
                        "tituloSerie" => "Circulation"
                        "fecha" => "2011"
                        "volumen" => "124"
                        "paginaInicial" => "2181"
                        "paginaFinal" => "2184"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            17 => array:3 [
              "identificador" => "bib0550"
              "etiqueta" => "18"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Idiopathic short QT interval&#58; a new clinical syndrome&#63;"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:3 [ …3]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1159/000047299"
                      "Revista" => array:6 [
                        "tituloSerie" => "Cardiology"
                        "fecha" => "2000"
                        "volumen" => "94"
                        "paginaInicial" => "99"
                        "paginaFinal" => "102"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            18 => array:3 [
              "identificador" => "bib0555"
              "etiqueta" => "19"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Sudden cardiac death and disorders of the QT interval&#58; anesthetic implications and focus on perioperative management"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:3 [ …3]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1053/j.jvca.2015.07.026"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Cardiothorac Vasc Anesth"
                        "fecha" => "2015"
                        "volumen" => "29"
                        "paginaInicial" => "1723"
                        "paginaFinal" => "1733"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            19 => array:3 [
              "identificador" => "bib0560"
              "etiqueta" => "20"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Right bundle branch block&#44; persistent ST segment elevation and sudden cardiac death&#58; a distinct clinical and electrocardiographic syndrome&#46; A multicenter report"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "J Am Coll Cardiol"
                        "fecha" => "1992"
                        "volumen" => "20"
                        "paginaInicial" => "1391"
                        "paginaFinal" => "1396"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            20 => array:3 [
              "identificador" => "bib0565"
              "etiqueta" => "21"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Brugada syndrome&#58; clinical&#44; genetic&#44; molecular&#44; cellular&#44; and ionic aspects"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.cpcardiol.2015.06.002"
                      "Revista" => array:6 [
                        "tituloSerie" => "Curr Probl Cardiol"
                        "fecha" => "2016"
                        "volumen" => "41"
                        "paginaInicial" => "7"
                        "paginaFinal" => "57"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            21 => array:3 [
              "identificador" => "bib0570"
              "etiqueta" => "22"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Genetics of Brugada syndrome"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.joa.2016.07.012"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Arrhythm"
                        "fecha" => "2016"
                        "volumen" => "32"
                        "paginaInicial" => "418"
                        "paginaFinal" => "425"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            22 => array:3 [
              "identificador" => "bib0575"
              "etiqueta" => "23"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "J-Wave syndromes expert consensus conference report&#58; emerging concepts and gaps in knowledge&#58; endorsed by the Asia Pacific Heart Rhythm Society &#40;APHRS&#41;&#44; the European Heart Rhythm Association &#40;EHRA&#41;&#44; the Heart Rhythm Society &#40;HRS&#41;&#44; and the Latin American Society of Cardiac Pacing and Electrophysiology &#40;Sociedad Latinoamericana de Estimulaci&#243;n Card&#237;aca y Electrofisiolog&#237;a &#91;SOLAECE&#93;&#41;"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:3 [ …3]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:2 [
                        "tituloSerie" => "Europace"
                        "fecha" => "2016"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            23 => array:3 [
              "identificador" => "bib0580"
              "etiqueta" => "24"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "HRS&#47;EHRA&#47;APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes&#58; document endorsed by HRS&#44; EHRA&#44; and APHRS in May 2013 and by ACCF&#44; AHA&#44; PACES&#44; and AEPC in June 2013"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:3 [ …3]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.hrthm.2013.05.014"
                      "Revista" => array:7 [
                        "tituloSerie" => "Heart Rhythm"
                        "fecha" => "2013"
                        "volumen" => "10"
                        "paginaInicial" => "1932"
                        "paginaFinal" => "1963"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                        "itemHostRev" => array:3 [
                          "pii" => "S0007091217311571"
                          "estado" => "S300"
                          "issn" => "00070912"
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            24 => array:3 [
              "identificador" => "bib0585"
              "etiqueta" => "25"
              "referencia" => array:1 [
                0 => array:1 [
                  "referenciaCompleta" => "Woosley R&#44; Heise CW&#44; Romero KA&#46; QTdrugs List&#46; AZCERT&#44; Inc&#46;&#44; 1822 Innovation Park Dr&#46;&#44; Oro Valley&#44; AZ 85755&#46; <a id="intr0045" class="elsevierStyleInterRef" href="http://www.crediblemeds.org/">www&#46;CredibleMeds&#46;org</a> &#91;accessed 12&#46;01&#46;17&#93;&#46;"
                ]
              ]
            ]
            25 => array:3 [
              "identificador" => "bib0590"
              "etiqueta" => "26"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Safe drug use in long QT syndrome and Brugada syndrome&#58; comparison of website statistics"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:3 [ …3]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1093/europace/eut018"
                      "Revista" => array:6 [
                        "tituloSerie" => "Europace"
                        "fecha" => "2013"
                        "volumen" => "15"
                        "paginaInicial" => "1042"
                        "paginaFinal" => "1049"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            26 => array:3 [
              "identificador" => "bib0595"
              "etiqueta" => "27"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Drug-induced proarrhythmia&#58; risk factors and electrophysiological mechanisms"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1038/nrcardio.2015.110"
                      "Revista" => array:6 [
                        "tituloSerie" => "Nat Rev Cardiol"
                        "fecha" => "2016"
                        "volumen" => "13"
                        "paginaInicial" => "36"
                        "paginaFinal" => "47"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            27 => array:3 [
              "identificador" => "bib0600"
              "etiqueta" => "28"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Genetics of congenital and drug-induced long QT syndromes&#58; current evidence and future research perspectives"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:3 [ …3]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1007/s10840-013-9779-5"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Interv Card Electrophysiol"
                        "fecha" => "2013"
                        "volumen" => "37"
                        "paginaInicial" => "9"
                        "paginaFinal" => "19"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            28 => array:3 [
              "identificador" => "bib0605"
              "etiqueta" => "29"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Effect of smoking on Tp-e interval&#44; Tp-e&#47;QT and Tp-e&#47;QTc ratios as indices of ventricular arrhythmogenesis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:3 [ …3]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.hlc.2014.03.016"
                      "Revista" => array:7 [
                        "tituloSerie" => "Heart Lung Circ"
                        "fecha" => "2014"
                        "volumen" => "23"
                        "paginaInicial" => "827"
                        "paginaFinal" => "832"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                        "itemHostRev" => array:3 [
                          "pii" => "S0007091217337686"
                          "estado" => "S300"
                          "issn" => "00070912"
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            29 => array:3 [
              "identificador" => "bib0610"
              "etiqueta" => "30"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "The effects of cigarette smoking on the Tp-e interval&#44; Tp-e&#47;QT ratio and Tp-e&#47;QTc ratio"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:3 [ …3]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Adv Clin Exp Med"
                        "fecha" => "2015"
                        "volumen" => "24"
                        "paginaInicial" => "973"
                        "paginaFinal" => "978"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            30 => array:3 [
              "identificador" => "bib0615"
              "etiqueta" => "31"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Impact of psychotropic drugs on QT interval dispersion in adult patients"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:3 [ …3]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Arq Bras Cardiol"
                        "fecha" => "2014"
                        "volumen" => "102"
                        "paginaInicial" => "465"
                        "paginaFinal" => "472"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            31 => array:3 [
              "identificador" => "bib0620"
              "etiqueta" => "32"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Psychiatric medications and sudden cardiac death&#58; putting the risk in perspective"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:1 [ …1]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.3928/02793695-20150527-55"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Psychosoc Nurs Ment Health Serv"
                        "fecha" => "2015"
                        "volumen" => "53"
                        "paginaInicial" => "23"
                        "paginaFinal" => "25"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            32 => array:3 [
              "identificador" => "bib0625"
              "etiqueta" => "33"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Non-cardiovascular drugs that inhibit hERG-encoded potassium channels and risk of sudden cardiac death"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:3 [ …3]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1136/hrt.2009.188367"
                      "Revista" => array:6 [
                        "tituloSerie" => "Heart"
                        "fecha" => "2011"
                        "volumen" => "97"
                        "paginaInicial" => "215"
                        "paginaFinal" => "220"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            33 => array:3 [
              "identificador" => "bib0630"
              "etiqueta" => "34"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "A possible mechanistic link between the CYP2C19 genotype&#44; the methadone metabolite ethylidene-1&#44;5-dimethyl-3&#44;3-diphenylpyrrolidene &#40;EDDP&#41;&#44; and methadone-induced corrected QT interval prolongation in a pilot study"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:3 [ …3]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1007/s40291-015-0137-4"
                      "Revista" => array:6 [
                        "tituloSerie" => "Mol Diagn Ther"
                        "fecha" => "2015"
                        "volumen" => "19"
                        "paginaInicial" => "131"
                        "paginaFinal" => "138"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            34 => array:3 [
              "identificador" => "bib0635"
              "etiqueta" => "35"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "QT interval prolongation&#58; prevalence&#44; risk factors and pharmacovigilance data among methadone-treated patients in France"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [ …3]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/j.1472-8206.2010.00871.x"
                      "Revista" => array:6 [
                        "tituloSerie" => "Fundam Clin Pharmacol"
                        "fecha" => "2011"
                        "volumen" => "25"
                        "paginaInicial" => "503"
                        "paginaFinal" => "510"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            35 => array:3 [
              "identificador" => "bib0640"
              "etiqueta" => "36"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "The role of macrolide antibiotics in increasing cardiovascular risk"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:3 [ …3]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jacc.2015.09.029"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Am Coll Cardiol"
                        "fecha" => "2015"
                        "volumen" => "66"
                        "paginaInicial" => "2173"
                        "paginaFinal" => "2184"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            36 => array:3 [
              "identificador" => "bib0645"
              "etiqueta" => "37"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Domperidone in Parkinson&#39;s disease&#58; a perilous arrhythmogenic or the gold standard&#63;"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:3 [ …3]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Curr Drug Saf"
                        "fecha" => "2013"
                        "volumen" => "8"
                        "paginaInicial" => "63"
                        "paginaFinal" => "68"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            37 => array:3 [
              "identificador" => "bib0650"
              "etiqueta" => "38"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Sudden death of cardiac origin and psychotropic drugs"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:3 [ …3]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.3389/fphar.2012.00076"
                      "Revista" => array:5 [
                        "tituloSerie" => "Front Pharmacol"
                        "fecha" => "2012"
                        "volumen" => "3"
                        "paginaInicial" => "76"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            38 => array:3 [
              "identificador" => "bib0655"
              "etiqueta" => "39"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Nitric oxide synthase 1 adaptor protein&#44; an emerging new genetic marker for QT prolongation and sudden cardiac death"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:3 [ …3]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Acta Cardiol Sin"
                        "fecha" => "2013"
                        "volumen" => "29"
                        "paginaInicial" => "217"
                        "paginaFinal" => "225"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            39 => array:3 [
              "identificador" => "bib0660"
              "etiqueta" => "40"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Drug-induced long QT syndrome and fatal arrhythmias in the intensive care unit"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [ …3]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/aas.12257"
                      "Revista" => array:7 [
                        "tituloSerie" => "Acta Anaesthesiol Scand"
                        "fecha" => "2014"
                        "volumen" => "58"
                        "paginaInicial" => "266"
                        "paginaFinal" => "272"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                        "itemHostRev" => array:3 [ …3]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            40 => array:3 [
              "identificador" => "bib0665"
              "etiqueta" => "41"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Impact of age and sex on QT prolongation in patients receiving psychotropics"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1177/070674371506000502"
                      "Revista" => array:6 [
                        "tituloSerie" => "Can J Psychiatry"
                        "fecha" => "2015"
                        "volumen" => "60"
                        "paginaInicial" => "206"
                        "paginaFinal" => "214"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            41 => array:3 [
              "identificador" => "bib0670"
              "etiqueta" => "42"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Acquired long QT syndrome&#58; frequency&#44; onset&#44; and risk factors in intensive care patients"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.4037/ccn2012900"
                      "Revista" => array:6 [
                        "tituloSerie" => "Crit Care Nurse"
                        "fecha" => "2012"
                        "volumen" => "32"
                        "paginaInicial" => "32"
                        "paginaFinal" => "41"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            42 => array:3 [
              "identificador" => "bib0675"
              "etiqueta" => "43"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "A case of sudden cardiac death due to pilsicainide-induced torsades de pointes"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.4070/kcj.2014.44.2.122"
                      "Revista" => array:6 [
                        "tituloSerie" => "Korean Circ J"
                        "fecha" => "2014"
                        "volumen" => "44"
                        "paginaInicial" => "122"
                        "paginaFinal" => "124"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            43 => array:3 [
              "identificador" => "bib0680"
              "etiqueta" => "44"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "The risk of sudden cardiac death in patients with non-ST elevation acute coronary syndrome and prolonged QTc interval&#58; effect of ranolazine"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1093/europace/eus400"
                      "Revista" => array:6 [
                        "tituloSerie" => "Europace"
                        "fecha" => "2013"
                        "volumen" => "15"
                        "paginaInicial" => "429"
                        "paginaFinal" => "436"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            44 => array:3 [
              "identificador" => "bib0685"
              "etiqueta" => "45"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Risk factors for QT prolongation associated with acute psychotropic drug overdose"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.ajem.2014.09.048"
                      "Revista" => array:6 [
                        "tituloSerie" => "Am J Emerg Med"
                        "fecha" => "2015"
                        "volumen" => "33"
                        "paginaInicial" => "142"
                        "paginaFinal" => "149"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            45 => array:3 [
              "identificador" => "bib0690"
              "etiqueta" => "46"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Cardiac toxicity in selective serotonin reuptake inhibitor users"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1097/PAF.0000000000000205"
                      "Revista" => array:6 [
                        "tituloSerie" => "Am J Forensic Med Pathol"
                        "fecha" => "2015"
                        "volumen" => "36"
                        "paginaInicial" => "293"
                        "paginaFinal" => "297"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            46 => array:3 [
              "identificador" => "bib0695"
              "etiqueta" => "47"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Meta-analysis of selective serotonin reuptake inhibitor-associated QTc prolongation"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.4088/JCP.13r08672"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Clin Psychiatry"
                        "fecha" => "2014"
                        "volumen" => "75"
                        "paginaInicial" => "e441"
                        "paginaFinal" => "e449"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            47 => array:3 [
              "identificador" => "bib0700"
              "etiqueta" => "48"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Drug-induced long QT in adult psychiatric inpatients&#58; the 5-year cross-sectional ECG Screening Outcome in Psychiatry study"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1176/appi.ajp.2013.12060860"
                      "Revista" => array:7 [
                        "tituloSerie" => "Am J Psychiatry"
                        "fecha" => "2013"
                        "volumen" => "170"
                        "paginaInicial" => "1468"
                        "paginaFinal" => "1476"
                        "link" => array:1 [ …1]
                        "itemHostRev" => array:3 [ …3]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            48 => array:3 [
              "identificador" => "bib0705"
              "etiqueta" => "49"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Citalopram&#44; QTc interval prolongation&#44; and torsade de pointes&#46; How should we apply the recent FDA ruling&#63;"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.amjmed.2011.12.002"
                      "Revista" => array:6 [
                        "tituloSerie" => "Am J Med"
                        "fecha" => "2012"
                        "volumen" => "125"
                        "paginaInicial" => "859"
                        "paginaFinal" => "868"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            49 => array:3 [
              "identificador" => "bib0710"
              "etiqueta" => "50"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Risk of QT&#47;QTc prolongation among newer non-SSRI antidepressants"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1177/1060028014550645"
                      "Revista" => array:6 [
                        "tituloSerie" => "Ann Pharmacother"
                        "fecha" => "2014"
                        "volumen" => "48"
                        "paginaInicial" => "1620"
                        "paginaFinal" => "1628"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            50 => array:3 [
              "identificador" => "bib0715"
              "etiqueta" => "51"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Antidepressants and the risk of sudden cardiac death and ventricular arrhythmia"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1002/pds.2181"
                      "Revista" => array:6 [
                        "tituloSerie" => "Pharmacoepidemiol Drug Saf"
                        "fecha" => "2011"
                        "volumen" => "20"
                        "paginaInicial" => "903"
                        "paginaFinal" => "913"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            51 => array:3 [
              "identificador" => "bib0720"
              "etiqueta" => "52"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Antipsychotic drugs and the risk of ventricular arrhythmia and&#47;or sudden cardiac death&#58; a nation-wide case-crossover study"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:3 [
                        "tituloSerie" => "J Am Heart Assoc"
                        "fecha" => "2015"
                        "volumen" => "4"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            52 => array:3 [
              "identificador" => "bib0725"
              "etiqueta" => "53"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Torsadogenic risk of antipsychotics&#58; combining adverse event reports with drug utilization data across Europe"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1371/journal.pone.0081208"
                      "Revista" => array:5 [
                        "tituloSerie" => "PLoS ONE"
                        "fecha" => "2013"
                        "volumen" => "8"
                        "paginaInicial" => "e81208"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            53 => array:3 [
              "identificador" => "bib0730"
              "etiqueta" => "54"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Antipsychotics and torsadogenic risk&#58; signals emerging from the US FDA Adverse Event Reporting System database"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1007/s40264-013-0032-z"
                      "Revista" => array:6 [
                        "tituloSerie" => "Drug Saf"
                        "fecha" => "2013"
                        "volumen" => "36"
                        "paginaInicial" => "467"
                        "paginaFinal" => "479"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            54 => array:3 [
              "identificador" => "bib0735"
              "etiqueta" => "55"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Risk of arrhythmia induced by psychotropic medications&#58; a proposal for clinical management"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1093/eurheartj/ehu100"
                      "Revista" => array:6 [
                        "tituloSerie" => "Eur Heart J"
                        "fecha" => "2014"
                        "volumen" => "35"
                        "paginaInicial" => "1306"
                        "paginaFinal" => "1315"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            55 => array:3 [
              "identificador" => "bib0740"
              "etiqueta" => "56"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "The contribution of national spontaneous reporting systems to detect signals of torsadogenicity&#58; issues emerging from the ARITMO project"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1007/s40264-015-0353-1"
                      "Revista" => array:6 [
                        "tituloSerie" => "Drug Saf"
                        "fecha" => "2016"
                        "volumen" => "39"
                        "paginaInicial" => "59"
                        "paginaFinal" => "68"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            56 => array:3 [
              "identificador" => "bib0745"
              "etiqueta" => "57"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Antipsychotics and the risks of sudden cardiac death and all-cause death&#58; cohort studies in Medicaid and dually-eligible Medicaid-Medicare beneficiaries of five states"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.4172/2155-9880.S10-006"
                      "Revista" => array:7 [
                        "tituloSerie" => "J Clin Exp Cardiolog"
                        "fecha" => "2013"
                        "volumen" => "10"
                        "numero" => "Suppl"
                        "paginaInicial" => "1"
                        "paginaFinal" => "9"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            57 => array:3 [
              "identificador" => "bib0750"
              "etiqueta" => "58"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "QTc prolongation&#58; is clozapine safe&#63; Study of 82 cases before and after clozapine treatment"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1002/hup.1221"
                      "Revista" => array:6 [
                        "tituloSerie" => "Hum Psychopharmacol"
                        "fecha" => "2011"
                        "volumen" => "26"
                        "paginaInicial" => "397"
                        "paginaFinal" => "403"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            58 => array:3 [
              "identificador" => "bib0755"
              "etiqueta" => "59"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Comparative mortality associated with ziprasidone and olanzapine in real-world use among 18&#44;154 patients with schizophrenia&#58; The Ziprasidone Observational Study of Cardiac Outcomes &#40;ZODIAC&#41;"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1176/appi.ajp.2010.08040484"
                      "Revista" => array:6 [
                        "tituloSerie" => "Am J Psychiatry"
                        "fecha" => "2011"
                        "volumen" => "168"
                        "paginaInicial" => "193"
                        "paginaFinal" => "201"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            59 => array:3 [
              "identificador" => "bib0760"
              "etiqueta" => "60"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Methodological challenges in the coding and adjudication of sudden deaths in a large simple trial with observational follow-up&#58; the ziprasidone observational study of cardiac outcomes &#40;ZODIAC&#41;"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1002/pds.2185"
                      "Revista" => array:6 [
                        "tituloSerie" => "Pharmacoepidemiol Drug Saf"
                        "fecha" => "2011"
                        "volumen" => "20"
                        "paginaInicial" => "1192"
                        "paginaFinal" => "1198"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            60 => array:3 [
              "identificador" => "bib0765"
              "etiqueta" => "61"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Drug safety evaluation of ziprasidone"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1517/14740338.2011.560114"
                      "Revista" => array:6 [
                        "tituloSerie" => "Expert Opin Drug Saf"
                        "fecha" => "2011"
                        "volumen" => "10"
                        "paginaInicial" => "437"
                        "paginaFinal" => "448"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            61 => array:3 [
              "identificador" => "bib0770"
              "etiqueta" => "62"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "The cardiac safety of aripiprazole treatment in patients at high risk for torsade&#58; a systematic review with a meta-analytic approach"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Psychopharmacology &#40;Berl&#41;"
                        "fecha" => "2015"
                        "volumen" => "232"
                        "paginaInicial" => "3297"
                        "paginaFinal" => "3308"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            62 => array:3 [
              "identificador" => "bib0775"
              "etiqueta" => "63"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Cardiovascular safety of antipsychotics&#58; a clinical overview"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1517/14740338.2016.1161021"
                      "Revista" => array:6 [
                        "tituloSerie" => "Expert Opin Drug Saf"
                        "fecha" => "2016"
                        "volumen" => "15"
                        "paginaInicial" => "679"
                        "paginaFinal" => "688"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            63 => array:3 [
              "identificador" => "bib0780"
              "etiqueta" => "64"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Quetiapine&#44; QTc interval prolongation&#44; and torsade de pointes&#58; a review of case reports"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1177/2045125313510194"
                      "Revista" => array:6 [
                        "tituloSerie" => "Ther Adv Psychopharmacol"
                        "fecha" => "2014"
                        "volumen" => "4"
                        "paginaInicial" => "130"
                        "paginaFinal" => "138"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            64 => array:3 [
              "identificador" => "bib0785"
              "etiqueta" => "65"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Increased risk of antipsychotic-related QT prolongation during nighttime&#58; a 24-hour holter electrocardiogram recording study"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1097/JCP.0b013e31823f6f21"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Clin Psychopharmacol"
                        "fecha" => "2012"
                        "volumen" => "32"
                        "paginaInicial" => "18"
                        "paginaFinal" => "22"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            65 => array:3 [
              "identificador" => "bib0790"
              "etiqueta" => "66"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "QT prolongation of the antipsychotic risperidone is predominantly related to its 9-hydroxy metabolite paliperidone"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1002/hup.1258"
                      "Revista" => array:6 [
                        "tituloSerie" => "Hum Psychopharmacol"
                        "fecha" => "2012"
                        "volumen" => "27"
                        "paginaInicial" => "39"
                        "paginaFinal" => "42"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            66 => array:3 [
              "identificador" => "bib0795"
              "etiqueta" => "67"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Prescribing pattern of antipsychotic drugs during the years 1996&#8211;2010&#58; a population-based database study in Europe with a focus on torsadogenic drugs"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/bcp.12955"
                      "Revista" => array:6 [
                        "tituloSerie" => "Br J Clin Pharmacol"
                        "fecha" => "2016"
                        "volumen" => "82"
                        "paginaInicial" => "487"
                        "paginaFinal" => "497"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            67 => array:3 [
              "identificador" => "bib0800"
              "etiqueta" => "68"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "QTc prolongation in patients acutely admitted to hospital for psychosis and treated with second generation antipsychotics"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1155/2013/375020"
                      "Revista" => array:5 [
                        "tituloSerie" => "Schizophr Res Treatment"
                        "fecha" => "2013"
                        "volumen" => "2013"
                        "paginaInicial" => "375020"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            68 => array:3 [
              "identificador" => "bib0805"
              "etiqueta" => "69"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Antipsychotic drug administration does not correlate with prolonged rate-corrected QT interval in children and adolescents&#58; results from a nested case-control study"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1089/cap.2011.0024"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Child Adolesc Psychopharmacol"
                        "fecha" => "2011"
                        "volumen" => "21"
                        "paginaInicial" => "365"
                        "paginaFinal" => "368"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            69 => array:3 [
              "identificador" => "bib0810"
              "etiqueta" => "70"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Azithromycin and the risk of cardiovascular death"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1056/NEJMoa1003833"
                      "Revista" => array:6 [
                        "tituloSerie" => "N Engl J Med"
                        "fecha" => "2012"
                        "volumen" => "366"
                        "paginaInicial" => "1881"
                        "paginaFinal" => "1890"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            70 => array:3 [
              "identificador" => "bib0815"
              "etiqueta" => "71"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Azithromycin and levofloxacin use and increased risk of cardiac arrhythmia and death"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1370/afm.1601"
                      "Revista" => array:6 [
                        "tituloSerie" => "Ann Fam Med"
                        "fecha" => "2014"
                        "volumen" => "12"
                        "paginaInicial" => "121"
                        "paginaFinal" => "127"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            71 => array:3 [
              "identificador" => "bib0820"
              "etiqueta" => "72"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Sudden cardiac arrest during anesthesia in a 30-month-old boy with syndactyly&#58; a case of genetically proven Timothy syndrome"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.3346/jkms.2013.28.5.788"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Korean Med Sci"
                        "fecha" => "2013"
                        "volumen" => "28"
                        "paginaInicial" => "788"
                        "paginaFinal" => "791"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            72 => array:3 [
              "identificador" => "bib0825"
              "etiqueta" => "73"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Domperidone and risk of ventricular arrhythmia and cardiac death&#58; a systematic review and meta-analysis"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1007/s40261-015-0360-0"
                      "Revista" => array:6 [
                        "tituloSerie" => "Clin Drug Investig"
                        "fecha" => "2016"
                        "volumen" => "36"
                        "paginaInicial" => "97"
                        "paginaFinal" => "107"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            73 => array:3 [
              "identificador" => "bib0830"
              "etiqueta" => "74"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Risk of out-of-hospital sudden cardiac death in users of domperidonem proton pump inhibitors&#44; or metoclopramide&#58; a population-based nested case-control study"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1007/s40264-015-0338-0"
                      "Revista" => array:6 [
                        "tituloSerie" => "Drug Saf"
                        "fecha" => "2015"
                        "volumen" => "38"
                        "paginaInicial" => "1187"
                        "paginaFinal" => "1199"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            74 => array:3 [
              "identificador" => "bib0835"
              "etiqueta" => "75"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Intravenous ondansetron and the QT interval in adult emergency department patients&#58; an observational study"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/acem.12836"
                      "Revista" => array:6 [
                        "tituloSerie" => "Acad Emerg Med"
                        "fecha" => "2016"
                        "volumen" => "23"
                        "paginaInicial" => "102"
                        "paginaFinal" => "105"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            75 => array:3 [
              "identificador" => "bib0840"
              "etiqueta" => "76"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Pro-arrhythmic potential of oral antihistamines &#40;H1&#41;&#58; combining adverse event reports with drug utilization data across Europe"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1371/journal.pone.0119551"
                      "Revista" => array:5 [
                        "tituloSerie" => "PLOS ONE"
                        "fecha" => "2015"
                        "volumen" => "10"
                        "paginaInicial" => "e0119551"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            76 => array:3 [
              "identificador" => "bib0845"
              "etiqueta" => "77"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Chemotherapy and QT prolongation&#58; overview with clinical perspective"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1007/s11936-014-0303-8"
                      "Revista" => array:5 [
                        "tituloSerie" => "Curr Treat Options Cardiovasc Med"
                        "fecha" => "2014"
                        "volumen" => "16"
                        "paginaInicial" => "303"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            77 => array:3 [
              "identificador" => "bib0850"
              "etiqueta" => "78"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "What links BRAF to the heart function&#63; New insights from the cardiotoxicity of BRAF inhibitors in cancer treatment"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.18632/oncotarget.5853"
                      "Revista" => array:6 [
                        "tituloSerie" => "Oncotarget"
                        "fecha" => "2015"
                        "volumen" => "6"
                        "paginaInicial" => "35589"
                        "paginaFinal" => "35601"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            78 => array:3 [
              "identificador" => "bib0855"
              "etiqueta" => "79"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Risk of serious cardiovascular problems with medications for attention-deficit hyperactivity disorder"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1007/s40263-012-0019-9"
                      "Revista" => array:6 [
                        "tituloSerie" => "CNS Drugs"
                        "fecha" => "2013"
                        "volumen" => "27"
                        "paginaInicial" => "15"
                        "paginaFinal" => "30"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            79 => array:3 [
              "identificador" => "bib0860"
              "etiqueta" => "80"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Do prescription stimulants increase the risk of adverse cardiovascular events&#63;&#58; A systematic review"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1186/1471-2261-12-41"
                      "Revista" => array:5 [
                        "tituloSerie" => "BMC Cardiovasc Disord"
                        "fecha" => "2012"
                        "volumen" => "12"
                        "paginaInicial" => "41"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            80 => array:3 [
              "identificador" => "bib0865"
              "etiqueta" => "81"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Methylphenidate and risk of serious cardiovascular events in adults"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1176/appi.ajp.2011.11010125"
                      "Revista" => array:6 [
                        "tituloSerie" => "Am J Psychiatry"
                        "fecha" => "2012"
                        "volumen" => "169"
                        "paginaInicial" => "178"
                        "paginaFinal" => "185"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            81 => array:3 [
              "identificador" => "bib0870"
              "etiqueta" => "82"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Coffee&#44; alcohol&#44; smoking&#44; physical activity and QT interval duration&#58; results from the Third National Health and Nutrition Examination Survey"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1371/journal.pone.0017584"
                      "Revista" => array:5 [
                        "tituloSerie" => "PLoS ONE"
                        "fecha" => "2011"
                        "volumen" => "6"
                        "paginaInicial" => "e17584"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            82 => array:3 [
              "identificador" => "bib0875"
              "etiqueta" => "83"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Ginseng&#58; a potential cause of long QT"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jelectrocard.2010.08.007"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Electrocardiol"
                        "fecha" => "2011"
                        "volumen" => "44"
                        "paginaInicial" => "357"
                        "paginaFinal" => "358"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            83 => array:3 [
              "identificador" => "bib0880"
              "etiqueta" => "84"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Polymorphic ventricular tachycardia &#40;Torsades de pointes&#41; due to licorice root tea"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Turk Kardiyol Dern Ars"
                        "fecha" => "2013"
                        "volumen" => "41"
                        "paginaInicial" => "241"
                        "paginaFinal" => "244"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            84 => array:3 [
              "identificador" => "bib0885"
              "etiqueta" => "85"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Drug-induced QT interval shortening&#58; potential harbinger of proarrhythmia and regulatory perspectives"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/j.1476-5381.2009.00191.x"
                      "Revista" => array:6 [
                        "tituloSerie" => "Br J Pharmacol"
                        "fecha" => "2010"
                        "volumen" => "159"
                        "paginaInicial" => "58"
                        "paginaFinal" => "69"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            85 => array:3 [
              "identificador" => "bib0890"
              "etiqueta" => "86"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Drug-induced QT-interval shortening following antiepileptic treatment with oral rufinamide"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.hrthm.2012.01.006"
                      "Revista" => array:6 [
                        "tituloSerie" => "Heart Rhythm"
                        "fecha" => "2012"
                        "volumen" => "9"
                        "paginaInicial" => "776"
                        "paginaFinal" => "781"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            86 => array:3 [
              "identificador" => "bib0895"
              "etiqueta" => "87"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Drug-induced Brugada syndrome by noncardiac agents"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/pace.12234"
                      "Revista" => array:6 [
                        "tituloSerie" => "Pacing Clin Electrophysiol"
                        "fecha" => "2013"
                        "volumen" => "36"
                        "paginaInicial" => "1570"
                        "paginaFinal" => "1577"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            87 => array:3 [
              "identificador" => "bib0900"
              "etiqueta" => "88"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "The safety of flecainide treatment of atrial fibrillation&#58; long-term incidence of sudden cardiac death and proarrhythmic events"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/j.1365-2796.2011.02395.x"
                      "Revista" => array:7 [
                        "tituloSerie" => "J Intern Med"
                        "fecha" => "2011"
                        "volumen" => "270"
                        "paginaInicial" => "281"
                        "paginaFinal" => "290"
                        "link" => array:1 [ …1]
                        "itemHostRev" => array:3 [ …3]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            88 => array:3 [
              "identificador" => "bib0905"
              "etiqueta" => "89"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Brugada electrocardiogram pattern &#8220;unmasked&#8221; by amiodarone infusion"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1097/01.mjt.0000433948.16654.91"
                      "Revista" => array:6 [
                        "tituloSerie" => "Am J Ther"
                        "fecha" => "2014"
                        "volumen" => "21"
                        "paginaInicial" => "540"
                        "paginaFinal" => "541"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            89 => array:3 [
              "identificador" => "bib0910"
              "etiqueta" => "90"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Sudden cardiac death is associated both with epilepsy and with use of antiepileptic medications"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1136/heartjnl-2014-305664"
                      "Revista" => array:6 [
                        "tituloSerie" => "Heart"
                        "fecha" => "2015"
                        "volumen" => "101"
                        "paginaInicial" => "17"
                        "paginaFinal" => "22"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            90 => array:3 [
              "identificador" => "bib0915"
              "etiqueta" => "91"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Polytherapy with sodium channel-blocking antiepileptic drugs is associated with arrhythmogenic ST-T abnormality in patients with epilepsy"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.seizure.2016.06.004"
                      "Revista" => array:7 [
                        "tituloSerie" => "Seizure"
                        "fecha" => "2016"
                        "volumen" => "40"
                        "paginaInicial" => "81"
                        "paginaFinal" => "87"
                        "link" => array:1 [ …1]
                        "itemHostRev" => array:3 [ …3]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            91 => array:3 [
              "identificador" => "bib0920"
              "etiqueta" => "92"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Type 1 Brugada pattern associated with nicotine toxicity"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jemermed.2015.08.008"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Emerg Med"
                        "fecha" => "2015"
                        "volumen" => "49"
                        "paginaInicial" => "e183"
                        "paginaFinal" => "e186"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
          ]
        ]
      ]
    ]
  ]
  "idiomaDefecto" => "en"
  "url" => "/21742049/0000003700000005/v1_201806100418/S2174204918301685/v1_201806100418/en/main.assets"
  "Apartado" => array:4 [
    "identificador" => "9924"
    "tipo" => "SECCION"
    "en" => array:2 [
      "titulo" => "Review Article"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "en"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/21742049/0000003700000005/v1_201806100418/S2174204918301685/v1_201806100418/en/main.pdf?idApp=UINPBA00004E&text.app=https://revportcardiol.org/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2174204918301685?idApp=UINPBA00004E"
]

Article information

ISSN: 21742049
Original language: English

DOI:10.1016/j.repce.2017.07.010

The statistics are updated each day

Year/Month	Html	Pdf	Total

2024 November	11	4	15
2024 October	57	88	145
2024 September	55	57	112
2024 August	71	54	125
2024 July	47	61	108
2024 June	77	46	123
2024 May	41	30	71
2024 April	38	34	72
2024 March	50	43	93
2024 February	44	33	77
2024 January	53	27	80
2023 December	39	31	70
2023 November	41	39	80
2023 October	42	48	90
2023 September	46	33	79
2023 August	50	28	78
2023 July	33	24	57
2023 June	35	33	68
2023 May	81	32	113
2023 April	67	17	84
2023 March	102	34	136
2023 February	79	29	108
2023 January	68	19	87
2022 December	95	43	138
2022 November	85	36	121
2022 October	81	36	117
2022 September	63	46	109
2022 August	61	36	97
2022 July	67	56	123
2022 June	62	43	105
2022 May	51	30	81
2022 April	52	39	91
2022 March	72	45	117
2022 February	63	37	100
2022 January	95	32	127
2021 December	69	34	103
2021 November	61	41	102
2021 October	83	46	129
2021 September	51	30	81
2021 August	72	32	104
2021 July	66	22	88
2021 June	61	21	82
2021 May	225	33	258
2021 April	125	68	193
2021 March	107	43	150
2021 February	106	31	137
2021 January	120	42	162
2020 December	96	21	117
2020 November	88	35	123
2020 October	78	22	100
2020 September	136	16	152
2020 August	109	12	121
2020 July	166	21	187
2020 June	122	30	152
2020 May	147	20	167
2020 April	136	31	167
2020 March	162	27	189
2020 February	213	27	240
2020 January	117	22	139
2019 December	91	14	105
2019 November	195	28	223
2019 October	97	8	105
2019 September	192	14	206
2019 August	181	11	192
2019 July	53	7	60
2019 June	32	10	42
2019 May	43	10	53
2019 April	23	26	49
2019 March	41	22	63
2019 February	32	3	35
2019 January	17	7	24
2018 December	20	10	30
2018 November	82	12	94
2018 October	59	17	76
2018 September	30	13	43
2018 August	32	8	40
2018 July	23	22	45
2018 June	42	28	70

Show all

Indexed in:

Follow us:

Statistics

Indexed in:

Follow us:

Statistics

Subscribe to our newsletter